<SEC-DOCUMENT>0001010086-18-000006.txt : 20180504
<SEC-HEADER>0001010086-18-000006.hdr.sgml : 20180504
<ACCEPTANCE-DATETIME>20180504160734
ACCESSION NUMBER:		0001010086-18-000006
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180504
DATE AS OF CHANGE:		20180504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIGA TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001010086
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133864870
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38436
		FILM NUMBER:		18807957

	BUSINESS ADDRESS:	
		STREET 1:		27 EAST 62ND STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10065
		BUSINESS PHONE:		212-672-9100

	MAIL ADDRESS:	
		STREET 1:		27 EAST 62ND STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SIGA PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19961108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>siga-20180331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s71827401477128BD5CAB75DCFBCB0200"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font><font style="font-family:inherit;font-size:12pt;">&#32;<br></font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Mark One)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">For the Quarterly Period Ended March 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Or</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">For the transition period from ________ to ___________</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission File No. 0-23047</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">SIGA Technologies, Inc.</font><font style="font-family:inherit;font-size:16pt;">&#32;<br></font><font style="font-family:inherit;font-size:9pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">13-3864870</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(State or other jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(IRS Employer Identification. No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:2px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">27 East 62nd Street</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">10065</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">New York, NY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(zip code)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Registrant&#8217;s telephone number, including area code: (212) 672-9100</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:226px;"></td><td style="width:226px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:9pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes&#160;</font><font style="font-family:Wingdings;font-size:9pt;">x</font><font style="font-family:inherit;font-size:9pt;">&#32;No </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:inherit;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">As of April 25, 2018, the registrant had outstanding 79,052,037 shares of common stock, par value $.0001, per share</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7CE751EC92D58F40C3CD75DCFBEDC4F0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;SIGA TECHNOLOGIES, INC. <br>FORM 10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Table of Contents </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:14%;"></td><td style="width:77%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page No.</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s76762D0A2289D45F63A975DCFC2095D7"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I-FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44299DF0CE21E2C3553775DCFC406A51"><font style="font-family:inherit;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44299DF0CE21E2C3553775DCFC406A51"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44299DF0CE21E2C3553775DCFC406A51">3</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9B536ADCA835769CD5275DCFFD40BCA"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9B536ADCA835769CD5275DCFFD40BCA"><font style="font-family:inherit;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9B536ADCA835769CD5275DCFFD40BCA">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA742C0D47F479FF72D4D75DD00D097FC"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA742C0D47F479FF72D4D75DD00D097FC"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA742C0D47F479FF72D4D75DD00D097FC">21</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62C71A6CB0E8972A1EC175DD01025632"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62C71A6CB0E8972A1EC175DD01025632"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62C71A6CB0E8972A1EC175DD01025632">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s96C8DDAB9B9FF1E7F86B75DD01225702"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II- OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9165FA3C03E002709CD175DCE9663AA6"><font style="font-family:inherit;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9165FA3C03E002709CD175DCE9663AA6"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9165FA3C03E002709CD175DCE9663AA6">23</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7435B2929FEE551221AE75DD01763DC1"><font style="font-family:inherit;font-size:10pt;">Item 1A</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7435B2929FEE551221AE75DD01763DC1"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7435B2929FEE551221AE75DD01763DC1">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s70CF54828E9F7DCF030A75DD01A93315"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s70CF54828E9F7DCF030A75DD01A93315"><font style="font-family:inherit;font-size:10pt;">Unregistered Sale of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s70CF54828E9F7DCF030A75DD01A93315">23</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62375C887678D8EF765A75DD01CAE53E"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62375C887678D8EF765A75DD01CAE53E"><font style="font-family:inherit;font-size:10pt;">Defaults upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s62375C887678D8EF765A75DD01CAE53E">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72C2884A29D40B9CDD7975DD01FC9177"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72C2884A29D40B9CDD7975DD01FC9177"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72C2884A29D40B9CDD7975DD01FC9177">23</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA8940881FCE2DDF1BC275DD021D01C3"><font style="font-family:inherit;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA8940881FCE2DDF1BC275DD021D01C3"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDA8940881FCE2DDF1BC275DD021D01C3">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD7C0EABB49C647815C3775DD024EB42B"><font style="font-family:inherit;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD7C0EABB49C647815C3775DD024EB42B"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD7C0EABB49C647815C3775DD024EB42B">24</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s672CC1120CC58F09FB1575DD0270732F"><font style="font-family:inherit;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s672CC1120CC58F09FB1575DD0270732F">25</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s76762D0A2289D45F63A975DCFC2095D7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</font></div><div><a name="s44299DF0CE21E2C3553775DCFC406A51"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1 - Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div><a name="s07BFF6373C9643F367F575DCE6E7C92F"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGA TECHNOLOGIES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,934,807</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,857,833</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Restricted cash, short-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,850,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,701,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,263,680</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,802,107</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,983,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,983,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,900,566</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,019,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30,932,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,364,493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">108,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">138,640</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Restricted cash, long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,754,940</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,542,448</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,296,804</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,592,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred tax asset, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,441,720</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,431,963</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">898,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">898,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">702,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">702,167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">133,135,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">144,670,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIENCY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Current liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">432,207</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,328,867</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,586,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,481,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,018,402</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,810,446</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">376,030,704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">377,641,485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,769,276</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,466,162</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">774,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">840,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">72,159,240</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">71,050,324</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">467,751,753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">467,808,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217; deficiency</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common stock ($.0001 par value, 600,000,000 shares authorized, 79,039,000 issued and outstanding at March 31, 2018, and December 31, 2017, respectively)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,904</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,904</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">214,556,941</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">214,229,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(549,181,345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(537,375,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total stockholders&#8217; deficiency</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(334,616,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(323,138,291</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total liabilities and stockholders&#8217; deficiency</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">133,135,253</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">144,670,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The accompanying notes are an integral part of these financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s1CC7D9D82A801926F0FC75DCE70C9ED2"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGA TECHNOLOGIES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Research and development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,747,934</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,201,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating expenses</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,056,546</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,869,869</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,007,827</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,360,490</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Patent expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">218,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">240,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,282,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,470,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,534,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,269,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,748,818</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,608,916</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss from change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,303,114</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(626,209</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,235</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,419</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,584,608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,499,876</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Benefit/(provision) for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(115,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,582,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,614,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss per share: basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average shares outstanding: basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">79,039,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">78,777,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The accompanying notes are an integral part of these financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s2180164FC5745A5C13A775DCE7380475"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGA TECHNOLOGIES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from operating activities:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,582,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,614,946</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash (used in) operating activities:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation and other amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29,790</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">36,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Increase in fair value of warrant liability</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,303,114</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">626,209</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">327,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred income taxes (benefit) provision</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,758</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,190</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,108,916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,108,916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes in assets and liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">645,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,724,261</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Inventory</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,090,409</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">184,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,389,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">119,433</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,423</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable, accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,792,043</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,894,379</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">169,269</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8,719,141</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(66,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(22,165</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash (used in) operating activities</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,561,703</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(932,976</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from investing activities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from financing activities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payment of employee tax obligations for common stock tendered</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(193,052</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash (used in) financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(193,052</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net decrease in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,561,703</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,126,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash, cash equivalents and restricted cash at the beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37,101,586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56,174,046</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash, cash equivalents and restricted cash at end of period</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28,539,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,048,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The accompanying notes are an integral part of these financial statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sB27BF5442BB1BAC5813A75DCFD1B7434"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGA TECHNOLOGIES, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="s6AC3B4EE061F39BF496075DCE76504F9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements are presented in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for quarterly reports on Form 10-Q and should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto for the year ended December 31, 2017, included in the 2017 Annual Report on Form 10-K. All terms used but not defined elsewhere herein have the meaning ascribed to them in the Company&#8217;s 2017 Annual Report on Form 10-K filed on March 6, 2018. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods presented have been included. The 2017 year-end condensed balance sheet data was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of the results expected for the full year.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is not entitled to receive additional procurement-related payments under the current BARDA Contract (</font><a style="font-family:inherit;font-size:10pt;" href="#s7E5C538EFD7E1A43B3DD75DCE76FACC5"><font style="font-family:inherit;font-size:10pt;">Note 3</font></a><font style="font-family:inherit;font-size:10pt;color:#222222;">) if and until United States Food &amp; Drug Administration ("FDA") approval of TPOXX&#174; has been achieved, and there is no difference between the approved product and courses of TPOXX&#174; that have been delivered to the U.S. Strategic National Stockpile (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">Strategic Stockpile</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">). Upon meeting the aforementioned requirements, a determination of which is currently expected in the third quarter of 2018, the Company will be entitled to a </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$41 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;hold back payment under the BARDA Contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">In the event that the Company does not receive a substantial portion of the hold back payment, or other substantial cash inflows, by October of 2018, then, based on currently forecasted operating costs, the Company will require additional sources of funding to continue operations and prevent an event of default under the term loan (</font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;color:#222222;">). In this case, the Company would seek to increase cash liquidity by: raising proceeds through a financing, entering into a new contract for TPOXX&#174; or any other product, a sale of assets, or the modification of the existing BARDA Contract; significantly reducing its operating expenses; or modifying the terms of the Term Loan Agreement. There can be no assurance that TPOXX&#174; will receive FDA approval on a timely basis, if at all, or that there will be no difference between the approved product and courses of TPOXX&#174; that have been delivered to the Strategic Stockpile. Furthermore, there can be no assurance that the Company would be able to increase cash liquidity, if needed, through a financing, a new contract for TPOXX&#174; or any other product, a sale of assets, the modification of the existing BARDA Contract, or a significant reduction of its operating expenses or operations, or that the lenders would agree to modify the Term Loan Agreement, if needed. Because of these conditions, substantial doubt exists about the Company's ability to continue as a going concern for one year from the financial statement issuance date.</font></div><div><a name="sC3A91219B5B7B433F4C575DCE76C7E28"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASC 606&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of ASC 606</font><font style="font-family:inherit;font-size:10pt;">. On&#160;January&#160;1, 2018, the Company adopted ASC 606 using the modified retrospective method applied to those contracts that were not completed as of&#160;January&#160;1, 2018. Results for reporting periods beginning after&#160;January&#160;1, 2018&#160;are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative impact of adopting ASC 606 as of January 1, 2018 is: a decrease to deferred revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">; a decrease to deferred costs of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">; an increase to receivables of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a net increase to opening accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of tax. For the&#160;three months ended March 31, 2018, the impact to revenues as a result of applying ASC 606 was an increase of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Obligations</font><font style="font-family:inherit;font-size:10pt;">.&#160;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;The Company&#8217;s research and development contract for the intravenous (IV) formulation of TPOXX&#174; (see "IV Formulation R&amp;D Contract" in Note 3) has a single performance </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obligation (research and development); individual services within the contract are not separately identifiable from other promises in the contract and, therefore, are not distinct from each other. The Company&#8217;s BARDA Contract (see Note 3) has three performance obligations: one relates to the manufacture and delivery of product (and performance of services in connection with the manufacture and delivery of product), and the other two performance obligations relate to research and development in connection with TPOXX&#174;. For contracts with multiple performance obligations, the Company allocates the contract&#8217;s transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract modifications may occur during the course of performance of our contracts. Contracts are often modified to account for changes in contract specifications or requirements. In most instances, contract modifications are for services that are not distinct, and, therefore, are accounted for as part of the existing contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s performance obligations are satisfied over time as work progresses or at a point in time.&#160;Substantially all of the Company&#8217;s revenue related to research and development performance obligations is recognized over time, because control transfers continuously to our customers.&#160;Typically, revenue is recognized over time using costs incurred to date relative to total estimated costs at completion to measure progress toward satisfying the Company&#8217;s performance obligations. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, material, overhead, and third-party services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue connected with courses of TPOXX&#174; delivered to the strategic stockpile and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time. Revenue associated with this performance obligation will be recognized&#160;when BARDA obtains control of the asset, which is upon delivery to and acceptance by the customer and at the point in time when the constraint on the consideration is resolved. The consideration, which is variable consideration, is expected to be constrained until the FDA&#8217;s approval of the final version of TPOXX&#174; (quantification and specification of the Replacement Obligation (as defined herein)) has occurred. It is expected that the possibility of product replacement pursuant to the Replacement Obligation, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&#8217;s regulatory review of the new drug application (NDA) for TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Estimates</font><font style="font-family:inherit;font-size:10pt;">.&#160;Accounting for long-term contracts and grants involves the use of various techniques to estimate total contract revenue and costs.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years.&#160;These assumptions include labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The nature of the work required to be performed on many of the Company&#8217;s performance obligations and the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. The consideration associated with manufacture and delivery of product as well as research and development services is variable as the consideration is either constrained or the total amount of services to be performed has not been finalized. The Company estimates variable consideration at the most likely amount to which it expects to be entitled. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur and when any uncertainty associated with variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our historical and anticipated performance, external factors, trends and all other information (historical, current and forecasted) that is reasonably available to us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant change in one or more of these estimates could affect the profitability of the Company&#8217;s contracts.&#160;As such, the Company reviews and updates its contract-related estimates regularly. The Company recognizes adjustments in estimated revenues, research and development expenses and cost of sales under the cumulative catch-up method. Under this method, the impact of the adjustment on revenues, research and development expenses and cost of sales recorded to date on a contract is recognized in the period the adjustment is identified.&#160; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Balances</font><font style="font-family:inherit;font-size:10pt;">.&#160;The timing of revenue recognition, billings and cash collections may result in billed accounts receivable, unbilled receivables (contract assets) and customer advances and deposits (contract liabilities) in the Consolidated Balance Sheet. Generally, amounts are billed as work progresses in accordance with agreed-upon contractual terms either at periodic intervals (monthly) or upon achievement of contractual milestones. Under typical payment terms of fixed price arrangements, the customer pays the Company either performance-based payments or progress payments. For the Company&#8217;s cost type arrangements, the customer generally pays the Company for its actual costs incurred. Such payments occur within a short period of time. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Performance Obligations</font><font style="font-family:inherit;font-size:10pt;">. Remaining performance obligations represents the transaction price for which work has not been performed and excludes unexercised contract options. As of March 31, 2018 the aggregate amount of transaction price allocated to remaining performance obligations for the BARDA Contract and the IV Formulation R&amp;D Contract was </font><font style="font-family:inherit;font-size:10pt;">$20.7 million</font><font style="font-family:inherit;font-size:10pt;">. The Company expects to recognize revenue over the next three to five years as the specific timing for satisfying the performance obligations is subjective and outside the Company&#8217;s control. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When the Company receives consideration, or such consideration is unconditionally due, prior to transferring goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales once control of goods and/or services have been transferred to the customer and all revenue recognition criteria have been met and any constraints have been resolved.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has deferred revenue in connection with the manufacture and delivery of TPOXX&#174; under the BARDA contract. Revenue recognition is currently constrained by the possibility of product replacement pursuant to the Replacement Obligation. It is expected that the possibility of required product replacement, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&#8217;s regulatory review of the new drug application (NDA) for TPOXX&#174;. Upon resolution of this constraint, deferred revenue is expected to be recorded as net sales.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the change in the Company's deferred revenue:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">378,896,803</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumulative effect of accounting change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,780,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Billings in advance of revenue recognition</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,269</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,286,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2018 and December 31, 2017, approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of deferred revenue was classified as accrued expenses and other current liabilities on the condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB&#8217;s Emerging Issues Task Force</font><font style="font-family:inherit;font-size:10pt;">. The new standard required that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities are required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions.  Adoption of this guidance impacts the cash flow disclosure for the three months ended March 31, 2017; cash flows from operating activities, as disclosed herein, is </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;less than the amount disclosed in the 2017 first quarter 10-Q.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the Company&#8217;s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;">, cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for additional information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,934,807</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,857,833</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,850,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,701,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,754,940</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,542,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,539,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,101,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,103,574</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,701,824</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,805,554</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333,332</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,048,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,174,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 26, 2017, the FASB issued ASU No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. The revised guidance will be applied prospectively, and is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company believes the adoption of ASU No. 2017-04 will not have a significant impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">, which relates to the accounting for leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-02 will have on its consolidated financial statements. The Company expects its real estate leases to be capitalized on its balance sheet.</font></div><div><a name="s7E5C538EFD7E1A43B3DD75DCE76FACC5"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Procurement Contract and Research Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) pursuant to which SIGA agreed to deliver </font><font style="font-family:inherit;font-size:10pt;">two million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; to the Strategic Stockpile. The contract with BARDA (as amended, modified, or supplemented from time to time, the &#8220;BARDA Contract&#8221;) includes a base contract (&#8220;Base Contract&#8221;) as well as options (described below). The Base Contract contemplates approximately </font><font style="font-family:inherit;font-size:10pt;">$472.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of payments, of which </font><font style="font-family:inherit;font-size:10pt;">$409.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is consideration for the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; and </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is available for certain development and supportive activities.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Base Contract, BARDA agreed to buy from the Company </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174;. Additionally, the Company agreed to contribute to BARDA </font><font style="font-family:inherit;font-size:10pt;">300,000</font><font style="font-family:inherit;font-size:10pt;">&#32;courses at no additional cost to BARDA. The delivery of </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; to the Strategic Stockpile is a requirement in order for the Company to be eligible to receive a </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back payment (see description of hold back payment below).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For courses of TPOXX&#174; that are physically delivered to the Strategic Stockpile, the Company has a product replacement obligation, at no cost to BARDA, in the event that the final version of TPOXX&#174; approved by the FDA is different from any courses of TPOXX&#174; that have been delivered to the Strategic Stockpile or if TPOXX&#174; does not meet any specified label claims, fails release testing or does not meet the </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX&#174; is recalled or deemed to be recalled for any reason (the "Replacement Obligation").</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$368.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Base Contract related to the manufacture and physical delivery of courses of TPOXX&#174;. Included in this amount are a </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;advance payment in 2011 for the completion of certain planning and preparatory activities related to the Base Contract; a </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment in 2012 for the completion of the product labeling strategy for TPOXX&#174;; an </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment in 2013 for the completion of the commercial validation campaign for TPOXX&#174;; a </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment in 2016 for submission of documentation to BARDA </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study had been submitted to and reviewed by a Data Safety and Monitoring Board (&#8220;DSMB&#8221;) and that such DSMB had recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA; and </font><font style="font-family:inherit;font-size:10pt;">$286.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of payments for physical deliveries of TPOXX&#174; to the Strategic Stockpile beginning in 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has cumulatively delivered </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; to the Strategic Stockpile. The dosage of courses delivered is </font><font style="font-family:inherit;font-size:10pt;">600</font><font style="font-family:inherit;font-size:10pt;">&#32;mg administered twice per day (</font><font style="font-family:inherit;font-size:10pt;">1,200</font><font style="font-family:inherit;font-size:10pt;">&#32;mg per day). In February 2016, the FDA confirmed (through dose concurrence) its earlier dosage guidance of </font><font style="font-family:inherit;font-size:10pt;">600</font><font style="font-family:inherit;font-size:10pt;">&#32;mg administered twice per day (</font><font style="font-family:inherit;font-size:10pt;">1,200</font><font style="font-family:inherit;font-size:10pt;">&#32;mg per day). Courses delivered to the Strategic Stockpile are currently subject to the Replacement Obligation (as discussed above).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is eligible under the Base Contract to receive a </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back payment, which represents an approximate </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back on the </font><font style="font-family:inherit;font-size:10pt;">$409.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of total payments related to the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; under the Base Contract. The </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back payment would be triggered by FDA approval of TPOXX&#174;, provided that the Company no longer has the Replacement Obligation to BARDA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the Base Contract, the BARDA Contract also includes remaining options that, if all were exercised by BARDA, would result in aggregate payments to the Company of </font><font style="font-family:inherit;font-size:10pt;">$122.7 million</font><font style="font-family:inherit;font-size:10pt;">, including: a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment to the Company in the event of FDA approval for extension to </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174; (from </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry as required in the Base Contract); up to </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of funding for development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX&#174;; and/or </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of funding for production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA, in its sole discretion, may choose not to exercise unexercised options. However, BARDA has indicated that it will evaluate, after the FDA&#8217;s review and evaluation of stability data, the Company's request that BARDA exercise the option for the </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment to the Company in the event of FDA approval of </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BARDA Contract expires in September 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in Note 2, cash inflows related to delivery of courses are recorded as deferred revenue due to the constraint on the consideration received. As of March 31, 2018, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$375.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of deferred revenue in connection with the BARDA contract (of which </font><font style="font-family:inherit;font-size:10pt;">$368.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;relates to the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; and the remainder relates to supportive activities). Deferred revenue under the BARDA Contract is classified as a long-term liability since there can be no assurance that the Replacement Obligation under the BARDA contract will be reasonably satisfied within twelve months. In addition, direct costs incurred by the Company to fulfill the delivery of courses, including the supplementing of courses previously delivered under the BARDA Contract, are being deferred and will be recognized as expenses in the period of the FDA&#8217;s approval of the final version of TPOXX&#174; (quantification and specification of the Replacement Obligation) has occurred. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, deferred direct costs under the BARDA Contract of approximately </font><font style="font-family:inherit;font-size:10pt;">$94.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$96.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, are included in deferred costs on the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Agreements and Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has an R&amp;D program for the intravenous (IV) formulation of TPOXX&#174;. This program is funded by a development contract with BARDA ("IV Formulation R&amp;D Contract"). This contract has a period of performance that terminates on December 30, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracts and grants include, among other things, options that may or may not be exercised at BARDA&#8217;s discretion. Moreover, contracts and grants contain customary terms and conditions including BARDA&#8217;s right to terminate or restructure a contract or grant for convenience at any time. As such, we may not be able to utilize all available funds.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s14B5A50EADEB22B102E275DCE7902ADB"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the deferral of revenue under the BARDA Contract (see </font><a style="font-family:inherit;font-size:10pt;" href="#sC3A91219B5B7B433F4C575DCE76C7E28"><font style="font-family:inherit;font-size:10pt;">Note 2</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for additional information), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs on the condensed consolidated balance sheet. Inventory includes costs related to the manufacture of TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, research and development expenses included net inventory-related losses of approximately</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$536,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">. The</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$536,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">loss for the three months ended</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, related to a</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$686,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">inventory write-down, partially offset by credits received from contract manufacturing organizations (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">CMOs</font><font style="font-family:inherit;font-size:10pt;">&#8221;)</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">in connection with the inventory write-down.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="sF842F9BE3F4A564639E475DCE799E1DE"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consisted of the following:&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less - accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,376,528</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,346,738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense on property, plant, and equipment was </font><font style="font-family:inherit;font-size:10pt;">$29,790</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$36,175</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div><a name="sF1FC6AF42E785779D13875DCE7A94045"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,494</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,538,340</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue-R&amp;D for TPOXX</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#160;intravenous formulation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405,096</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,980</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vacation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,755</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (primarily R&amp;D vendors and CMOs) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">977,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,586,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,481,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s5D048EEA20CF789A615B75DCE7B0EADE"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Warrant</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, in connection with the entry into the Loan Agreement (see </font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;">&#32;for additional information), the Company issued a warrant (the </font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">Warrant</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) to the Lender to purchase a number of shares of the Company&#8217;s common stock equal to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;divided by the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$2.29</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and (ii) the subscription price paid in connection with the Rights Offering. The Warrant provides for weighted average anti-dilution protection and is exercisable in whole or in part for ten (</font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">) years from the date of issuance. The subscription price paid was </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with the Rights Offering; accordingly, the exercise price of the Warrant was set at </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reported the change in fair value in the statement of operations. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the issuance date of the Warrant, the fair value of the liability classified Warrant was </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company applied a Monte Carlo Simulation-model to calculate the fair value of the liability classified Warrant using the following assumptions: risk free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.60%</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend yield; an expected life of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">&#32;years; and a volatility factor of </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">. The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation as of December 31, 2016. These models generated substantially equal fair values for the Warrant. As such, the Company utilized a Black-Scholes model for </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;to determine the fair value of the Warrant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Warrant was </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the liability classified Warrant was calculated using the following assumptions: risk free interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.72%</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend yield; an expected life of </font><font style="font-family:inherit;font-size:10pt;">8.42</font><font style="font-family:inherit;font-size:10pt;">&#32;years; and a volatility factor of </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded losses of </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as a result of the change in fair value of the liability classified Warrant.</font></div><div><a name="sC86DE93E1758717E99EE75DCE80F8DE9"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Debt</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the &#8220;Loan Agreement&#8221;) with OCM Strategic Credit SIGTEC Holdings, LLC (&#8220;Lender&#8221;), pursuant to which the Company received </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(less fees and other items) on November 16, 2016 having satisfied certain pre-conditions. Such </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;had been placed in an escrow account on September 30, 2016 (the &#8220;Escrow Funding Date&#8221;). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering (see </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;">) on November 16, 2016. As part of the satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the &#8220;Escrow Release Date&#8221;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Term Loan&#8221;), of which (i) </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was placed in a reserve account (the &#8220;Reserve Account&#8221;) only to be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was also placed in the Reserve Account and up to the full amount of such </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is due and owing and any of such </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;remains in the Reserve Account; and (iii) </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final payment to satisfy the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus</font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustments as set forth in the Loan Agreement. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the effective interest rate on the Term Loan, which includes interest payments and accretion of unamortized costs and fees, was </font><font style="font-family:inherit;font-size:10pt;">18.96%</font><font style="font-family:inherit;font-size:10pt;">. The Company incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of interest expense during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid from restricted cash and the remaining </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;accreted to the Term Loan balance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Term Loan shall mature on the earliest to occur of (i) the four-year anniversary of the Escrow Release Date, and (ii) the acceleration of certain obligations pursuant to the Loan Agreement. At maturity, </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of principal will be repaid, and an additional </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will be paid (see below). Prior to maturity, there are no scheduled principal payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the three and one-half year anniversary of the Escrow Release Date, any prepayment of the Term Loan is subject to a make-whole provision in which interest payments related to the prepaid amount are due (subject to a discount of treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Term Loan, the Company has granted the Lender a lien on and security interest in all of the Company&#8217;s right, title and interest in substantially all of the Company&#8217;s tangible and intangible assets, including all intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. These covenants, among other things, require a minimum cash balance throughout the term of the Term Loan and the achievement of regulatory milestones by certain dates, and contain certain limitations on the ability of the Company to incur unreimbursed research and development expenditures over a certain threshold, make capital expenditures over a certain threshold, incur indebtedness, dispose of assets outside of the ordinary course of business and enter into certain merger or consolidation transactions. The aforementioned minimum cash requirement is </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for 2018 until the earlier of (i) December 31, 2018 or (ii) </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">&#32;days after FDA approval of TPOXX&#174;; thereafter, the minimum cash requirement will be </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) the material inaccuracy of representations or warranties made thereunder, (iii) non-compliance with covenants thereunder, (iv) non-payment of amounts due under, or the acceleration of, other material indebtedness of the Company and (v) bankruptcy or insolvency events. Upon the occurrence and during the continuance of an event of default under the Loan Agreement, the interest rate may increase by </font><font style="font-family:inherit;font-size:10pt;">2.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum above the rate of interest otherwise in effect, and the Lenders would be entitled to accelerate the maturity of the Company&#8217;s outstanding obligations thereunder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is in compliance with the Loan Agreement covenants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Loan Agreement, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs (including interest on amounts held in the escrow account between September 30, 2016 and November 15, 2016). Furthermore, an additional </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will become payable when principal of the Term Loan is repaid. As part of the Company's entry into the Loan Agreement, the Company issued the Warrant (see Note 7) with a fair market value of </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Warrant, as well as costs related to the Term Loan issuance, were recorded as deductions to the Term Loan balance on the Balance Sheet. These amounts are being amortized using the effective interest method over the life of the related Term Loan. The </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that will be paid when principal is repaid is being accreted to the Term Loan balance each quarter on a per diem basis. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Term Loan balance is </font><font style="font-family:inherit;font-size:10pt;">$72.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sDA5F14B8733F3B1185B975DCE87DB0A1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as a liability are recorded at their fair market value as of each reporting period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Quoted prices for identical instruments in active markets.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Instruments where significant value drivers are unobservable to third parties.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of certain common stock warrants on a recurring basis and classify such liability classified warrants in Level 3. As described in </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;">, the fair value of the liability classified warrant was </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the debt was </font><font style="font-family:inherit;font-size:10pt;">$74.9 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and the carrying value of the debt was </font><font style="font-family:inherit;font-size:10pt;">$72.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement.&#160; The fair value of the loan was measured using level 3 inputs.&#160; The discount rate was determined using market participant assumptions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no transfers between levels of the fair value hierarchy for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">. In addition, there were no Level 1 or Level 2 financial instruments as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements of Level 3 liability classified warrant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,466,162</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,303,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,769,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="sB8DFE517545CC9B1EE2D75DCE8976A50"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Per Share Data</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred losses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and as a result, the equity instruments listed below are excluded from the calculation of diluted earnings (loss) per share as the effect of the exercise, conversion or vesting of such instruments would be anti-dilutive. The weighted average number of equity instruments excluded consists of:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:66%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,062,467</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709,967</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-Settled Stock Appreciation Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,393</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,031</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472,001</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,307,464</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Includes </font><font style="font-family:inherit;font-size:8pt;">294,118</font><font style="font-family:inherit;font-size:8pt;">&#32;restricted stock units that have vested but have not converted into common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.</font></div><div><a name="s7C9CE2982117526A5FEF75DCE8C4D6E0"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.</font></div><div><a name="s8A10193F0ECD92EAFF2F75DCE8D8A96E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Board of Directors and Outside Counsel</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A member of the Company&#8217;s Board of Directors is a member of the Company&#8217;s outside counsel. During the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred expenses of </font><font style="font-family:inherit;font-size:10pt;">$107,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$78,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to services provided by the outside counsel. On </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company&#8217;s outstanding payables and accrued expenses included a </font><font style="font-family:inherit;font-size:10pt;">$37,000</font><font style="font-family:inherit;font-size:10pt;">&#32;liability to the outside counsel.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 26, 2017 the Company and MacAndrews &amp; Forbes Incorporated (&#8220;M&amp;F&#8221;) entered into a ten-year Office Lease agreement (the &#8220;New HQ Lease&#8221;), pursuant to which the Company agreed to lease </font><font style="font-family:inherit;font-size:10pt;">3,200</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet at 27 East 62</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">nd</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Street, New York, New York. The Company is utilizing premises leased under the New HQ Lease as its new corporate headquarters. The Company's rental obligations consist of a fixed rent of </font><font style="font-family:inherit;font-size:10pt;">$25,333</font><font style="font-family:inherit;font-size:10pt;">&#32;per month in the first sixty-three months of the term, subject to a rent abatement for the first six months of the term. From the first day of the sixty-fourth month of the term through the expiration or earlier termination of the lease, the Company's rental obligations consist of a fixed rent of </font><font style="font-family:inherit;font-size:10pt;">29,333</font><font style="font-family:inherit;font-size:10pt;">&#32;per month. In addition to the fixed rent, the Company will pay a facility fee in consideration of the landlord making available certain ancillary services, commencing on the first anniversary of entry into the lease. The facility fee will be </font><font style="font-family:inherit;font-size:10pt;">$3,333</font><font style="font-family:inherit;font-size:10pt;">&#32;per month for the second year of the term and increasing by </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;percent each year thereafter, to </font><font style="font-family:inherit;font-size:10pt;">$4,925</font><font style="font-family:inherit;font-size:10pt;">&#32;per month in the final year of the term. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 31, 2017, the Company and M&amp;F entered into a Termination of Sublease Agreement (the &#8220;Old HQ Sublease Termination Agreement&#8221;), pursuant to which the Company and M&amp;F agreed to terminate the sublease dated January 9, 2013 for </font><font style="font-family:inherit;font-size:10pt;">6,676</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of rental square footage located at 660 Madison Avenue, Suite 1700, New York, New York (such sublease being the &#8220;Old HQ Sublease&#8221; and the location being the &#8220;Old HQ&#8221;). Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&amp;F and a new subtenant (the &#8220;Replacement M&amp;F Sublease&#8221;), which occurred on August 2, 2017. The Old HQ Sublease Termination Agreement obligates the Company to pay, on a monthly basis, an amount equal to the discrepancy (the &#8220;Rent Discrepancy&#8221;) between the sum of certain operating expenses and taxes (&#8220;Additional Rent&#8221;) and fixed rent under the overlease between M&amp;F and the landlord at 660 Madison Avenue and the sum of Additional Rent and fixed rent under the Replacement M&amp;F Sublease. Under the Old HQ Sublease Termination Agreement, the Company and M&amp;F release each other from any liability under the Old HQ Sublease. For the time period between August 2, 2017 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and August 31, 2020 (the expiration date of the Old HQ Sublease), the Company estimates that it will pay a total of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in Rent Discrepancy under the Old HQ Sublease Termination Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the above-mentioned transactions, the Company has discontinued usage of Old HQ in the third quarter of 2017. As such, during the year ended December 31, 2017 the Company recorded a loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in accordance with Accounting Standards Codification (</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">ASC</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) 420, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exit or Disposal Obligations</font><font style="font-family:inherit;font-size:10pt;">. This loss primarily represented the discounted value of estimated Rent Discrepancy payments to occur in the future, and included costs related to the termination of the old HQ Sublease. The Company also wrote-off approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of leasehold improvements and furniture and fixtures related to the Old HQ. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity relating to the liability that was recorded as a result of the lease termination:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Termination liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814,622</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges (included in selling, general and administrative expenses) </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments, net of sublease income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78,153</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the lease termination liability is included in Other liabilities on the Condensed Consolidated Balance sheet with the remainder included in accrued expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5E043DC140B5F295DB4875DCE94ECBC5"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#32;requires that a valuation allowance be established when it is </font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">more likely than not</font><font style="font-family:inherit;font-size:12pt;">&#8221; </font><font style="font-family:inherit;font-size:10pt;">that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the company's performance, the market environment in which the company operates, the utilization of past tax credits, length of carryback and carryforward periods, existing contracts, and unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels in the future years. Based on the available evidence, the Company continues to conclude that its deferred tax assets are not realizable on a more-likely-than-not basis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 118, which provides guidance on accounting for the tax effects of the 2017 Tax Cuts and Jobs Act ("TCJA"). The purpose of SAB No. 118 was to address any uncertainty or diversity of view in applying&#160;ASC Topic 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;in the reporting period in which the TCJA was enacted. SAB No. 118 addresses situations where the accounting is incomplete for certain income tax effects of the TCJA upon issuance of a company&#8217;s financial statements for the reporting period that includes the enactment date. SAB No. 118 allows for a provisional amount to be recorded if it is a reasonable estimate of the impact of the TCJA. Additionally, SAB No. 118 allows for a measurement period to finalize the impacts of the TCJA, not to extend beyond one year from the date of enactment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company&#8217;s accounting for certain elements of the TCJA was incomplete as of the period ended December 31, 2017, and remains incomplete as of March 31, 2018. However, the Company was able to make reasonable estimates of the effect of the TCJA and, therefore, recorded provisional estimates for these items. The final impact of the TCJA may differ from the provisional amounts that have been recognized, due to, among other things, legislative or administrative actions to clarify the intent of the statutory language as well as any changes in accounting standards for income taxes or related interpretations in response to the TCJA. Additionally, the Company's U.S. tax return for 2017 will be filed during the second or third quarter of 2018 and any changes to the tax positions for temporary differences compared to the estimates used may result in an adjustment of the estimated tax benefit recorded as of December 31, 2017.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$2,352</font><font style="font-family:inherit;font-size:10pt;">&#32;on a pre-tax loss of </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">. The effective tax rate differs from the statutory rate as no income tax benefit was recorded for current year operating losses due to the Company&#8217;s assessment regarding tax realizability of its deferred tax assets</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="sD9B536ADCA835769CD5275DCFFD40BCA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion should be read in conjunction with our consolidated financial statements and notes to those statements and other financial information appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, the following discussion and other parts of this Quarterly Report contain forward-looking information that involves risks and uncertainties</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX&#174;, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A new drug application (&#8220;NDA&#8221;) for TPOXX&#174; was submitted by the Company to the United States Food &amp; Drug Administration (&#8220;FDA&#8221;) in December 2017. In February 2018, the Company received notice that the FDA granted priority review of the NDA and that the FDA's target final action date is August 8, 2018. While TPOXX&#174; is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that has been delivered to the U.S. Strategic National Stockpile (&#8220;Strategic Stockpile&#8221;) under the Project BioShield Act of 2004 (&#8220;Project BioShield&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lead Product-TPOXX&#174;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) pursuant to which SIGA agreed to deliver two million courses of TPOXX&#174; to the Strategic Stockpile. The contract with BARDA (as amended, modified, or supplemented from time to time the &#8220;BARDA Contract&#8221;) includes a base contract (&#8220;Base Contract&#8221;) as well as options. The Base Contract contemplates approximately </font><font style="font-family:inherit;font-size:10pt;">$472.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of payments, of which </font><font style="font-family:inherit;font-size:10pt;">$409.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is consideration for the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; and </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is available for certain reimbursements in connection with development and supportive activities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Base Contract, BARDA agreed to buy from the Company </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174;. Additionally, the Company agreed to contribute to BARDA </font><font style="font-family:inherit;font-size:10pt;">300,000</font><font style="font-family:inherit;font-size:10pt;">&#32;courses at no additional cost to BARDA. The delivery of </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;courses of TPOXX&#174; to the Strategic Stockpile is a requirement in order for the Company to be eligible to receive a </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back payment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the Base Contract, the BARDA Contract also contains various remaining options that, if exercised by BARDA: would result in a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment to us in the event of FDA approval for extension to </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174; (from </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry as required in the Base Contract); up to </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of funding for development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX&#174;; and/or </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of funding for production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA may choose in its sole discretion not to exercise any or all of the unexercised options. BARDA has indicated that it will evaluate, after the FDA's review and evaluation of stability data, our request that BARDA exercise the option for the </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment to us in the event of FDA approval of </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BARDA Contract expires in September 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For courses of TPOXX&#174; that are physically delivered to the Strategic Stockpile, we have a replacement obligation (&#8220;Replacement Obligation&#8221;), in the event that the final version of TPOXX&#174; approved by the FDA is different from any course of TPOXX&#174; that has been delivered to the Strategic Stockpile or if TPOXX&#174; does not meet any specific label claims, fails release testing or does not meet the </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX&#174; is recalled or deemed to be recalled for any reason.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. We are not entitled to receive additional procurement-related payments under the current BARDA Contract (</font><a style="font-family:inherit;font-size:10pt;" href="#s7E5C538EFD7E1A43B3DD75DCE76FACC5"><font style="font-family:inherit;font-size:10pt;">Note 3</font></a><font style="font-family:inherit;font-size:10pt;">&#32;to the condensed consolidated financial statements) if and until FDA approval of TPOXX&#174; has been achieved and there is no difference between </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the approved product and courses of TPOXX&#174; that have been delivered to the Strategic Stockpile. Upon meeting the aforementioned requirements, a determination of which is expected in the third quarter of 2018, we will be entitled to a </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;hold back payment under the BARDA Contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that we do not receive a substantial portion of the hold back payment, or other substantial cash inflows, by October of 2018, then, based on currently forecasted operating costs, we will require additional sources of funding to continue operations and prevent an event of default under the Term Loan Agreement (</font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;">&#32;to the condensed consolidated financial statements). In this case, we would seek to increase cash liquidity by: raising proceeds through a financing, entering into a new contract for TPOXX&#174; or any other product, a sale of assets, or modification of the existing BARDA Contract; significantly reducing operating expenses; or modifying the terms of the Term Loan Agreement. There can be no assurance that TPOXX&#174; will receive FDA approval on a timely basis, if at all, or that there will be no difference between the approved product and courses of TPOXX&#174; that have been delivered to the Strategic Stockpile. Furthermore, there can be no assurance that we would be able to increase cash liquidity, if needed, through a financing, a new contract for TPOXX&#174; or any other product, a sale of assets, the modification of the existing BARDA Contract, or a significant reduction of operating expenses or operations, or that the lenders would agree to modify the Term Loan Agreement, if needed. Because of these conditions, substantial doubt exists about our ability to continue as a going concern within one year after the financial statement issuance date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Estimates </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The methods, estimates and judgments we use in applying our accounting policies have a significant impact on the results we report in our consolidated financial statements, which we discuss under the heading &#8220;Results of Operations&#8221; following this section of our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Information regarding our critical accounting policies and estimates appear in Item 7, Management; Discussion of Analysis and of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2017 as filed on March 6, 2018. During the three months ended March 31, 2018 the only change to our Critical Accounting Policies was with respect to revenue recognition, which is discussed below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our revenue is derived from long-term contracts that can span multiple years. We account for revenue in accordance with ASC Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;ASC 606&#8221;).&#160;The unit of account in ASC 606 is a performance obligation.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;Our performance obligations are satisfied over time as work progresses or at a point in time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantially all of our revenue associated with research and development performance obligations is recognized over time. Because control transfers over time with these performance obligations, revenue is recognized based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We generally use the cost-to-cost measure of progress for performance obligations connected with research and development activities because it best depicts the transfer of control to the customer, which occurs as we incur costs under our contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs to fully satisfy the performance obligation. Contract costs include labor, material, overhead and third-party services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under the BARDA Contract (see Note 3 to the consolidated financial statements) connected with courses of TPOXX&#174; that are manufactured and delivered to the Strategic Stockpile and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time. Revenue associated with this performance obligation will be recognized&#160;when BARDA obtains control of the asset, which will be upon delivery to and acceptance by the customer and at the point in time when the constraint on the consideration is reasonably resolved. The consideration, which is variable, is expected to be constrained until the FDA&#8217;s approval of the final version of TPOXX&#174; (quantification and specification of the Replacement Obligation) has occurred. It is expected that the possibility of product replacement, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&#8217;s regulatory review of the new drug application (NDA) for TPOXX&#174;.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the nature of the work required to be performed on many of our performance obligations, the estimation of total revenue and costs to satisfy the obligations is complex, subject to many variables and requires significant judgment. The consideration associated with these types of performance obligations is considered variable. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur and when any uncertainty associated with variable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our historical and anticipated performance, external factors, trends and all other information (historical, current and forecasted) that is reasonably available to us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracts are often modified to account for additional services to be performed. We consider contract modifications to exist when the modification either creates new enforceable rights and obligations, or changes existing enforceable rights and obligations. The effect of a contract modification on the transaction price and our measure of progress for the performance obligation to which it relates, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a process in which management reviews the progress and execution of our performance obligations. As part of this process, management reviews information including, but not limited to, any outstanding key contract matters, progress towards completion and the related program schedule, identified risks and opportunities and the related changes in estimates of revenues and costs. The risks and opportunities include management&#8217;s judgment about the ability and cost to achieve the schedule, technical requirements and other contract requirements. Management must make assumptions and estimates regarding labor productivity, the complexity of the work to be performed, customer behavior and execution by our subcontractors, among other variables.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on this analysis, any quarterly adjustments to revenues, research and development expenses and cost of sales are recognized as necessary in the period they become known. Changes in estimates of revenues, research and development expenses and cost of sales are recognized quarterly on a cumulative catch-up basis, which recognizes in the current period the cumulative effect of the changes on current and prior periods based on a performance obligation&#8217;s percentage of completion.&#160;A significant change in one or more of these estimates could affect the profitability of one or more of our performance obligations. </font></div><div><a name="s8C1235DFCBD08A9FE5C675DD0008D4AD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from research and development contracts for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, were </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The decrease in revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">66.4%</font><font style="font-family:inherit;font-size:10pt;">, primarily reflects a decrease in revenues from our federal contracts supporting the development of TPOXX&#174;. Revenues from federal contracts supporting the development of TPOXX&#174; have decreased because the number and scale of studies that were active during the quarter have decreased in comparison to the prior year activity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, General and Administrative (&#8220;SG&amp;A&#8221;) expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, were </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, reflecting an increase of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. The increase is primarily attributable to the application fee associated with listing our stock on The Nasdaq Global Market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and Development (&#8220;R&amp;D&#8221;) expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, reflecting a decrease of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">(52.7)%</font><font style="font-family:inherit;font-size:10pt;">. The decrease is attributable to a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;decrease in direct vendor-related expenses supporting the development of TPOXX&#174; (number and scale of active studies decreased) as well as a decrease in inventory write-down expenses; for the three months ended March 31, 2017, the Company incurred a net expense of $536,000 in connection with an inventory write-down. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$218,472</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$240,597</font><font style="font-family:inherit;font-size:10pt;">, respectively. These expenses reflect our ongoing efforts to protect our lead drug candidates in various geographic territories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The $3.7 million of interest for the three months ended March 31, 2018 includes: $2.6 million of cash payments from restricted cash and $1.1 million of accretion of unamortized costs and fees related to the Term Loan balance. The $3.6 million of interest for the three months ended March 31, 2017 included $2.5 million of cash payments from restricted cash and $1.1 million of accretion of unamortized costs and fees related to the Term Loan balance. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the fair value of liability classified warrants to acquire common stock were recorded within the income statement. For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we recorded a loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, reflecting an increase in fair value of liability classified warrants primarily due to the increase in our stock price. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we incurred pre-tax losses of </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and a corresponding income tax benefit/(expense) of </font><font style="font-family:inherit;font-size:10pt;">$2,352</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$(115,070)</font><font style="font-family:inherit;font-size:10pt;">, respectively. The effective tax rate during the </font><font style="font-family:inherit;font-size:10pt;">three months </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">0.02%</font><font style="font-family:inherit;font-size:10pt;">. Our effective tax rate for the period ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;differs from the statutory rate as no income tax benefit was recorded for current year operating losses due to the Company&#8217;s assessment regarding tax realizability of its deferred tax assets.</font></div><div><a name="sF3F92A49BFEC1FEAB96775DCE96544CA"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in unrestricted cash and cash equivalents compared with </font><font style="font-family:inherit;font-size:10pt;">$19.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at December&#160;31, 2017. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of restricted cash. The restricted cash is utilized to pay interest on the Term Loan as it becomes due and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the restricted cash may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See </font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;">&#32;to the condensed consolidated financial statements for additional information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. We are not entitled to receive additional procurement-related payments under the current BARDA Contract</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><a style="font-family:inherit;font-size:10pt;" href="#s7E5C538EFD7E1A43B3DD75DCE76FACC5"><font style="font-family:inherit;font-size:10pt;">Note 3</font></a><font style="font-family:inherit;font-size:10pt;color:#222222;">&#32;to the condensed consolidated financial statements) if and until FDA approval of the oral formulation of TPOXX&#174; has been achieved and there is no difference between the approved product and courses of TPOXX&#174; that have been delivered to the Strategic Stockpile. Upon meeting the aforementioned requirements, a determination of which is currently expected in the third quarter of 2018, we will be entitled to a $41 million hold back payment under the BARDA Contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$8.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. &#160;For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, cash usage was primarily due to $6.8 million of cash operating expenses (net loss adjusted for non-cash items noted in the cash flow statement such as non-cash interest expense and the change in fair value of our warrants). For the&#160;</font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we received </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from BARDA for product delivery, which was offset by recurring operating costs and $1.3 million of payments to contract manufacturing organizations for the manufacture and related support of TPOXX&#174;.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company had no cash flow associated with investing activities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was no financing-related cash flow activity for the three months ended March 31, 2018. Net cash used by financing activities for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, which consisted of cash used to repurchase common stock in order to meet minimum statutory tax withholding requirements in respect of restricted shares issued to employees. </font></div><div><a name="s2AFAE467CCA5BDB3A16075DD005B9F0D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not have any off-balance sheet arrangements, other than its leases.</font></div><div><a name="s86AE52D4EBFC85D38DF975DD007C9818"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">For discussion regarding the impact of accounting standards that were recently issued but not yet effective, on the Company's condensed consolidated financial statements, see </font><a style="font-family:inherit;font-size:10pt;" href="#sC3A91219B5B7B433F4C575DCE76C7E28"><font style="font-family:inherit;font-size:10pt;">Note 2</font></a><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Recently Issues Accounting Standards,</font><font style="font-family:inherit;font-size:10pt;">&#32;of Notes to Condensed Consolidated Financial Statements.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div><a name="s6877C46431ECBEDD29A575DD00AD8069"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor Statement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain statements in this Quarterly Report on Form 10-Q, including certain statements contained in &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the progress of SIGA&#8217;s development programs and timelines for bringing products to market and the enforceability of the BARDA Contract. The words or phrases &#8220;can be,&#8221; &#8220;expects,&#8221; &#8220;may affect,&#8221; &#8220;may depend,&#8221; &#8220;believes,&#8221; &#8220;estimate,&#8221; &#8220;project&#8221; and similar words and phrases are intended to identify such forward-looking statements. Such forward-looking statements are subject to various known and unknown risks and uncertainties and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA&#8217;s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA&#8217;s control, including, but not limited to, (i) the risk that potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) the risk that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, including from anticipated governmental contracts and grants (iv) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (v) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (vi) the risk that any challenge to SIGA&#8217;s patent and other property rights, if adversely determined, could affect SIGA&#8217;s business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to SIGA&#8217;s products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that one or more protests could be filed and upheld in whole or in part or other governmental action taken, in either case leading to a delay of performance under the BARDA Contract or other governmental contracts, (ix) the risk that the BARDA Contract is modified or canceled at the request or requirement of the U.S. government, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA&#8217;s efforts to develop or market its products, (xi) the risk that changes in domestic and foreign economic and market conditions may affect SIGA&#8217;s ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA&#8217;s businesses, (xiii) the risk that the U.S. government&#8217;s responses (including inaction) to the national and global economic situation may affect SIGA&#8217;s business adversely, (xiv) the risk that SIGA&#8217;s internal controls will not be effective in detecting or preventing a misstatement in SIGA&#8217;s financial statements, and (xv) the risk that some amounts recorded as deferred revenue ultimately may not be recognized as revenue when received. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in the presentation, is set forth in SIGA's filings with the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q and SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's Web site at </font><a style="font-family:inherit;font-size:10pt;" href="#"><font style="font-family:inherit;font-size:10pt;">http://www.sec.gov</font></a><font style="font-family:inherit;font-size:10pt;">. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.</font></div><div><a name="sA742C0D47F479FF72D4D75DD00D097FC"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our investment portfolio includes cash and cash equivalents. Our main investment objectives are the preservation of investment capital and the maximization of after-tax returns on our investment portfolio. We believe that our investment policy is conservative, both in the duration of our investments and the credit quality of the investments we hold. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. As such, we believe that, the securities we hold are subject to market risk, changes in the financial standing of the issuer of such securities and our interest income is sensitive to changes in the general level of U.S. interest rates. Additionally, we are also subject to the risk of rising LIBOR rates; whenever the minimum rates for one-month, two-month, three-month and six-month LIBOR rates (&#8220;minimum LIBOR rate&#8221;) are above 1%, then the interest rate charged on the Term Loan could increase materially depending on the magnitude of any increase in LIBOR rates. For every increase of </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;in the minimum LIBOR rate (e.g. an increase from a LIBOR rate of </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">), annual interest payments on the Term Loan would increase by approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. Furthermore, we are subject to the impact of stock price fluctuations of our common stock in that we have a liability classified warrant in which </font><font style="font-family:inherit;font-size:10pt;">2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of SIGA common stock can be purchased at a strike price of </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">. For every </font><font style="font-family:inherit;font-size:10pt;">$1</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the stock price of SIGA, the intrinsic value of the liability classified warrant will increase by approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s62C71A6CB0E8972A1EC175DD01025632"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The term &#8220;disclosure controls and procedures&#8221; is defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934. Management recognizes that any disclosure controls and procedures no matter how well designed and operated, can only provide reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;at a reasonable level of assurance.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s96C8DDAB9B9FF1E7F86B75DD01225702"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7CE751EC92D58F40C3CD75DCFBEDC4F0"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II-OTHER INFORMATION</font></div><div><a name="s9165FA3C03E002709CD175DCE9663AA6"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.</font></div><div><a name="s7435B2929FEE551221AE75DD01763DC1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations and financial conditions are subject to numerous risks and uncertainties described in our </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s70CF54828E9F7DCF030A75DD01A93315"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sale of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s62375C887678D8EF765A75DD01CAE53E"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Defaults upon Senior Securities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s72C2884A29D40B9CDD7975DD01FC9177"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mine Safety Disclosures</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No disclosure is required pursuant to this item.</font></div><div><a name="sDA8940881FCE2DDF1BC275DD021D01C3"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Other Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No disclosure is required pursuant to this item.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="sD7C0EABB49C647815C3775DD024EB42B"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="siga-exhibit3112018q1.htm"><font style="font-family:inherit;font-size:10pt;">31.1</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="siga-exhibit3122018q1.htm"><font style="font-family:inherit;font-size:10pt;">31.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="siga-exhibit3212018q1.htm"><font style="font-family:inherit;font-size:10pt;">32.1</font></a></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="siga-exhibit3222018q1.htm"><font style="font-family:inherit;font-size:10pt;">32.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s672CC1120CC58F09FB1575DD0270732F"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:5%;"></td><td style="width:44%;"></td><td style="width:6%;"></td><td style="width:26%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SIGA TECHNOLOGIES, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 4, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Daniel J. Luckshire</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daniel J. Luckshire</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Accounting Officer)&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>siga-exhibit3112018q1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9B647902CA86111FEDD575DD03168175"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by Chief Executive Officer Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Phillip L. Gomez, Ph.D., certify that: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 4, 2018</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Phillip L. Gomez, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phillip L. Gomez, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>siga-exhibit3122018q1.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD229970D1B209AB7A14375DD050A4F31"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification by Chief Financial Officer Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Daniel J. Luckshire, certify that: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of SIGA Technologies, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 4, 2018</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Daniel J. Luckshire</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daniel J. Luckshire</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>siga-exhibit3212018q1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3386D9FD58A60A5B2D9875DD03BE3DF7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of SIGA Technologies, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Phillip L. Gomez, Ph. D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:67.7734375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Phillip L. Gomez, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phillip L. Gomez, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 4, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>siga-exhibit3222018q1.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDEB3E0E5D76BE2B576B275DD04647847"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of SIGA Technologies, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Daniel J. Luckshire, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:67.7734375%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Daniel J. Luckshire</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daniel J. Luckshire</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 4, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>siga-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:915833f260434a13bc8439e54d9a40bc,x:df90017ddf0b4fa1a9fb90c050d71ee6-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:siga="http://www.siga.com/20180331" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="siga-20180331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Apr25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201618Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q3May13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-05-13</xbrli:startDate>
			<xbrli:endDate>2011-05-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q3May13_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-05-13</xbrli:startDate>
			<xbrli:endDate>2011-05-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2May2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-05-01</xbrli:startDate>
			<xbrli:endDate>2011-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-01-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-01-01</xbrli:startDate>
			<xbrli:endDate>2011-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2May2011_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-05-01</xbrli:startDate>
			<xbrli:endDate>2011-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:ProcurementContractAxis">siga:BardaContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sep2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-02</xbrli:startDate>
			<xbrli:endDate>2016-09-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_ClassOfWarrantOrRightAxis_siga_SubscriptionRightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">siga:SubscriptionRightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-02</xbrli:startDate>
			<xbrli:endDate>2016-09-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_siga_DebtInstrumentCapacitybySpecificPurposeAxis_siga_PaymentsRelatedtoLitigationMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:DebtInstrumentCapacitybySpecificPurposeAxis">siga:PaymentsRelatedtoLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_siga_DebtInstrumentCapacitybySpecificPurposeAxis_siga_RepaymentofInterestsMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:DebtInstrumentCapacitybySpecificPurposeAxis">siga:RepaymentofInterestsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_VariableRateAxis_siga_USTreasuryRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">siga:USTreasuryRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Sep2_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">siga:LoanAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongtermDebtTypeAxis_siga_SeniorSecuredTermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">siga:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_LongtermDebtTypeAxis_siga_SeniorSecuredTermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">siga:SeniorSecuredTermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May01-May31_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:OperatingLeaseNameAxis">siga:NewHQLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q1SD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-01-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:OperatingLeaseNameAxis">siga:NewHQLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-26</xbrli:startDate>
			<xbrli:endDate>2017-05-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_siga_OperatingLeaseNameAxis_siga_OldHQSubleaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:OperatingLeaseNameAxis">siga:OldHQSubleaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001010086</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="siga:OperatingLeaseNameAxis">siga:NewHQLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">siga:MacAndrewsForbesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="course">
		<xbrli:measure>siga:course</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Contract">
		<xbrli:measure>siga:contract</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2018Q1YTD" id="Fact-35B67AA2DF5EB2ED8BDF75DCE657A8F5">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q1YTD" id="Fact-43F56D2ABA29B49A4B2D75DCE64CF02D">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q1YTD" id="Fact-6BCC4C0D39D84598EB3075DCE658168F">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q1YTD" id="Fact-4ECE04EE4FAA60B4B56575DCE6553402">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q1YTD" id="Fact-841002B2889B31A158ED75DCE64CE561">2018-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q1YTD" id="Fact-465EF57B9BABD99F3A6975DCE6522880">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q1YTD" id="Fact-76A1E185A7FDBA76529575DCE6597C56">0001010086</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q2Apr25" decimals="INF" id="Fact-88F0171F0371C45C808275DCE65345F7" unitRef="shares">79052037</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2018Q1YTD" id="Fact-5F32E6CBBCF02D15AD0175DCE65D9140">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q1YTD" id="Fact-89FB43E7D63604C4794075DCE6C9BEBC">SIGA TECHNOLOGIES INC</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2018Q1YTD" id="Fact-3EBCC3E3D4EBFD9E59BE75DCE6579D08">SIGAQ</dei:TradingSymbol>
	<siga:AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry contextRef="D2011Q3May13" decimals="-5" id="Fact-B14B36E5AF4A3A95DE272A275FF5CD50" unitRef="usd">50000000</siga:AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry>
	<siga:ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable contextRef="D2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" id="Fact-12DFE178F6246EAEF1DF2EDDB434A95A">P10Y</siga:ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable>
	<siga:ComputerEquipment contextRef="FI2017Q4" decimals="0" id="Fact-20C3004CDA329F18A59275DCE68649AF" unitRef="usd">701762</siga:ComputerEquipment>
	<siga:ComputerEquipment contextRef="FI2018Q1" decimals="0" id="Fact-2DAE7B8027C07226204175DCE6A492E8" unitRef="usd">701762</siga:ComputerEquipment>
	<siga:ContractValueDetailOfOptionExercisableDevelopmentActivities contextRef="D2011Q3May13" decimals="-5" id="Fact-89E7ADDDEFC8FBE439A02A3057E7BEC4" unitRef="usd">58300000</siga:ContractValueDetailOfOptionExercisableDevelopmentActivities>
	<siga:ContractValueDetailOfOptionExercisableProductionActivities contextRef="D2011Q3May13" decimals="-5" id="Fact-F20EF925CA97268DD4AC2A334E3BB520" unitRef="usd">14400000</siga:ContractValueDetailOfOptionExercisableProductionActivities>
	<siga:ContractValueOfDevelopmentAndSupportActivities contextRef="D2011Q3May13" decimals="-5" id="Fact-2CDC70C12C1E266B0B0E29FD60023A18" unitRef="usd">62500000</siga:ContractValueOfDevelopmentAndSupportActivities>
	<siga:ContractValueOptionFDAApproval contextRef="D2011Q3May13" decimals="-5" id="Fact-FE3D1CCDB09D37AE39E52A342BDCD3DD" unitRef="usd">50000000</siga:ContractValueOptionFDAApproval>
	<siga:ContractValueofManufacturingandDeliveryActivities contextRef="D2011Q3May13" decimals="-5" id="Fact-3659A464C840A0D661F729F62A011D3B" unitRef="usd">409800000</siga:ContractValueofManufacturingandDeliveryActivities>
	<siga:ContractValueofManufacturingandDeliveryActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F2F11F7791182C783178C05A59665E1C" unitRef="usd">368900000</siga:ContractValueofManufacturingandDeliveryActivities>
	<siga:ContractValueofVariousOptions contextRef="D2011Q3May13" decimals="-5" id="Fact-3150ABD3E78C06C0666C2A23B08993B6" unitRef="usd">122700000</siga:ContractValueofVariousOptions>
	<siga:FacilityFeeAfterInitialPeriod contextRef="D2017Q2May01-May31_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="0" id="Fact-0AA237E02A8EAD03E8A02F31AC27D721" unitRef="usd">4925</siga:FacilityFeeAfterInitialPeriod>
	<siga:FacilityFeeAnnualIncreasePercent contextRef="D2017Q2May01-May31_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="INF" id="Fact-FB430C2BFE478C42A9002F30AC37A420" unitRef="number">0.05</siga:FacilityFeeAnnualIncreasePercent>
	<siga:GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract contextRef="D2011Q3May13" decimals="-5" id="Fact-296E51E90B5D4195955429F8A7D5CDBF" unitRef="Contract">1700000</siga:GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract>
	<siga:GovernmentContractNumberofFreeCourses contextRef="D2011Q3May13_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="0" id="Fact-372750F080588F25B6682A030D25745A" unitRef="course">300000</siga:GovernmentContractNumberofFreeCourses>
	<siga:GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered contextRef="D2011Q2May2011_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-163854274558F421A46F2A0053B113EC" unitRef="course">2000000</siga:GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered>
	<siga:GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered contextRef="FD2018Q1YTD_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-DF301F2FD242A834B9DB2A1D87CF18F9" unitRef="course">2000000</siga:GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered>
	<siga:GovernmentContractValueOfAward1 contextRef="D2011Q3May13" decimals="-5" id="Fact-3E35AB33E0F91211F25129E431E95D12" unitRef="usd">472300000</siga:GovernmentContractValueOfAward1>
	<siga:IncreaseInFairValueOfWarrants contextRef="FD2017Q1QTD" decimals="0" id="Fact-05ECD9AF60E74D6707F375DCE6C7DF94" unitRef="usd">626209</siga:IncreaseInFairValueOfWarrants>
	<siga:IncreaseInFairValueOfWarrants contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="-5" id="Fact-480F2CA388FEE03581AE2EEE7A915DC6" unitRef="usd">-600000</siga:IncreaseInFairValueOfWarrants>
	<siga:IncreaseInFairValueOfWarrants contextRef="FD2018Q1YTD" decimals="0" id="Fact-772461B88E9FACBFD3C775DCE637BA75" unitRef="usd">3303114</siga:IncreaseInFairValueOfWarrants>
	<siga:IncreaseInFairValueOfWarrants contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="-5" id="Fact-187BDF714C19FB38C09C2EEE24FD6BDB" unitRef="usd">3300000</siga:IncreaseInFairValueOfWarrants>
	<siga:InitialFacilityFee contextRef="D2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="INF" id="Fact-D22B4E47F3B021AD429E2F2D450050AA" unitRef="usd">3333</siga:InitialFacilityFee>
	<siga:InventoryWriteDowns contextRef="FD2018Q1YTD" decimals="0" id="Fact-3ED62A5260718AD80ED02ECC927ACC11" unitRef="usd">686000</siga:InventoryWriteDowns>
	<siga:LeaseTerminationLiability contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherLiabilitiesMember" decimals="-5" id="Fact-4A2FECBA381621C484DD2F4B8B98594E" unitRef="usd">400000</siga:LeaseTerminationLiability>
	<siga:LineofCreditFacilityAdditionalBorrowingCapacity contextRef="FI2018Q2_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-0F753BBE573FF2B3108B2EFDF3A8478C" unitRef="usd">5000000</siga:LineofCreditFacilityAdditionalBorrowingCapacity>
	<siga:LineofCreditFacilityDebtDefaultIncreaseinInterestRate contextRef="FD2018Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="4" id="Fact-BAE2B916103E082D068E2F09F286D8FB" unitRef="number">0.0200</siga:LineofCreditFacilityDebtDefaultIncreaseinInterestRate>
	<siga:LineofCreditFacilityMinimumCashRequirement contextRef="D2018Q1Jan1-Dec31_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-FA088D671D40BA01A0D72F082DF5774B" unitRef="usd">5000000</siga:LineofCreditFacilityMinimumCashRequirement>
	<siga:LineofCreditFacilityMinimumCashRequirement contextRef="FD2019Q4YTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="-5" id="Fact-B756555869D8D9E9A9F02F08F2815889" unitRef="usd">20000000</siga:LineofCreditFacilityMinimumCashRequirement>
	<siga:MilestonePayment contextRef="FD2012Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-F63E36CADC50FC501C6F2A1449BAD80C" unitRef="usd">12300000</siga:MilestonePayment>
	<siga:MilestonePayment contextRef="FD2013Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-EF75A6A28802017D05052A154E38CF08" unitRef="usd">8200000</siga:MilestonePayment>
	<siga:MilestonePayment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-43355E0FCE4BAF35814F2A62875A2C30" unitRef="usd">20500000</siga:MilestonePayment>
	<siga:MonthlyRentalPaymentsAfterInitialPeriod contextRef="D2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="0" id="Fact-733F9E533E12350DBCF72F2C7CD07215" unitRef="usd">29333</siga:MonthlyRentalPaymentsAfterInitialPeriod>
	<siga:MonthlyRentalPaymentsForInitialPeriod contextRef="D2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="0" id="Fact-4C585BBD2F35CA5DEBC62F2C1EEEAD61" unitRef="usd">25333</siga:MonthlyRentalPaymentsForInitialPeriod>
	<siga:NumberOfCoursesToBeDelivered1 contextRef="D2011Q2May2011" decimals="-5" id="Fact-40278A0220E51B575C0B29E1634905A9" unitRef="course">2000000</siga:NumberOfCoursesToBeDelivered1>
	<siga:PatentPreparationFees contextRef="FD2017Q1QTD" decimals="0" id="Fact-89B409B4CA1B696450F475DCE6C1FA9E" unitRef="usd">240597</siga:PatentPreparationFees>
	<siga:PatentPreparationFees contextRef="FD2018Q1YTD" decimals="0" id="Fact-E4967985BFEE376731E075DCE67BF152" unitRef="usd">218472</siga:PatentPreparationFees>
	<siga:ProceedsFromAdvancePaymentsGovernmentContracts contextRef="D2011Q4YTD" decimals="-6" id="Fact-9A777040E66A292FFC382A0F9C0C6533" unitRef="usd">41000000</siga:ProceedsFromAdvancePaymentsGovernmentContracts>
	<siga:ProceedsFromAdvancePaymentsGovernmentContracts contextRef="D2011Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-57BE75D44DD8EF895AB92A1320C978CF" unitRef="usd">41000000</siga:ProceedsFromAdvancePaymentsGovernmentContracts>
	<siga:ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts contextRef="FI2018Q1" decimals="-5" id="Fact-7E8D8497877D2B1E645429DE18F98E9C" unitRef="usd">368900000</siga:ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts>
	<siga:ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts contextRef="FD2013Q4YTD_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-5B9A1A21D60DA7D7FF262F86BEFA63FA" unitRef="usd">286900000</siga:ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts>
	<siga:Reducedholdbackamount contextRef="D2011Q3May13_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-6" id="Fact-91A6442D2F804C649C102A48DA661EDA" unitRef="usd">41000000</siga:Reducedholdbackamount>
	<siga:ResearchAndDevelopmentRevenue contextRef="FD2017Q1QTD" decimals="0" id="Fact-374654B9DDD1BA3917EC75DCE6AF059D" unitRef="usd">5201786</siga:ResearchAndDevelopmentRevenue>
	<siga:ResearchAndDevelopmentRevenue contextRef="FD2018Q1YTD" decimals="0" id="Fact-44B291766FD6CBB1A61E75DCE65DCE4A" unitRef="usd">1747934</siga:ResearchAndDevelopmentRevenue>
	<siga:RestrictedStockUnits contextRef="FD2018Q1YTD" decimals="INF" id="Fact-BF5717BF35940326970EE3A6EBB6C014" unitRef="shares">294118</siga:RestrictedStockUnits>
	<siga:StockIssuanceFeesExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-3FF9F891C2F559F7EA0F75DCE6319F5A" unitRef="usd">1108916</siga:StockIssuanceFeesExpense>
	<siga:StockIssuanceFeesExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-4BEDE87A5E48FB46FA5775DCE630E420" unitRef="usd">1108916</siga:StockIssuanceFeesExpense>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="0" id="Fact-93C33EC0F6CA7832E4AB75DCE65486D0" unitRef="usd">1328867</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q1" decimals="0" id="Fact-2419E6211D4A6167431875DCE667B4C9" unitRef="usd">432207</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="FI2018Q1_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember" decimals="0" id="Fact-18BAF1AD7419172B65AA2F25D7E1229E" unitRef="usd">37000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:AccountsReceivableNet contextRef="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-5" id="Fact-77E57B6876C3E5FC4A50F88ADEE93040" unitRef="usd">100000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="0" id="Fact-54662666BF578EFA724275DCE66E4547" unitRef="usd">1802107</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q1" decimals="0" id="Fact-12F51F8F34478F3ABE9775DCE64D5640" unitRef="usd">1263680</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedBonusesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-CD09A594153913FDD7F575DCE6A6D63D" unitRef="usd">2538340</us-gaap:AccruedBonusesCurrent>
	<us-gaap:AccruedBonusesCurrent contextRef="FI2018Q1" decimals="0" id="Fact-71008695415329D2B46175DCE635270A" unitRef="usd">454494</us-gaap:AccruedBonusesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-23465F02B6B383B8DB5175DCE671A091" unitRef="usd">5481579</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="0" id="Fact-FA456D34B6D552E4B93D75DCE675481F" unitRef="usd">3586195</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-EF1B065030D84E94BCA575DCE67C4681" unitRef="usd">381980</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q1" decimals="0" id="Fact-321C5B83B48CB02355BA75DCE6B40997" unitRef="usd">405096</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedVacationCurrent contextRef="FI2017Q4" decimals="0" id="Fact-F5ED4BEF632904DF0E8975DCE688DCCA" unitRef="usd">328588</us-gaap:AccruedVacationCurrent>
	<us-gaap:AccruedVacationCurrent contextRef="FI2018Q1" decimals="0" id="Fact-4A1F681087E9A7E350D175DCE63218CD" unitRef="usd">361755</us-gaap:AccruedVacationCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="0" id="Fact-444EF26AE0EB2D9E74F875DCE68994F0" unitRef="usd">3346738</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q1" decimals="0" id="Fact-1F3F84D9F5524DADE4A975DCE6952222" unitRef="usd">3376528</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="0" id="Fact-6BAA712D3B74C7C666F175DCE66D3769" unitRef="usd">214229581</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q1" decimals="0" id="Fact-35121D75A954370011F475DCE66D10C6" unitRef="usd">214556941</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2018Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-19289344762C6FC6352B2F044247CF33" unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-221133A51E0274558E7175DCE647F9F4" unitRef="shares">1709967</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-275AB4E812291EA677F175DCE6750559" unitRef="shares">1307464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="0" id="Fact-D6ABAB339A8FA331680675DCE64DE4C1" unitRef="shares">360031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-7F54791875D1D711446275DCE668CC54" unitRef="shares">2690950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-18DBB34FED8C4F7FA76E75DCE662C337" unitRef="shares">1062467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-3D09353A887887EFDAAE75DCE67A5D70" unitRef="shares">1472001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="0" id="Fact-5F14D82D829C4A32A32A75DCE6705271" unitRef="shares">162393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="Fact-AD3DC92BC1E7BEB3000075DCE656640D" unitRef="shares">2690950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2013Q1SD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="0" id="Fact-D6CDFDBE6F624277E55ABB29DEB7E9C9" unitRef="sqft">6676</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q2May26_siga_OperatingLeaseNameAxis_siga_NewHQLeaseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="0" id="Fact-B696A993AF714D699C3D2F2A93AFDFC2" unitRef="sqft">3200</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="0" id="Fact-A38DE07854645B7AF67B75DCE65BB3F4" unitRef="usd">144670379</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q1" decimals="0" id="Fact-D94EDD2275ADC5ABB3E775DCE65B6CB2" unitRef="usd">133135253</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="0" id="Fact-0C6CDCE38024A0CABBFD75DCE66064A9" unitRef="usd">37364493</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q1" decimals="0" id="Fact-DF60C1DA1EA4281B6CFA75DCE6632776" unitRef="usd">30932438</us-gaap:AssetsCurrent>
	<us-gaap:BusinessExitCosts1 contextRef="FD2018Q1YTD_siga_OperatingLeaseNameAxis_siga_OldHQSubleaseMember" decimals="-5" id="Fact-B1AC14B55F58B49E49F4BB2A88D49672" unitRef="usd">1100000</us-gaap:BusinessExitCosts1>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="0" id="Fact-272D6B5084C2A4389A592F777372383D" unitRef="usd">28701824</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="0" id="Fact-56D3C2148C44F2F4EF1D2F7773827CB9" unitRef="usd">30103574</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="0" id="Fact-DA05370B895E76E8A08B75DCE6791CBD" unitRef="usd">19857833</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="0" id="Fact-90644535BFC279409E1175DCE648E030" unitRef="usd">13934807</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="0" id="Fact-EF498CAFA5419B57B50A75DCE6B22F86" unitRef="usd">56174046</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q1" decimals="0" id="Fact-253ADD538B0E56A3F15575DCE636690F" unitRef="usd">55048018</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-17C6394E3D99A82589BE75DCE6B83209" unitRef="usd">37101586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q1" decimals="0" id="Fact-E165E0C84BED2A36AE6B75DCE634A1A9" unitRef="usd">28539883</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2017Q1QTD" decimals="0" id="Fact-3C30D492DFF428A1A57575DCE6AC0828" unitRef="usd">-1126028</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2018Q1YTD" decimals="0" id="Fact-6FD332DB58117854424375DCE6BE2D9C" unitRef="usd">-8561703</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Sep2" decimals="2" id="Fact-64753D97FEE0209561102EDBBBBE95AD" unitRef="usdPerShare">2.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="2" id="Fact-BC752AE0B3C2E50E0AA42ED688BCCC58" unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_us-gaap_ClassOfWarrantOrRightAxis_siga_SubscriptionRightMember" decimals="2" id="Fact-2A10B75CC6D8FD7B27EF2ED7384C3955" unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016Q3Sep2_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="-5" id="Fact-050144885B970CA2B2282ED1EE7678ED" unitRef="shares">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-15EFD69DD5984D1E9DC875DCE64EF682" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q1" id="Fact-E31FBD20C82FCE2C8B5875DCE65C1D9F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-F699B9006832A2D8F5FE75DCE62ACB4D" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-6A99E68B4E4FF8ECAD0775DCE630D945" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-7EE25668B5897E3F07EE75DCE6AF6EFC" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q1" decimals="INF" id="Fact-C3CAB8525AFD7AB119D675DCE68106FB" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-356EC4D7096E77257B2075DCE677981C" unitRef="shares">79039000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q1" decimals="INF" id="Fact-C1992CA58DE25757365475DCE672FE88" unitRef="shares">79039000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-55DE46EE72C7F89171E075DCE6ABEAFA" unitRef="shares">79039000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q1" decimals="INF" id="Fact-3D3AC1B58EF50FF7C77A75DCE6A822FD" unitRef="shares">79039000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="0" id="Fact-72449C1BA4C5912CBA2A75DCE665131D" unitRef="usd">7904</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q1" decimals="0" id="Fact-81C286FAE5BF62D65C9775DCE649BCC5" unitRef="usd">7904</us-gaap:CommonStockValue>
	<us-gaap:ContractWithCustomerLiability contextRef="FI2017Q4" decimals="0" id="Fact-999CD50233A05948C63502784F9E2F43" unitRef="usd">378896803</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiability contextRef="FI2018Q1" decimals="0" id="Fact-D1F339BA38C82AFE92FA027883CED8BD" unitRef="usd">377286022</us-gaap:ContractWithCustomerLiability>
	<us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="FD2018Q1YTD" decimals="0" id="Fact-4216D6D90ECF8343DDB702785A8817DE" unitRef="usd">-1780050</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
	<us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2018Q1YTD" decimals="0" id="Fact-802873FE7AAD872B59300278772DF917" unitRef="usd">169269</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="0" id="Fact-328B6F0C57426FE6481E75DCE6BD609E" unitRef="usd">-2352</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="FD2018Q1YTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_VariableRateAxis_siga_USTreasuryRateMember" decimals="4" id="Fact-2FBEE2A7BA856133A93E2F06A24E75AF" unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="FD2018Q1YTD_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="3" id="Fact-16592C904972AD97299A2F000CBA2131" unitRef="number">0.115</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFeeAmount contextRef="FI2018Q1_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-D1997E9EBBA39DF57DA72F05D14BC36A" unitRef="usd">4000000</us-gaap:DebtInstrumentFeeAmount>
	<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="FD2018Q1YTD_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="4" id="Fact-6E5B6B92FB38B79E45E52F01912A0438" unitRef="number">0.1896</us-gaap:DebtInstrumentInterestRateDuringPeriod>
	<us-gaap:DeferredCosts contextRef="FI2017Q4" decimals="0" id="Fact-B9D06923639E980D243975DCE6595B40" unitRef="usd">96592334</us-gaap:DeferredCosts>
	<us-gaap:DeferredCosts contextRef="FI2017Q4_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-91BC9F9626AE5F32CF1B2A3963B3612C" unitRef="usd">96500000</us-gaap:DeferredCosts>
	<us-gaap:DeferredCosts contextRef="FI2018Q1" decimals="0" id="Fact-26155761AA5AE9522F2B75DCE62C2464" unitRef="usd">94296804</us-gaap:DeferredCosts>
	<us-gaap:DeferredCosts contextRef="FI2018Q1_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-B92DBCED75F626E640242A382753D239" unitRef="usd">94300000</us-gaap:DeferredCosts>
	<us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-5" id="Fact-05ABEE6673A9E924E3C0F88A612A19F5" unitRef="usd">2100000</us-gaap:DeferredCostsCurrentAndNoncurrent>
	<us-gaap:DeferredFinanceCostsGross contextRef="I2016Q3Sep2_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-6E0BEF71FB51D7EDC7002F0A8D8B9F88" unitRef="usd">8200000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q1QTD" decimals="0" id="Fact-CD707BF8E87210D02148D8155951E03E" unitRef="usd">21190</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="0" id="Fact-F3565CDF880AF906B504D80A78626B86" unitRef="usd">-9758</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4" decimals="0" id="Fact-2DCC389C4804C5CFD770D3E25211DD34" unitRef="usd">1255318</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" decimals="-5" id="Fact-54C0669E1996050DF09DF88836D90542" unitRef="usd">1300000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2018Q1" decimals="0" id="Fact-512FEEDD854C1ACC4271D3E1BD3B7F54" unitRef="usd">1255318</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2018Q1_siga_ProcurementContractAxis_siga_BardaContractMember" decimals="-5" id="Fact-280B024804957D24F8252A3A7627EDB5" unitRef="usd">375500000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" decimals="-5" id="Fact-10276BA81D9D4A88498D0223F18A8415" unitRef="usd">1300000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="I2018Q1Jan01_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-5" id="Fact-43DCB8F11C80086B9955F889EF014ED4" unitRef="usd">1800000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4" decimals="0" id="Fact-39379BF2D13B5FCAC7C175DCE64E6728" unitRef="usd">377641485</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2018Q1" decimals="0" id="Fact-5C4A39069F91731DC0AF75DCE678752D" unitRef="usd">376030704</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2017Q4" decimals="0" id="Fact-8D399F28EE215FE7793C2F371C638487" unitRef="usd">2431963</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2018Q1" decimals="0" id="Fact-C4CC89F3A600C9954DCB2F37198E09F5" unitRef="usd">2441720</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1QTD" decimals="0" id="Fact-AC06695BC4CA6BF5D9AC75DCE633D67E" unitRef="usd">36175</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C8D2BEF43717B36A751B2F8B21D91AE7" unitRef="usd">36000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q1YTD" decimals="-3" id="Fact-2707755CD01A3CE295282F8AF7C67055" unitRef="usd">30000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q1YTD" decimals="0" id="Fact-5A019410ABF12C5526BB75DCE6A30FA8" unitRef="usd">29790</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-94F0100E16135178361475DCE660EBEB" unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q1YTD" decimals="2" id="Fact-7F4C95F4152AEB5A36BA75DCE67E552E" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="0" id="Fact-75056EDC39377DC64F4575DCE6BAD896" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="0" id="Fact-C4E096626F3E5998ACBF75DCE65D3435" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" id="Fact-744409591AB0E00670352EE612B86FFA">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2018Q1YTD_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember" id="Fact-9442B88F22B605F0A8C22EF24265C3A3">P8Y5M1D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="Fact-C4EE472B6B9012B0EFC92EE4BAB7F93B" unitRef="number">0.75</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-FDAB831FE10E787EE18E2EE10978D636" unitRef="number">0.0160</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="4" id="Fact-EDE0EB26D03462D6E53A2EEB81EFF8E1" unitRef="number">0.0272</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q1YTD" decimals="0" id="Fact-64C0B3F09CAA74E9CF4F2F92D78C3943" unitRef="usd">3303114</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4" decimals="0" id="Fact-35F184831C96A37BE1032F92D791957B" unitRef="usd">11466162</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q1" decimals="0" id="Fact-F39116C3648EBB0790F22F92D7861912" unitRef="usd">14769276</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2017Q4" decimals="0" id="Fact-CF6928424A97DFD81D4175DCE687DCB9" unitRef="usd">363588</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2018Q1" decimals="0" id="Fact-8D0A5DE81FB790351CCB75DCE691C5F7" unitRef="usd">363588</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="0" id="Fact-C3DE09A319786847F20475DCE64BA42A" unitRef="usd">898334</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q1" decimals="0" id="Fact-C8090C9E4F83BF13AAED75DCE65BBC63" unitRef="usd">898334</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="FD2018Q1YTD_siga_OperatingLeaseNameAxis_siga_OldHQSubleaseMember" decimals="-5" id="Fact-50A948F54F31E6709FFF2F49BB2749AF" unitRef="usd">100000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q1QTD" decimals="0" id="Fact-75B5B41C0CEDCD57796175DCE62B79DE" unitRef="usd">-8499876</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q1YTD" decimals="0" id="Fact-69062ACAE7B28686488275DCE6BCCCCE" unitRef="usd">-11584608</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1QTD" decimals="0" id="Fact-DA19A358328AF07CD12B75DCE67743E3" unitRef="usd">115070</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q1QTD" decimals="0" id="Fact-6AF40B2DC3F50F8C323B75DCE697841B" unitRef="usd">-1894379</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q1YTD" decimals="0" id="Fact-80EB0E5CEAD18DC6CE4575DCE6419104" unitRef="usd">-2792043</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q1QTD" decimals="0" id="Fact-3B5372CBB99997C7D75675DCE66FBB12" unitRef="usd">1724261</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q1YTD" decimals="0" id="Fact-0BDB46BBDDCA16A222D675DCE631FFB4" unitRef="usd">-645730</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2017Q1QTD" decimals="0" id="Fact-912E319A7C229BF04D8B75DCE63EE057" unitRef="usd">6389282</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredCharges contextRef="FD2018Q1YTD" decimals="0" id="Fact-1279619BD5AB1DB8588F75DCE66BAA86" unitRef="usd">-184864</us-gaap:IncreaseDecreaseInDeferredCharges>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q1QTD" decimals="0" id="Fact-3C8D8480044C0E7256AC75DCE6B71E2A" unitRef="usd">8719141</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2018Q1YTD" decimals="0" id="Fact-9B71BC6F14F9B1A104B075DCE63357FC" unitRef="usd">169269</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q1QTD" decimals="0" id="Fact-66B4980EABB087A781E375DCE6BEAD2C" unitRef="usd">-7090409</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q1YTD" decimals="0" id="Fact-51A9CAC91B422CCB14E775DCE6C4E76D" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q1QTD" decimals="0" id="Fact-F896DD645F8F8F328C0E75DCE6B85D82" unitRef="usd">-22165</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q1YTD" decimals="0" id="Fact-DE4FEA1BC136E798B49B75DCE6C03F7A" unitRef="usd">-66122</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-DB29E68B7B3ABCC58A9375DCE64B0583" unitRef="usd">-22423</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-78B70B85ACB9F212CE9075DCE6ABA437" unitRef="usd">-119433</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-7D7B21E06305A39E65A975DCE632F663" unitRef="usd">3608916</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-37361A442801E867D36B75DCE6894CEF" unitRef="usd">3748818</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2018Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-AEB3A3F50B311C7CB4F42F02BF501249" unitRef="usd">3700000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestPaid contextRef="FD2018Q1QTD_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-83892738DB9C4EE790C72F03709804BF" unitRef="usd">2600000</us-gaap:InterestPaid>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="0" id="Fact-AA7D7F0DC993BA518F632F89C5C72614" unitRef="usd">957804</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2018Q1" decimals="0" id="Fact-56EA5225785028B651482F89C5BAA53C" unitRef="usd">957804</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="0" id="Fact-B07A62F2A72A15AABB3D75DCE66B8CA3" unitRef="usd">2983249</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q1" decimals="0" id="Fact-3ED78E0FC5006E97BB0A75DCE64A241E" unitRef="usd">2983249</us-gaap:InventoryNet>
	<us-gaap:InventoryWorkInProcessAndRawMaterials contextRef="FI2017Q4" decimals="0" id="Fact-68F71C49C4D1B1C6A1212F89C5B6ACDA" unitRef="usd">2025445</us-gaap:InventoryWorkInProcessAndRawMaterials>
	<us-gaap:InventoryWorkInProcessAndRawMaterials contextRef="FI2018Q1" decimals="0" id="Fact-12B6925CB19C5E5E4A2E2F89C5BD0258" unitRef="usd">2025445</us-gaap:InventoryWorkInProcessAndRawMaterials>
	<us-gaap:InventoryWriteDown contextRef="FD2018Q1YTD" decimals="0" id="Fact-8942BF815513D14E03E52ECB1EB0A4DC" unitRef="usd">536000</us-gaap:InventoryWriteDown>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2017Q4" decimals="0" id="Fact-7D30D3DA0A16153E6D0175DCE689B5A9" unitRef="usd">2420028</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2018Q1" decimals="0" id="Fact-9140B37F0643777F453E75DCE68274B9" unitRef="usd">2420028</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LegalFees contextRef="FD2017Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember" decimals="0" id="Fact-13ECE895C8B604BC7C292F2422FF8C6C" unitRef="usd">78000</us-gaap:LegalFees>
	<us-gaap:LegalFees contextRef="FD2018Q1QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ManagementMember" decimals="0" id="Fact-B4B6309BA2908324F51C2F232FD4A932" unitRef="usd">107000</us-gaap:LegalFees>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="0" id="Fact-B5985C27216C68A7EEBB75DCE65F0322" unitRef="usd">467808670</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q1" decimals="0" id="Fact-366F2815E574EA71319F75DCE651BAA3" unitRef="usd">467751753</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="0" id="Fact-558FC104AE9EC4A7798E75DCE64E09D2" unitRef="usd">144670379</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q1" decimals="0" id="Fact-849570225178D8B43B0875DCE62CDA6B" unitRef="usd">133135253</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-671077F9BCFBC6F36CCA75DCE6730588" unitRef="usd">6810446</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q1" decimals="0" id="Fact-1FF828035CFD82FCC5FB75DCE675ED31" unitRef="usd">4018402</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases contextRef="FI2018Q1_siga_DebtInstrumentCapacitybySpecificPurposeAxis_siga_PaymentsRelatedtoLitigationMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-06E947412D50B207AC532EFF5EFB1219" unitRef="usd">50000000</us-gaap:LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases>
	<us-gaap:LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases contextRef="FI2018Q1_siga_DebtInstrumentCapacitybySpecificPurposeAxis_siga_RepaymentofInterestsMember_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-9ED6377BB160A32013FE2EFB74E760E3" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2018Q1_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-DF4EE22032B4E16488992EFA56D0682F" unitRef="usd">80000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q3Sep2_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-3752D124773953CD10262EF91041BA49" unitRef="usd">80000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="FI2018Q1_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-5" id="Fact-2CCA3E9C4E17678D64DA2F0C758B23A8" unitRef="usd">72200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="0" id="Fact-19F5A17B6A0FA670BD7275DCE6721208" unitRef="usd">71050324</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q1" decimals="0" id="Fact-A187BC36FEC1D817DA9275DCE674DF0B" unitRef="usd">72159240</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_LongtermDebtTypeAxis_siga_SeniorSecuredTermLoanMember" decimals="-5" id="Fact-3E0ACBD9023BC53CB1DB2F163306680E" unitRef="usd">74900000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q1_us-gaap_LongtermDebtTypeAxis_siga_SeniorSecuredTermLoanMember" decimals="-5" id="Fact-4B4C64CC2E8736FB98C72F16ED319998" unitRef="usd">72200000</us-gaap:LongTermDebt>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1QTD" decimals="0" id="Fact-71D6F374EBB8E4B04CB575DCE65C455A" unitRef="usd">-193052</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q1YTD" decimals="0" id="Fact-8A3262AC4B3D804CE40D75DCE6A2FAAD" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1QTD" decimals="0" id="Fact-54B485687163F12F423375DCE6470BB8" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q1YTD" decimals="0" id="Fact-B5E79C1803440DE85DBE75DCE62F83AE" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1QTD" decimals="0" id="Fact-C1B44F81E82163828E2375DCE6920994" unitRef="usd">-932976</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q1YTD" decimals="0" id="Fact-C71BE743C76F6DC581CF75DCE6481866" unitRef="usd">-8561703</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="0" id="Fact-8A74AA3F85560CFB85BB75DCE68B972A" unitRef="usd">-8614946</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD" decimals="0" id="Fact-C0C2A79AD7BD23DD2F7875DCE68DDE55" unitRef="usd">-11582256</us-gaap:NetIncomeLoss>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-19DA372DA264F68ED12675DCE69ED9F6" unitRef="usd">4419</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-2A4904310C68C900137D75DCE68AEFF5" unitRef="usd">2235</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD" decimals="0" id="Fact-67DB49BE69FBE931A2FA75DCE67C6A63" unitRef="usd">9470956</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1YTD" decimals="0" id="Fact-735022CE7DABEF1BE36475DCE6883B63" unitRef="usd">6282845</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1QTD" decimals="0" id="Fact-29E62A008CAAA9BFD76575DCE6B899D4" unitRef="usd">-4269170</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD" decimals="0" id="Fact-4EF65CA6E07F71DF8DE075DCE69B69F3" unitRef="usd">-4534911</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-B4EBFA37F9EFADE006F275DCE6AA2816" unitRef="usd">977353</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="0" id="Fact-2465AB8120F5B8CD977D75DCE697D719" unitRef="usd">1109532</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="0" id="Fact-F325903746C23CD8D0F975DCE666A577" unitRef="usd">702167</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q1" decimals="0" id="Fact-A72BB60C00D2C730CA5D75DCE65BCFEA" unitRef="usd">702167</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilities contextRef="FI2017Q4" decimals="0" id="Fact-0C339340EB8D1F3DE0C775DCE66489F2" unitRef="usd">840253</us-gaap:OtherLiabilities>
	<us-gaap:OtherLiabilities contextRef="FI2018Q1" decimals="0" id="Fact-6F203E352ED5BB99B30975DCE62E97A0" unitRef="usd">774131</us-gaap:OtherLiabilities>
	<us-gaap:PaymentsForRestructuring contextRef="FD2018Q1YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="-3" id="Fact-781D4A3E9E5062641C3A75DCE6379AE9" unitRef="usd">78153000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q1QTD" decimals="0" id="Fact-0E176D96918B245B7722D815661EEEB2" unitRef="usd">193052</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q1YTD" decimals="0" id="Fact-B5CA047111F6BA586D09D8109B0CA562" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="0" id="Fact-6815048159AB477A61EB75DCE6718DAC" unitRef="usd">2019999</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q1" decimals="0" id="Fact-EA9264EFA4B06318923875DCE62F25E2" unitRef="usd">1900566</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="0" id="Fact-8722F0BFEAF2CEA2668A2F8A4CB29A79" unitRef="usd">3485378</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q1" decimals="0" id="Fact-10301CFA390A1357A3DF2F8A4CC093F1" unitRef="usd">3485378</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="0" id="Fact-26D019EF4D3F87EE3C1175DCE66CC3D3" unitRef="usd">138640</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q1" decimals="0" id="Fact-C138A6B95F4D472CC85475DCE62C3872" unitRef="usd">108850</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-58044C0D35F3FA3874FC75DCE6CDC6B5" unitRef="usd">6360490</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-A67EA445BA4E23AC3E9475DCE6B045CF" unitRef="usd">3007827</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCash contextRef="FI2018Q1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201618Member" decimals="-5" id="Fact-45A6AD4143072691A55F078A7FB802A9" unitRef="usd">2500000</us-gaap:RestrictedCash>
	<us-gaap:RestrictedCashAndCashEquivalents contextRef="FI2018Q1_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember_us-gaap_DebtInstrumentAxis_siga_LoanAgreementMember" decimals="-6" id="Fact-50888A5478F3C2BA0FECBA6C7136F671" unitRef="usd">5000000</us-gaap:RestrictedCashAndCashEquivalents>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="0" id="Fact-5647C82BD80B45E1DF3775DCE678BEC4" unitRef="usd">10701305</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="0" id="Fact-8AD204B1CEFE6ABBA37975DCE64BDCD8" unitRef="usd">10850136</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
	<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2017Q4" decimals="0" id="Fact-CDF06EE74A07E89E82C375DCE661D0AE" unitRef="usd">6542448</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
	<us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2018Q1" decimals="0" id="Fact-86E9E6310DC6524E79D975DCE66CCF41" unitRef="usd">3754940</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
	<us-gaap:RestrictedCashCurrent contextRef="FI2016Q4" decimals="0" id="Fact-DFF9FD4A8BACED44B6642F7812763277" unitRef="usd">10138890</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashCurrent contextRef="FI2017Q1" decimals="0" id="Fact-0ECFB2803F92672E3E372F781286B502" unitRef="usd">10138890</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashCurrent contextRef="FI2017Q4" decimals="0" id="Fact-07068AF2FC6D279E3A992F78127C9B39" unitRef="usd">10701305</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashCurrent contextRef="FI2018Q1" decimals="0" id="Fact-B47BF81F6BF9C5FAAFD42F781297650B" unitRef="usd">10850136</us-gaap:RestrictedCashCurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-991C1918FAF4DD7F24522F7871309D2D" unitRef="usd">17333332</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2017Q1" decimals="0" id="Fact-9CDB8E0CDB35840B8EC82F7870BD9598" unitRef="usd">14805554</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2017Q4" decimals="0" id="Fact-9696F8074FC7E40F92452F7871959CC4" unitRef="usd">6542448</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2018Q1" decimals="0" id="Fact-61D9C1FC1CD0700077682F7870E7FBCA" unitRef="usd">3754940</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestructuringCharges contextRef="FD2018Q1YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="-3" id="Fact-EEC5D668DDF7819CFF2E75DCE63635E5" unitRef="usd">3376000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="-3" id="Fact-695BFAE0E24B1EE0564375DCE62DED70" unitRef="usd">814622000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2018Q1_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_siga_MacAndrewsForbesMember" decimals="-3" id="Fact-D58B3470640A11F88CAD75DCE62A4C29" unitRef="usd">739845000</us-gaap:RestructuringReserve>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="0" id="Fact-E729B4D5134576A134E775DCE6780C72" unitRef="usd">-537375776</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q1" decimals="0" id="Fact-F41EB9F4D52E19A46EEA75DCE66724C3" unitRef="usd">-549181345</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Jan01" decimals="-5" id="Fact-4FA2A33BB9C432AD861FDA1F97FCBCD3" unitRef="usd">200000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRemainingPerformanceObligation contextRef="FI2018Q1" decimals="-5" id="Fact-8012988A18834F524380DA24B6FF916D" unitRef="usd">20700000</us-gaap:RevenueRemainingPerformanceObligation>
	<us-gaap:Revenues contextRef="FD2018Q1YTD_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" decimals="-6" id="Fact-0FBB79228838935CDC06DA203ED2F566" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q1QTD" decimals="0" id="Fact-C8B13050B78312AB0C9175DCE62BEE83" unitRef="usd">2869869</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q1YTD" decimals="0" id="Fact-6D14C0A58F5CB1BB32FB75DCE66FC137" unitRef="usd">3056546</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1QTD" decimals="0" id="Fact-E3991CA6D59394CEE55975DCE69E8BDB" unitRef="usd">87594</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1YTD" decimals="0" id="Fact-F13DA466BCE91F9E087B75DCE6359D46" unitRef="usd">327360</us-gaap:ShareBasedCompensation>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="0" id="Fact-95CC6E1DB24BAD92554975DCE6779737" unitRef="usd">-323138291</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="0" id="Fact-75991A21FC15FEB923CA75DCE64967FD" unitRef="usd">-334616500</us-gaap:StockholdersEquity>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q4" decimals="0" id="Fact-4D98609B74308A34DB7B2F385ED5017D" unitRef="usd">11466162</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q1" decimals="0" id="Fact-79AFC7F737BA358BFB762F385EDE02AF" unitRef="usd">14769276</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="-5" id="Fact-56B412D5ECF6A3CDA0CD2EEA7CC81FF3" unitRef="usd">14800000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2016Q3Sep2_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="-5" id="Fact-C498032AA19A95641DB82EE3E0DED32C" unitRef="usd">5800000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q1QTD" decimals="0" id="Fact-B7A826509EBE9D26EF1E75DCE667E611" unitRef="shares">78777144</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q1YTD" decimals="0" id="Fact-F23860D338A4D04E0A3B75DCE6CAA2E2" unitRef="shares">79039000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<siga:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-66ED5C8EE65F204D8D6175DCE672D3C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bonus&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;454,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,538,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue-R&amp;amp;D for TPOXX&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;&amp;#174;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;intravenous formulation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,255,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,255,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;405,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vacation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;328,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other (primarily R&amp;amp;D vendors and CMOs) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,109,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;977,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,586,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,481,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</siga:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
	<siga:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock contextRef="FD2018Q1YTD" id="Fact-9A9A73C3908B9E7A34B475DCE66988BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bonus&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;454,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,538,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue-R&amp;amp;D for TPOXX&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;&amp;#174;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;intravenous formulation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,255,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,255,318&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;405,096&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,980&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vacation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361,755&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;328,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other (primarily R&amp;amp;D vendors and CMOs) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,109,532&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;977,353&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,586,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,481,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</siga:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
	<siga:ProcurementContractAndResearchAgreementsTextBlock contextRef="FD2018Q1YTD" id="Fact-1307120FDB4F6FE0CE0775DCE6824587">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Procurement Contract and Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority (&amp;#8220;BARDA&amp;#8221;) pursuant to which SIGA agreed to deliver &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; to the Strategic Stockpile. The contract with BARDA (as amended, modified, or supplemented from time to time, the &amp;#8220;BARDA Contract&amp;#8221;) includes a base contract (&amp;#8220;Base Contract&amp;#8221;) as well as options (described below). The Base Contract contemplates approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$472.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of payments, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$409.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is consideration for the manufacture and delivery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is available for certain development and supportive activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Base Contract, BARDA agreed to buy from the Company &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174;. Additionally, the Company agreed to contribute to BARDA &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses at no additional cost to BARDA. The delivery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; to the Strategic Stockpile is a requirement in order for the Company to be eligible to receive a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$41 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; hold back payment (see description of hold back payment below).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For courses of TPOXX&amp;#174; that are physically delivered to the Strategic Stockpile, the Company has a product replacement obligation, at no cost to BARDA, in the event that the final version of TPOXX&amp;#174; approved by the FDA is different from any courses of TPOXX&amp;#174; that have been delivered to the Strategic Stockpile or if TPOXX&amp;#174; does not meet any specified label claims, fails release testing or does not meet the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX&amp;#174; is recalled or deemed to be recalled for any reason (the "Replacement Obligation").&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$368.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Base Contract related to the manufacture and physical delivery of courses of TPOXX&amp;#174;. Included in this amount are a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$41.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; advance payment in 2011 for the completion of certain planning and preparatory activities related to the Base Contract; a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment in 2012 for the completion of the product labeling strategy for TPOXX&amp;#174;; an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment in 2013 for the completion of the commercial validation campaign for TPOXX&amp;#174;; a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment in 2016 for submission of documentation to BARDA indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study had been submitted to and reviewed by a Data Safety and Monitoring Board (&amp;#8220;DSMB&amp;#8221;) and that such DSMB had recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$286.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of payments for physical deliveries of TPOXX&amp;#174; to the Strategic Stockpile beginning in 2013. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has cumulatively delivered &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; to the Strategic Stockpile. The dosage of courses delivered is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; mg administered twice per day (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,200&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; mg per day). In February 2016, the FDA confirmed (through dose concurrence) its earlier dosage guidance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; mg administered twice per day (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,200&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; mg per day). Courses delivered to the Strategic Stockpile are currently subject to the Replacement Obligation (as discussed above).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is eligible under the Base Contract to receive a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$41 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; hold back payment, which represents an approximate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; hold back on the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$409.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of total payments related to the manufacture and delivery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; under the Base Contract. The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$41 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; hold back payment would be triggered by FDA approval of TPOXX&amp;#174;, provided that the Company no longer has the Replacement Obligation to BARDA. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the Base Contract, the BARDA Contract also includes remaining options that, if all were exercised by BARDA, would result in aggregate payments to the Company of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$122.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including: a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment to the Company in the event of FDA approval for extension to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month expiry for TPOXX&amp;#174; (from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month expiry as required in the Base Contract); up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$58.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of funding for development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX&amp;#174;; and/or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of funding for production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA, in its sole discretion, may choose not to exercise unexercised options. However, BARDA has indicated that it will evaluate, after the FDA&amp;#8217;s review and evaluation of stability data, the Company's request that BARDA exercise the option for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment to the Company in the event of FDA approval of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month expiry for TPOXX&amp;#174;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The BARDA Contract expires in September 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As described in Note 2, cash inflows related to delivery of courses are recorded as deferred revenue due to the constraint on the consideration received. As of March 31, 2018, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$375.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of deferred revenue in connection with the BARDA contract (of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$368.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; relates to the manufacture and delivery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; courses of TPOXX&amp;#174; and the remainder relates to supportive activities). Deferred revenue under the BARDA Contract is classified as a long-term liability since there can be no assurance that the Replacement Obligation under the BARDA contract will be reasonably satisfied within twelve months. In addition, direct costs incurred by the Company to fulfill the delivery of courses, including the supplementing of courses previously delivered under the BARDA Contract, are being deferred and will be recognized as expenses in the period of the FDA&amp;#8217;s approval of the final version of TPOXX&amp;#174; (quantification and specification of the Replacement Obligation) has occurred. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, deferred direct costs under the BARDA Contract of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$94.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$96.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, are included in deferred costs on the condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research Agreements and Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has an R&amp;amp;D program for the intravenous (IV) formulation of TPOXX&amp;#174;. This program is funded by a development contract with BARDA ("IV Formulation R&amp;amp;D Contract"). This contract has a period of performance that terminates on December 30, 2020. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contracts and grants include, among other things, options that may or may not be exercised at BARDA&amp;#8217;s discretion. Moreover, contracts and grants contain customary terms and conditions including BARDA&amp;#8217;s right to terminate or restructure a contract or grant for convenience at any time. As such, we may not be able to utilize all available funds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</siga:ProcurementContractAndResearchAgreementsTextBlock>
	<siga:RestrictedCashandCashEquivalentsPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-BE9E8C390DA7CA863261B57634FBFDF7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2018, the Company adopted ASU No. 2016-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB&amp;#8217;s Emerging Issues Task Force&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The new standard required that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities are required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions.  Adoption of this guidance impacts the cash flow disclosure for the three months ended March 31, 2017; cash flows from operating activities, as disclosed herein, is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; less than the amount disclosed in the 2017 first quarter 10-Q.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A portion of the Company&amp;#8217;s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 7&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional information.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</siga:RestrictedCashandCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-0051BAB7101B20E57CC275DCE6760EF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="FD2018Q1YTD" id="Fact-E27699307D5F9C7CF277F861B81B4B90">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-A382F69670F968665F4075DCE69DD319">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the &amp;#8220;Loan Agreement&amp;#8221;) with OCM Strategic Credit SIGTEC Holdings, LLC (&amp;#8220;Lender&amp;#8221;), pursuant to which the Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (less fees and other items) on November 16, 2016 having satisfied certain pre-conditions. Such &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had been placed in an escrow account on September 30, 2016 (the &amp;#8220;Escrow Funding Date&amp;#8221;). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering (see &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 7&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) on November 16, 2016. As part of the satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the &amp;#8220;Escrow Release Date&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the &amp;#8220;Term Loan&amp;#8221;), of which (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was placed in a reserve account (the &amp;#8220;Reserve Account&amp;#8221;) only to be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was also placed in the Reserve Account and up to the full amount of such &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is due and owing and any of such &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; remains in the Reserve Account; and (iii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final payment to satisfy the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to adjustments as set forth in the Loan Agreement. For the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the effective interest rate on the Term Loan, which includes interest payments and accretion of unamortized costs and fees, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.96%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company incurred approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of interest expense during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was paid from restricted cash and the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; accreted to the Term Loan balance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Term Loan shall mature on the earliest to occur of (i) the four-year anniversary of the Escrow Release Date, and (ii) the acceleration of certain obligations pursuant to the Loan Agreement. At maturity, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of principal will be repaid, and an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be paid (see below). Prior to maturity, there are no scheduled principal payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Through the three and one-half year anniversary of the Escrow Release Date, any prepayment of the Term Loan is subject to a make-whole provision in which interest payments related to the prepaid amount are due (subject to a discount of treasury rate plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Term Loan, the Company has granted the Lender a lien on and security interest in all of the Company&amp;#8217;s right, title and interest in substantially all of the Company&amp;#8217;s tangible and intangible assets, including all intellectual property.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. These covenants, among other things, require a minimum cash balance throughout the term of the Term Loan and the achievement of regulatory milestones by certain dates, and contain certain limitations on the ability of the Company to incur unreimbursed research and development expenditures over a certain threshold, make capital expenditures over a certain threshold, incur indebtedness, dispose of assets outside of the ordinary course of business and enter into certain merger or consolidation transactions. The aforementioned minimum cash requirement is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for 2018 until the earlier of (i) December 31, 2018 or (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days after FDA approval of TPOXX&amp;#174;; thereafter, the minimum cash requirement will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Loan Agreement includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) the material inaccuracy of representations or warranties made thereunder, (iii) non-compliance with covenants thereunder, (iv) non-payment of amounts due under, or the acceleration of, other material indebtedness of the Company and (v) bankruptcy or insolvency events. Upon the occurrence and during the continuance of an event of default under the Loan Agreement, the interest rate may increase by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum above the rate of interest otherwise in effect, and the Lenders would be entitled to accelerate the maturity of the Company&amp;#8217;s outstanding obligations thereunder.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company is in compliance with the Loan Agreement covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Loan Agreement, the Company incurred &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs (including interest on amounts held in the escrow account between September 30, 2016 and November 15, 2016). Furthermore, an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will become payable when principal of the Term Loan is repaid. As part of the Company's entry into the Loan Agreement, the Company issued the Warrant (see Note 7) with a fair market value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of the Warrant, as well as costs related to the Term Loan issuance, were recorded as deductions to the Term Loan balance on the Balance Sheet. These amounts are being amortized using the effective interest method over the life of the related Term Loan. The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that will be paid when principal is repaid is being accreted to the Term Loan balance each quarter on a per diem basis. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Term Loan balance is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$72.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-231CDB5E1973D076612875DCE68DD076">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Per Share Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company incurred losses for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as a result, the equity instruments listed below are excluded from the calculation of diluted earnings (loss) per share as the effect of the exercise, conversion or vesting of such instruments would be anti-dilutive. The weighted average number of equity instruments excluded consists of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three months ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,062,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,709,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-Settled Stock Appreciation Rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;360,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,472,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,307,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,690,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,690,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1) Includes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;294,118&lt;/font&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt; restricted stock units that have vested but have not converted into common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q1YTD" id="Fact-94A2E3B1C51DAEDF076375DCE6B11426">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as a liability are recorded at their fair market value as of each reporting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Quoted prices for identical instruments in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Instruments where significant value drivers are unobservable to third parties.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of certain common stock warrants on a recurring basis and classify such liability classified warrants in Level 3. As described in &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 7&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the liability classified warrant was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the debt was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$74.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;and the carrying value of the debt was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$72.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement.&amp;#160; The fair value of the loan was measured using level 3 inputs.&amp;#160; The discount rate was determined using market participant assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were no transfers between levels of the fair value hierarchy for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, there were no Level 1 or Level 2 financial instruments as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements of Level 3 liability classified warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,466,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in fair value of warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,303,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,769,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q1YTD" id="Fact-379E28FE238043CE213475DCE63B4FC0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements of Level 3 liability classified warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,466,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in fair value of warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,303,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant liability at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,769,276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-600884FAF6C7CEA1459F75DCE633BFE8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2016 Warrant&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 2, 2016, in connection with the entry into the Loan Agreement (see &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 8&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional information), the Company issued a warrant (the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrant&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) to the Lender to purchase a number of shares of the Company&amp;#8217;s common stock equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; divided by the lower of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.29&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and (ii) the subscription price paid in connection with the Rights Offering. The Warrant provides for weighted average anti-dilution protection and is exercisable in whole or in part for ten (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) years from the date of issuance. The subscription price paid was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with the Rights Offering; accordingly, the exercise price of the Warrant was set at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reported the change in fair value in the statement of operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 2, 2016, the issuance date of the Warrant, the fair value of the liability classified Warrant was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company applied a Monte Carlo Simulation-model to calculate the fair value of the liability classified Warrant using the following assumptions: risk free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.60%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividend yield; an expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years; and a volatility factor of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation as of December 31, 2016. These models generated substantially equal fair values for the Warrant. As such, the Company utilized a Black-Scholes model for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to determine the fair value of the Warrant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the Warrant was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of the liability classified Warrant was calculated using the following assumptions: risk free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.72%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividend yield; an expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.42&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years; and a volatility factor of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded losses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as a result of the change in fair value of the liability classified Warrant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-F2FC265B32FAAEB5EB3F75DCE66F55AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASC 740, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; requires that a valuation allowance be established when it is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;more likely than not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8221; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the company's performance, the market environment in which the company operates, the utilization of past tax credits, length of carryback and carryforward periods, existing contracts, and unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels in the future years. Based on the available evidence, the Company continues to conclude that its deferred tax assets are not realizable on a more-likely-than-not basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the SEC staff issued Staff Accounting Bulletin (&amp;#8220;SAB&amp;#8221;) No. 118, which provides guidance on accounting for the tax effects of the 2017 Tax Cuts and Jobs Act ("TCJA"). The purpose of SAB No. 118 was to address any uncertainty or diversity of view in applying&amp;#160;ASC Topic 740, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;in the reporting period in which the TCJA was enacted. SAB No. 118 addresses situations where the accounting is incomplete for certain income tax effects of the TCJA upon issuance of a company&amp;#8217;s financial statements for the reporting period that includes the enactment date. SAB No. 118 allows for a provisional amount to be recorded if it is a reasonable estimate of the impact of the TCJA. Additionally, SAB No. 118 allows for a measurement period to finalize the impacts of the TCJA, not to extend beyond one year from the date of enactment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company&amp;#8217;s accounting for certain elements of the TCJA was incomplete as of the period ended December 31, 2017, and remains incomplete as of March 31, 2018. However, the Company was able to make reasonable estimates of the effect of the TCJA and, therefore, recorded provisional estimates for these items. The final impact of the TCJA may differ from the provisional amounts that have been recognized, due to, among other things, legislative or administrative actions to clarify the intent of the statutory language as well as any changes in accounting standards for income taxes or related interpretations in response to the TCJA. Additionally, the Company's U.S. tax return for 2017 will be filed during the second or third quarter of 2018 and any changes to the tax positions for temporary differences compared to the estimates used may result in an adjustment of the estimated tax benefit recorded as of December 31, 2017.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded an income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,352&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on a pre-tax loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The effective tax rate differs from the statutory rate as no income tax benefit was recorded for current year operating losses due to the Company&amp;#8217;s assessment regarding tax realizability of its deferred tax assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-7E9462B76F10CD1EC54675DCE6668DB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Due to the deferral of revenue under the BARDA Contract (see &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sC3A91219B5B7B433F4C575DCE76C7E28"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 2&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional information), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs on the condensed consolidated balance sheet. Inventory includes costs related to the manufacture of TPOXX&amp;#174;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;957,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;957,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,983,249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,983,249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;, research and development expenses included net inventory-related losses of approximately&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;$536,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;. The&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;$536,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;loss for the three months ended&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;March 31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;, related to a&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;$686,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;inventory write-down, partially offset by credits received from contract manufacturing organizations (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;CMOs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;in connection with the inventory write-down.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2018Q1YTD" id="Fact-83BA526757041E68EEF475DCE6A9178A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company&amp;#8217;s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;ASC 606&amp;#8221;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Adoption of ASC 606&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On&amp;#160;January&amp;#160;1, 2018, the Company adopted ASC 606 using the modified retrospective method applied to those contracts that were not completed as of&amp;#160;January&amp;#160;1, 2018. Results for reporting periods beginning after&amp;#160;January&amp;#160;1, 2018&amp;#160;are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under ASC 605, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The cumulative impact of adopting ASC 606 as of January 1, 2018 is: a decrease to deferred revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; a decrease to deferred costs of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; an increase to receivables of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a net increase to opening accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of tax. For the&amp;#160;three months ended March 31, 2018, the impact to revenues as a result of applying ASC 606 was an increase of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Performance Obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606.&amp;#160;A contract&amp;#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&amp;#160;The Company&amp;#8217;s research and development contract for the intravenous (IV) formulation of TPOXX&amp;#174; (see "IV Formulation R&amp;amp;D Contract" in Note 3) has a single performance obligation (research and development); individual services within the contract are not separately identifiable from other promises in the contract and, therefore, are not distinct from each other. The Company&amp;#8217;s BARDA Contract (see Note 3) has three performance obligations: one relates to the manufacture and delivery of product (and performance of services in connection with the manufacture and delivery of product), and the other two performance obligations relate to research and development in connection with TPOXX&amp;#174;. For contracts with multiple performance obligations, the Company allocates the contract&amp;#8217;s transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract modifications may occur during the course of performance of our contracts. Contracts are often modified to account for changes in contract specifications or requirements. In most instances, contract modifications are for services that are not distinct, and, therefore, are accounted for as part of the existing contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s performance obligations are satisfied over time as work progresses or at a point in time.&amp;#160;Substantially all of the Company&amp;#8217;s revenue related to research and development performance obligations is recognized over time, because control transfers continuously to our customers.&amp;#160;Typically, revenue is recognized over time using costs incurred to date relative to total estimated costs at completion to measure progress toward satisfying the Company&amp;#8217;s performance obligations. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, material, overhead, and third-party services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue connected with courses of TPOXX&amp;#174; delivered to the strategic stockpile and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time. Revenue associated with this performance obligation will be recognized&amp;#160;when BARDA obtains control of the asset, which is upon delivery to and acceptance by the customer and at the point in time when the constraint on the consideration is resolved. The consideration, which is variable consideration, is expected to be constrained until the FDA&amp;#8217;s approval of the final version of TPOXX&amp;#174; (quantification and specification of the Replacement Obligation (as defined herein)) has occurred. It is expected that the possibility of product replacement pursuant to the Replacement Obligation, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&amp;#8217;s regulatory review of the new drug application (NDA) for TPOXX&amp;#174;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contract Estimates&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;Accounting for long-term contracts and grants involves the use of various techniques to estimate total contract revenue and costs.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years.&amp;#160;These assumptions include labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The nature of the work required to be performed on many of the Company&amp;#8217;s performance obligations and the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. The consideration associated with manufacture and delivery of product as well as research and development services is variable as the consideration is either constrained or the total amount of services to be performed has not been finalized. The Company estimates variable consideration at the most likely amount to which it expects to be entitled. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur and when any uncertainty associated with variable consideration is resolved. The Company&amp;#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our historical and anticipated performance, external factors, trends and all other information (historical, current and forecasted) that is reasonably available to us.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A significant change in one or more of these estimates could affect the profitability of the Company&amp;#8217;s contracts.&amp;#160;As such, the Company reviews and updates its contract-related estimates regularly. The Company recognizes adjustments in estimated revenues, research and development expenses and cost of sales under the cumulative catch-up method. Under this method, the impact of the adjustment on revenues, research and development expenses and cost of sales recorded to date on a contract is recognized in the period the adjustment is identified.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contract Balances&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;The timing of revenue recognition, billings and cash collections may result in billed accounts receivable, unbilled receivables (contract assets) and customer advances and deposits (contract liabilities) in the Consolidated Balance Sheet. Generally, amounts are billed as work progresses in accordance with agreed-upon contractual terms either at periodic intervals (monthly) or upon achievement of contractual milestones. Under typical payment terms of fixed price arrangements, the customer pays the Company either performance-based payments or progress payments. For the Company&amp;#8217;s cost type arrangements, the customer generally pays the Company for its actual costs incurred. Such payments occur within a short period of time. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining Performance Obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Remaining performance obligations represents the transaction price for which work has not been performed and excludes unexercised contract options. As of March 31, 2018 the aggregate amount of transaction price allocated to remaining performance obligations for the BARDA Contract and the IV Formulation R&amp;amp;D Contract was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company expects to recognize revenue over the next three to five years as the specific timing for satisfying the performance obligations is subjective and outside the Company&amp;#8217;s control. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred Revenue&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When the Company receives consideration, or such consideration is unconditionally due, prior to transferring goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales once control of goods and/or services have been transferred to the customer and all revenue recognition criteria have been met and any constraints have been resolved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has deferred revenue in connection with the manufacture and delivery of TPOXX&amp;#174; under the BARDA contract. Revenue recognition is currently constrained by the possibility of product replacement pursuant to the Replacement Obligation. It is expected that the possibility of required product replacement, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&amp;#8217;s regulatory review of the new drug application (NDA) for TPOXX&amp;#174;. Upon resolution of this constraint, deferred revenue is expected to be recorded as net sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the change in the Company's deferred revenue:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;378,896,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cumulative effect of accounting change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,780,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Billings in advance of revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;169,269&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;377,286,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of March 31, 2018 and December 31, 2017, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of deferred revenue was classified as accrued expenses and other current liabilities on the condensed consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2018, the Company adopted ASU No. 2016-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB&amp;#8217;s Emerging Issues Task Force&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The new standard required that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities are required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions.  Adoption of this guidance impacts the cash flow disclosure for the three months ended March 31, 2017; cash flows from operating activities, as disclosed herein, is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; less than the amount disclosed in the 2017 first quarter 10-Q.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A portion of the Company&amp;#8217;s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See &lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 7&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for additional information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,934,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,857,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-short term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,850,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,701,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-long term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,754,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,542,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,539,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,101,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,103,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,701,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-short term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,138,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,138,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-long term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,805,554&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,048,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,174,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 26, 2017, the FASB issued ASU No. 2017-04, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&amp;#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. The revised guidance will be applied prospectively, and is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company believes the adoption of ASU No. 2017-04 will not have a significant impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which relates to the accounting for leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-02 will have on its consolidated financial statements. The Company expects its real estate leases to be capitalized on its balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-04C6F6EB3186737ECD3F75DCE68C67DB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Condensed Consolidated Financial Statements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The financial statements are presented in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for quarterly reports on Form 10-Q and should be read in conjunction with the Company&amp;#8217;s audited financial statements and notes thereto for the year ended December 31, 2017, included in the 2017 Annual Report on Form 10-K. All terms used but not defined elsewhere herein have the meaning ascribed to them in the Company&amp;#8217;s 2017 Annual Report on Form 10-K filed on March 6, 2018. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods presented have been included. The 2017 year-end condensed balance sheet data was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results expected for the full year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is not entitled to receive additional procurement-related payments under the current BARDA Contract (&lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#s7E5C538EFD7E1A43B3DD75DCE76FACC5"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 3&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;) if and until United States Food &amp;amp; Drug Administration ("FDA") approval of TPOXX&amp;#174; has been achieved, and there is no difference between the approved product and courses of TPOXX&amp;#174; that have been delivered to the U.S. Strategic National Stockpile (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;Strategic Stockpile&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;). Upon meeting the aforementioned requirements, a determination of which is currently expected in the third quarter of 2018, the Company will be entitled to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;$41 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt; hold back payment under the BARDA Contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;In the event that the Company does not receive a substantial portion of the hold back payment, or other substantial cash inflows, by October of 2018, then, based on currently forecasted operating costs, the Company will require additional sources of funding to continue operations and prevent an event of default under the term loan (&lt;/font&gt;&lt;a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note 8&lt;/font&gt;&lt;/a&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#222222;"&gt;). In this case, the Company would seek to increase cash liquidity by: raising proceeds through a financing, entering into a new contract for TPOXX&amp;#174; or any other product, a sale of assets, or the modification of the existing BARDA Contract; significantly reducing its operating expenses; or modifying the terms of the Term Loan Agreement. There can be no assurance that TPOXX&amp;#174; will receive FDA approval on a timely basis, if at all, or that there will be no difference between the approved product and courses of TPOXX&amp;#174; that have been delivered to the Strategic Stockpile. Furthermore, there can be no assurance that the Company would be able to increase cash liquidity, if needed, through a financing, a new contract for TPOXX&amp;#174; or any other product, a sale of assets, the modification of the existing BARDA Contract, or a significant reduction of its operating expenses or operations, or that the lenders would agree to modify the Term Loan Agreement, if needed. Because of these conditions, substantial doubt exists about the Company's ability to continue as a going concern for one year from the financial statement issuance date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-D11A0A69A28EF3B432B675DCE6503037">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, plant and equipment consisted of the following:&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,420,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,420,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;701,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;701,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,485,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,485,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less - accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,376,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,346,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;138,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization expense on property, plant, and equipment was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29,790&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36,175&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q1YTD" id="Fact-4CA3DCE97D82DDC9F60E75DCE64F4EC0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, plant and equipment consisted of the following:&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,420,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,420,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;701,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;701,762&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;363,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,485,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,485,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less - accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,376,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,346,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;108,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;138,640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-4B125C1DE0C1B2E94CC975DCE67BA9B4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Board of Directors and Outside Counsel&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A member of the Company&amp;#8217;s Board of Directors is a member of the Company&amp;#8217;s outside counsel. During the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company incurred expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$107,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to services provided by the outside counsel. On &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company&amp;#8217;s outstanding payables and accrued expenses included a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability to the outside counsel.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Real Estate Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 26, 2017 the Company and MacAndrews &amp;amp; Forbes Incorporated (&amp;#8220;M&amp;amp;F&amp;#8221;) entered into a ten-year Office Lease agreement (the &amp;#8220;New HQ Lease&amp;#8221;), pursuant to which the Company agreed to lease &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,200&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet at 27 East 62&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;Street, New York, New York. The Company is utilizing premises leased under the New HQ Lease as its new corporate headquarters. The Company's rental obligations consist of a fixed rent of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month in the first sixty-three months of the term, subject to a rent abatement for the first six months of the term. From the first day of the sixty-fourth month of the term through the expiration or earlier termination of the lease, the Company's rental obligations consist of a fixed rent of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month. In addition to the fixed rent, the Company will pay a facility fee in consideration of the landlord making available certain ancillary services, commencing on the first anniversary of entry into the lease. The facility fee will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month for the second year of the term and increasing by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; percent each year thereafter, to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,925&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month in the final year of the term. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 31, 2017, the Company and M&amp;amp;F entered into a Termination of Sublease Agreement (the &amp;#8220;Old HQ Sublease Termination Agreement&amp;#8221;), pursuant to which the Company and M&amp;amp;F agreed to terminate the sublease dated January 9, 2013 for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,676&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of rental square footage located at 660 Madison Avenue, Suite 1700, New York, New York (such sublease being the &amp;#8220;Old HQ Sublease&amp;#8221; and the location being the &amp;#8220;Old HQ&amp;#8221;). Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&amp;amp;F and a new subtenant (the &amp;#8220;Replacement M&amp;amp;F Sublease&amp;#8221;), which occurred on August 2, 2017. The Old HQ Sublease Termination Agreement obligates the Company to pay, on a monthly basis, an amount equal to the discrepancy (the &amp;#8220;Rent Discrepancy&amp;#8221;) between the sum of certain operating expenses and taxes (&amp;#8220;Additional Rent&amp;#8221;) and fixed rent under the overlease between M&amp;amp;F and the landlord at 660 Madison Avenue and the sum of Additional Rent and fixed rent under the Replacement M&amp;amp;F Sublease. Under the Old HQ Sublease Termination Agreement, the Company and M&amp;amp;F release each other from any liability under the Old HQ Sublease. For the time period between August 2, 2017 and August 31, 2020 (the expiration date of the Old HQ Sublease), the Company estimates that it will pay a total of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in Rent Discrepancy under the Old HQ Sublease Termination Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the above-mentioned transactions, the Company has discontinued usage of Old HQ in the third quarter of 2017. As such, during the year ended December 31, 2017 the Company recorded a loss of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in accordance with Accounting Standards Codification (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) 420, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Exit or Disposal Obligations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This loss primarily represented the discounted value of estimated Rent Discrepancy payments to occur in the future, and included costs related to the termination of the old HQ Sublease. The Company also wrote-off approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of leasehold improvements and furniture and fixtures related to the Old HQ. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes activity relating to the liability that was recorded as a result of the lease termination:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lease Termination liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;814,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Charges (included in selling, general and administrative expenses) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash payments, net of sublease income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(78,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;739,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the lease termination liability is included in Other liabilities on the Condensed Consolidated Balance sheet with the remainder included in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-74EE3911EF46E648F4F675DCE6904FE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company incurred losses for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as a result, the equity instruments listed below are excluded from the calculation of diluted earnings (loss) per share as the effect of the exercise, conversion or vesting of such instruments would be anti-dilutive. The weighted average number of equity instruments excluded consists of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Three months ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,062,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,709,967&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-Settled Stock Appreciation Rights&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;360,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,472,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,307,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,690,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,690,950&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-6641F5EE428726699C1AF866D1B6298C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,934,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,857,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-short term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,850,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,701,305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-long term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,754,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,542,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,539,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,101,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,103,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,701,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-short term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,138,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,138,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted cash-long term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,805,554&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,333,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and restricted cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,048,018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,174,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2018Q1YTD" id="Fact-F1FDAE2FC8D402C9E80B75DCE66B30D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Work in-process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,025,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;957,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;957,804&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,983,249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,983,249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2018Q1YTD" id="Fact-985D4147A5E42AC2C35775DCE63F9133">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes activity relating to the liability that was recorded as a result of the lease termination:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lease Termination liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;814,622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Charges (included in selling, general and administrative expenses) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash payments, net of sublease income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(78,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;739,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the lease termination liability is included in Other liabilities on the Condensed Consolidated Balance sheet with the remainder included in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>siga-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.siga.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:siga="http://www.siga.com/20180331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="siga-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="siga-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="siga-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="siga-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.siga.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatements" roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatements">
        <link:definition>2101100 - Disclosure - Condensed Consolidated Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedFinancialStatementsNarrativeDetails" roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails">
        <link:definition>2401401 - Disclosure - Condensed Consolidated Financial Statements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.siga.com/role/Debt">
        <link:definition>2108100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.siga.com/role/DebtNarrativeDetails">
        <link:definition>2408401 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformationDocument" roleURI="http://www.siga.com/role/DocumentAndEntityInformationDocument">
        <link:definition>0001000 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstruments" roleURI="http://www.siga.com/role/FairValueOfFinancialInstruments">
        <link:definition>2109100 - Disclosure - Fair Value of Financial INstruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails">
        <link:definition>2409403 - Disclosure - Fair Value of Financial INstruments - Change in Level 3 Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsNarrativeDetails" roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails">
        <link:definition>2409402 - Disclosure - Fair Value of Financial INstruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsTables" roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables">
        <link:definition>2309301 - Disclosure - Fair Value of Financial INstruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.siga.com/role/FinancialInstruments">
        <link:definition>2107100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.siga.com/role/FinancialInstrumentsDetails">
        <link:definition>2407401 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.siga.com/role/IncomeTaxes">
        <link:definition>2113100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.siga.com/role/IncomeTaxesDetails">
        <link:definition>2413401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.siga.com/role/Inventory">
        <link:definition>2104100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.siga.com/role/InventoryDetails">
        <link:definition>2404402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.siga.com/role/InventoryTables">
        <link:definition>2304301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PerShareData" roleURI="http://www.siga.com/role/PerShareData">
        <link:definition>2110100 - Disclosure - Per Share Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PerShareDataDetails" roleURI="http://www.siga.com/role/PerShareDataDetails">
        <link:definition>2410402 - Disclosure - Per Share Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PerShareDataTables" roleURI="http://www.siga.com/role/PerShareDataTables">
        <link:definition>2310301 - Disclosure - Per Share Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProcurementContractAndResearchAgreements" roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreements">
        <link:definition>2103100 - Disclosure - Procurement Contract and Research Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProcurementContractAndResearchAgreementsDetails" roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails">
        <link:definition>2403401 - Disclosure - Procurement Contract and Research Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.siga.com/role/PropertyPlantAndEquipment">
        <link:definition>2105100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2405402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.siga.com/role/RelatedPartyTransactions">
        <link:definition>2112100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.siga.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2412402 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsRelatedPartyActivityDetails" roleURI="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails">
        <link:definition>2412403 - Disclosure - Related Party Transactions - Related Party Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.siga.com/role/RelatedPartyTransactionsTables">
        <link:definition>2312301 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents, Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Contract with Customer, Asset and Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry" name="AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_BalanceSheetParentheticalAbstract" name="BalanceSheetParentheticalAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_BardaContractMember" name="BardaContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable" name="ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_ComputerEquipment" name="ComputerEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="siga_ContractValueDetailOfOptionExercisableDevelopmentActivities" name="ContractValueDetailOfOptionExercisableDevelopmentActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ContractValueDetailOfOptionExercisableProductionActivities" name="ContractValueDetailOfOptionExercisableProductionActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ContractValueOfDevelopmentAndSupportActivities" name="ContractValueOfDevelopmentAndSupportActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ContractValueOptionFDAApproval" name="ContractValueOptionFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ContractValueofManufacturingandDeliveryActivities" name="ContractValueofManufacturingandDeliveryActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ContractValueofVariousOptions" name="ContractValueofVariousOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_DebtInstrumentCapacitybySpecificPurposeAxis" name="DebtInstrumentCapacitybySpecificPurposeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_DebtInstrumentCapacitybySpecificPurposeDomain" name="DebtInstrumentCapacitybySpecificPurposeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_FacilityFeeAfterInitialPeriod" name="FacilityFeeAfterInitialPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_FacilityFeeAnnualIncreasePercent" name="FacilityFeeAnnualIncreasePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract" name="GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_GovernmentContractNumberofFreeCourses" name="GovernmentContractNumberofFreeCourses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered" name="GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_GovernmentContractValueOfAward1" name="GovernmentContractValueOfAward1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_IncreaseInFairValueOfWarrants" name="IncreaseInFairValueOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_InitialFacilityFee" name="InitialFacilityFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_InventoryWriteDowns" name="InventoryWriteDowns" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_LeaseTerminationLiability" name="LeaseTerminationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="siga_LineofCreditFacilityAdditionalBorrowingCapacity" name="LineofCreditFacilityAdditionalBorrowingCapacity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate" name="LineofCreditFacilityDebtDefaultIncreaseinInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_LineofCreditFacilityMinimumCashRequirement" name="LineofCreditFacilityMinimumCashRequirement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_LoanAgreementMember" name="LoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_MacAndrewsForbesMember" name="MacAndrewsForbesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_MilestonePayment" name="MilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_MonthlyRentalPaymentsAfterInitialPeriod" name="MonthlyRentalPaymentsAfterInitialPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_MonthlyRentalPaymentsForInitialPeriod" name="MonthlyRentalPaymentsForInitialPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_NewHQLeaseMember" name="NewHQLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_NumberOfCoursesToBeDelivered1" name="NumberOfCoursesToBeDelivered1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_OldHQSubleaseMember" name="OldHQSubleaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_OperatingLeaseNameAxis" name="OperatingLeaseNameAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_OperatingLeaseNameDomain" name="OperatingLeaseNameDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_PatentPreparationFees" name="PatentPreparationFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_PaymentsRelatedtoLitigationMember" name="PaymentsRelatedtoLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_ProceedsFromAdvancePaymentsGovernmentContracts" name="ProceedsFromAdvancePaymentsGovernmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts" name="ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts" name="ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="siga_ProcurementContractAndResearchAgreementsTextBlock" name="ProcurementContractAndResearchAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_ProcurementContractAxis" name="ProcurementContractAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_ProcurementContractDomain" name="ProcurementContractDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_ProcurementContractLineItems" name="ProcurementContractLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_ProcurementContractTable" name="ProcurementContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_Reducedholdbackamount" name="Reducedholdbackamount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_RepaymentofInterestsMember" name="RepaymentofInterestsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_ResearchAndDevelopmentRevenue" name="ResearchAndDevelopmentRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="siga_RestrictedCashandCashEquivalentsPolicyTextBlock" name="RestrictedCashandCashEquivalentsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_RestrictedStockUnits" name="RestrictedStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_SeniorSecuredTermLoanMember" name="SeniorSecuredTermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="siga_StockIssuanceFeesExpense" name="StockIssuanceFeesExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_SubscriptionRightMember" name="SubscriptionRightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="siga_USTreasuryRateMember" name="USTreasuryRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>siga-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CommitmentsAndContingencies" xlink:href="siga-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:href="siga-20180331.xsd#ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Debt" xlink:href="siga-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DebtNarrativeDetails" xlink:href="siga-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:href="siga-20180331.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstruments" xlink:href="siga-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:href="siga-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxes" xlink:href="siga-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxesDetails" xlink:href="siga-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Inventory" xlink:href="siga-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryDetails" xlink:href="siga-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryTables" xlink:href="siga-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareData" xlink:href="siga-20180331.xsd#PerShareData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataDetails" xlink:href="siga-20180331.xsd#PerShareDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataTables" xlink:href="siga-20180331.xsd#PerShareDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactions" xlink:href="siga-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_7956b3ca-f782-1311-282b-f61b8b1547a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedBonusesCurrent_7956b3ca-f782-1311-282b-f61b8b1547a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_9a892e27-e80d-dc6f-5258-af2522cd72c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_DeferredRevenue_9a892e27-e80d-dc6f-5258-af2522cd72c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_cfb764f4-058e-3980-a6a4-8e9d4481cdd1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedVacationCurrent_cfb764f4-058e-3980-a6a4-8e9d4481cdd1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d69779e7-80bd-4b93-0bb0-641eb2f586cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d69779e7-80bd-4b93-0bb0-641eb2f586cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aa03feac-7644-913e-0208-3bf6e84c2b98" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aa03feac-7644-913e-0208-3bf6e84c2b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_35cb0f84-dbd0-e82b-6765-c429f7121c7c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_DeferredCosts_35cb0f84-dbd0-e82b-6765-c429f7121c7c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_79b86299-04f6-ff11-6b66-c6ef1f697685" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_79b86299-04f6-ff11-6b66-c6ef1f697685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_4ac76402-c1d4-8f1b-a756-a36ba9f9779c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_4ac76402-c1d4-8f1b-a756-a36ba9f9779c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_81d717e1-3e46-8423-3e5f-d98aacc74856" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilities_81d717e1-3e46-8423-3e5f-d98aacc74856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_25092478-5ed6-8062-67ab-930a3e97a921" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_25092478-5ed6-8062-67ab-930a3e97a921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_019a49e8-ae3e-0ad0-8549-c1620e69cd20" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_019a49e8-ae3e-0ad0-8549-c1620e69cd20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_StockIssuanceFeesExpense" xlink:label="loc_siga_StockIssuanceFeesExpense_26a050c2-1ba2-7fe0-2f12-d2558c1d33b3" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_siga_StockIssuanceFeesExpense_26a050c2-1ba2-7fe0-2f12-d2558c1d33b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_df42b422-74b8-5f19-6fc7-0cf65a21f80f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_73e959a8-32b6-697e-66b5-86ef5a29476e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_25092478-5ed6-8062-67ab-930a3e97a921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_25092478-5ed6-8062-67ab-930a3e97a921" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ResearchAndDevelopmentRevenue" xlink:label="loc_siga_ResearchAndDevelopmentRevenue_851fe910-15ca-54a9-1404-c1620e46f35c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_siga_ResearchAndDevelopmentRevenue_851fe910-15ca-54a9-1404-c1620e46f35c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_PatentPreparationFees" xlink:label="loc_siga_PatentPreparationFees_9ad03a80-16a5-7795-a974-c1620f16811b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_siga_PatentPreparationFees_9ad03a80-16a5-7795-a974-c1620f16811b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_019a49e8-ae3e-0ad0-8549-c1620e69cd20" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_019a49e8-ae3e-0ad0-8549-c1620e69cd20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_a080ad5e-1839-b502-5666-a53bf2b006ac" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_a080ad5e-1839-b502-5666-a53bf2b006ac" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/PerShareData" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/PerShareDataDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/PerShareDataTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_f0ea2165-5b3b-6de9-7b02-17c18660730c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_f0ea2165-5b3b-6de9-7b02-17c18660730c" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ComputerEquipment" xlink:label="loc_siga_ComputerEquipment_1fba482b-b44a-d1fe-75e6-c1620e6383f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_siga_ComputerEquipment_1fba482b-b44a-d1fe-75e6-c1620e6383f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_4cb0d2ac-0cb3-6a50-d84b-44ca2020e7fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_4cb0d2ac-0cb3-6a50-d84b-44ca2020e7fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_2c642bd3-af0e-2712-c577-dff033ad00ba" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_RestrictedCashCurrent_2c642bd3-af0e-2712-c577-dff033ad00ba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fb3f4117-3448-7901-1609-fbf2b3e475d2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0a3a0d3-8732-f4e7-3bda-ee235d574c3b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fb3f4117-3448-7901-1609-fbf2b3e475d2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>siga-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CommitmentsAndContingencies" xlink:href="siga-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:href="siga-20180331.xsd#ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Debt" xlink:href="siga-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DebtNarrativeDetails" xlink:href="siga-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:href="siga-20180331.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstruments" xlink:href="siga-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:href="siga-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxes" xlink:href="siga-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxesDetails" xlink:href="siga-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Inventory" xlink:href="siga-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryDetails" xlink:href="siga-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryTables" xlink:href="siga-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareData" xlink:href="siga-20180331.xsd#PerShareData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataDetails" xlink:href="siga-20180331.xsd#PerShareDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataTables" xlink:href="siga-20180331.xsd#PerShareDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactions" xlink:href="siga-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractLineItems" xlink:label="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractTable" xlink:label="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:to="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAxis" xlink:label="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:to="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:to="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E_default" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:to="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_BardaContractMember" xlink:label="loc_siga_BardaContractMember_78207F9363CE9CD791274F2BAD8A1FD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:to="loc_siga_BardaContractMember_78207F9363CE9CD791274F2BAD8A1FD8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_Reducedholdbackamount" xlink:label="loc_siga_Reducedholdbackamount_50D652B100DC9C33F1874F2BAD8A0118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:to="loc_siga_Reducedholdbackamount_50D652B100DC9C33F1874F2BAD8A0118" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:to="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:to="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:to="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:to="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:to="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6F41768CB1B29DFD56072F76DCFEC58B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:to="loc_us-gaap_WarrantMember_6F41768CB1B29DFD56072F76DCFEC58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:to="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeAxis" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeDomain" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:to="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10_default" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeDomain" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:to="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_RepaymentofInterestsMember" xlink:label="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:to="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_PaymentsRelatedtoLitigationMember" xlink:label="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:to="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:to="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:to="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_USTreasuryRateMember" xlink:label="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:to="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LoanAgreementMember" xlink:label="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:to="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases" xlink:label="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityMinimumCashRequirement" xlink:label="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate" xlink:label="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_58BD71200B6D306E4D1A2F76DD05D679" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_58BD71200B6D306E4D1A2F76DD05D679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_SeniorSecuredTermLoanMember" xlink:label="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:to="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:to="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:to="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0CF801CAFD6317418BEB2F76DCE6CC6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:to="loc_us-gaap_WarrantMember_0CF801CAFD6317418BEB2F76DCE6CC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_66425583661E463C0BD72F76DCE76BFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_66425583661E463C0BD72F76DCE76BFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:to="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:to="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:to="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_F9307FA4D8EFFF03A0A22F76DD2698A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:to="loc_us-gaap_WarrantMember_F9307FA4D8EFFF03A0A22F76DD2698A4" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_SubscriptionRightMember" xlink:label="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:to="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_CEFE658840A6B8F9D5222F76DD27DAFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:to="loc_us-gaap_WarrantMember_CEFE658840A6B8F9D5222F76DD27DAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable" xlink:label="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/PerShareData" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/PerShareDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_54358D2569AB6A9B6022E3A4732EE7DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_WarrantMember_54358D2569AB6A9B6022E3A4732EE7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_RestrictedStockUnits" xlink:label="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/PerShareDataTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractLineItems" xlink:label="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractTable" xlink:label="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAxis" xlink:label="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:to="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:to="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3_default" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:to="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_BardaContractMember" xlink:label="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:to="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_NumberOfCoursesToBeDelivered1" xlink:label="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractValueOfAward1" xlink:label="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofManufacturingandDeliveryActivities" xlink:label="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract" xlink:label="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOfDevelopmentAndSupportActivities" xlink:label="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberofFreeCourses" xlink:label="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_Reducedholdbackamount" xlink:label="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromAdvancePaymentsGovernmentContracts" xlink:label="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MilestonePayment" xlink:label="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered" xlink:label="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofVariousOptions" xlink:label="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry" xlink:label="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableDevelopmentActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableProductionActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOptionFDAApproval" xlink:label="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:to="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameAxis" xlink:label="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameDomain" xlink:label="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:to="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D_default" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameDomain" xlink:label="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:to="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_NewHQLeaseMember" xlink:label="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:to="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OldHQSubleaseMember" xlink:label="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:to="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:to="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:to="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:to="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MacAndrewsForbesMember" xlink:label="loc_siga_MacAndrewsForbesMember_881A1B281AA935AE8164270D85717CFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:to="loc_siga_MacAndrewsForbesMember_881A1B281AA935AE8164270D85717CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsForInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsAfterInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_InitialFacilityFee" xlink:label="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAnnualIncreasePercent" xlink:label="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAfterInitialPeriod" xlink:label="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LeaseTerminationLiability" xlink:label="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:to="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:to="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MacAndrewsForbesMember" xlink:label="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:to="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:to="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:to="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:to="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:to="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_80B9EAA11F963BF2D81908B941B9238E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:to="loc_us-gaap_SecuredDebtMember_80B9EAA11F963BF2D81908B941B9238E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LoanAgreementMember" xlink:label="loc_siga_LoanAgreementMember_C3C25F9101445FFE33EA08B941BA3FF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:to="loc_siga_LoanAgreementMember_C3C25F9101445FFE33EA08B941BA3FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0F82A122ABFB9BB303D308B941C0FCFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_DeferredRevenue_0F82A122ABFB9BB303D308B941C0FCFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>siga-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896_label_en-US" xlink:label="lab_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</link:label>
    <link:label id="lab_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896_documentation_en-US" xlink:label="lab_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_BalanceSheetParentheticalAbstract" xlink:label="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:to="lab_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:to="lab_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:to="lab_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:type="arc" />
    <link:label id="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45_terseLabel_en-US" xlink:label="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Procurement Contract [Table]</link:label>
    <link:label id="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45_label_en-US" xlink:label="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Procurement Contract [Table]</link:label>
    <link:label id="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45_documentation_en-US" xlink:label="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Procurement Contract [Table]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractTable" xlink:label="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:to="lab_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="arc" />
    <link:label id="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8_terseLabel_en-US" xlink:label="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Procurement Contract [Axis]</link:label>
    <link:label id="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8_label_en-US" xlink:label="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Procurement Contract [Axis]</link:label>
    <link:label id="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8_documentation_en-US" xlink:label="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Procurement Contract [Axis]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAxis" xlink:label="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:to="lab_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="arc" />
    <link:label id="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3_terseLabel_en-US" xlink:label="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Procurement Contract [Domain]</link:label>
    <link:label id="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3_label_en-US" xlink:label="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Procurement Contract [Domain]</link:label>
    <link:label id="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3_documentation_en-US" xlink:label="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Procurement Contract [Domain]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:to="lab_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="arc" />
    <link:label id="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A_terseLabel_en-US" xlink:label="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARDA Contract</link:label>
    <link:label id="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A_label_en-US" xlink:label="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Barda Contract [Member]</link:label>
    <link:label id="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A_documentation_en-US" xlink:label="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Barda Contract [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_BardaContractMember" xlink:label="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:to="lab_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="arc" />
    <link:label id="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783_terseLabel_en-US" xlink:label="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Procurement Contract [Line Items]</link:label>
    <link:label id="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783_label_en-US" xlink:label="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Procurement Contract [Line Items]</link:label>
    <link:label id="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783_documentation_en-US" xlink:label="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Procurement Contract [Line Items]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractLineItems" xlink:label="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="lab_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:type="arc" />
    <link:label id="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98_terseLabel_en-US" xlink:label="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of courses to be delivered</link:label>
    <link:label id="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98_label_en-US" xlink:label="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Courses To Be Delivered 1</link:label>
    <link:label id="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98_documentation_en-US" xlink:label="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_NumberOfCoursesToBeDelivered1" xlink:label="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:to="lab_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="arc" />
    <link:label id="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3_terseLabel_en-US" xlink:label="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of contract</link:label>
    <link:label id="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3_label_en-US" xlink:label="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract, Value of Award 1</link:label>
    <link:label id="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3_documentation_en-US" xlink:label="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of base contract award.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractValueOfAward1" xlink:label="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:to="lab_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021_terseLabel_en-US" xlink:label="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Value of Manufacturing and Delivery Activities</link:label>
    <link:label id="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021_label_en-US" xlink:label="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value of Manufacturing and Delivery Activities</link:label>
    <link:label id="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021_documentation_en-US" xlink:label="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of manufacturing and delivery activities.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofManufacturingandDeliveryActivities" xlink:label="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:to="lab_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="arc" />
    <link:label id="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3_terseLabel_en-US" xlink:label="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of courses under modified contract</link:label>
    <link:label id="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3_label_en-US" xlink:label="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract, Number of Courses Purchased Under Modified Contract</link:label>
    <link:label id="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3_documentation_en-US" xlink:label="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government contract, number of courses to be purchased under modified contract.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract" xlink:label="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:to="lab_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E_terseLabel_en-US" xlink:label="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract value of development and support activities</link:label>
    <link:label id="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E_label_en-US" xlink:label="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value of Development and Support Activities</link:label>
    <link:label id="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E_documentation_en-US" xlink:label="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of development and support activities</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOfDevelopmentAndSupportActivities" xlink:label="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:to="lab_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="arc" />
    <link:label id="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08_terseLabel_en-US" xlink:label="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government contract, number of free courses</link:label>
    <link:label id="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08_label_en-US" xlink:label="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract, Number of Free Courses</link:label>
    <link:label id="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08_documentation_en-US" xlink:label="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberofFreeCourses" xlink:label="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:to="lab_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="arc" />
    <link:label id="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A_terseLabel_en-US" xlink:label="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduced holdback amount</link:label>
    <link:label id="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A_label_en-US" xlink:label="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduced holdback amount</link:label>
    <link:label id="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A_documentation_en-US" xlink:label="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduced holdback  be received from BARDA</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_Reducedholdbackamount" xlink:label="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:to="lab_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="arc" />
    <link:label id="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A_terseLabel_en-US" xlink:label="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from manufacture and physical delivery of courses, government contract</link:label>
    <link:label id="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A_label_en-US" xlink:label="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts</link:label>
    <link:label id="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A_documentation_en-US" xlink:label="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from manufacture and physical delivery of courses, government contracts.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:to="lab_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="arc" />
    <link:label id="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15_terseLabel_en-US" xlink:label="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from advance payments under the BARDA contract</link:label>
    <link:label id="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15_label_en-US" xlink:label="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Advance Payments, Government Contracts</link:label>
    <link:label id="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15_documentation_en-US" xlink:label="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from advance payments, government contracts</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromAdvancePaymentsGovernmentContracts" xlink:label="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:to="lab_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="arc" />
    <link:label id="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A_terseLabel_en-US" xlink:label="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A_label_en-US" xlink:label="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A_documentation_en-US" xlink:label="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from milestone payment, Government contracts</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_MilestonePayment" xlink:label="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:to="lab_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="arc" />
    <link:label id="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830_terseLabel_en-US" xlink:label="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Physical Delivery Of Courses, Government Contracts</link:label>
    <link:label id="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830_label_en-US" xlink:label="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Physical Delivery Of Courses, Government Contracts</link:label>
    <link:label id="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830_documentation_en-US" xlink:label="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from physical delivery of courses, government contract.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:to="lab_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="arc" />
    <link:label id="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A_terseLabel_en-US" xlink:label="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government contract, total number of courses required to be delivered</link:label>
    <link:label id="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A_label_en-US" xlink:label="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Contract, Total Number of Courses Required to Be Delivered</link:label>
    <link:label id="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A_documentation_en-US" xlink:label="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Contract, Total Number of Courses Required to Be Delivered</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered" xlink:label="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:to="lab_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2_terseLabel_en-US" xlink:label="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract value of various options</link:label>
    <link:label id="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2_label_en-US" xlink:label="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value of Various Options</link:label>
    <link:label id="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2_documentation_en-US" xlink:label="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of various options exercisable at BARDA's discretion.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofVariousOptions" xlink:label="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:to="lab_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="arc" />
    <link:label id="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA_terseLabel_en-US" xlink:label="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of option to be received from BARDA for approval for extension of 84 moth expiry</link:label>
    <link:label id="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA_label_en-US" xlink:label="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of option to be received from BARDA for approval for extension of 84 moth expiry</link:label>
    <link:label id="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA_documentation_en-US" xlink:label="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of option to be received from BARDA for approval for extension of 84 moth expiry</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry" xlink:label="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:to="lab_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330_terseLabel_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Value, Detail Of Option Exercisable, Development Activities</link:label>
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330_label_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value, Detail Of Option Exercisable, Development Activities</link:label>
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330_documentation_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableDevelopmentActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:to="lab_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B_terseLabel_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Value, Detail Of Option Exercisable, Production Activities</link:label>
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B_label_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value, Detail Of Option Exercisable, Production Activities</link:label>
    <link:label id="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B_documentation_en-US" xlink:label="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableProductionActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:to="lab_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="arc" />
    <link:label id="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D_terseLabel_en-US" xlink:label="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Value, Option, FDA Approval</link:label>
    <link:label id="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D_label_en-US" xlink:label="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Value, Option, FDA Approval</link:label>
    <link:label id="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D_documentation_en-US" xlink:label="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOptionFDAApproval" xlink:label="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:to="lab_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:to="lab_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7_label_en-US" xlink:label="lab_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:to="lab_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4_label_en-US" xlink:label="lab_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:to="lab_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write down of inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:to="lab_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:type="arc" />
    <link:label id="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF_terseLabel_en-US" xlink:label="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-downs</link:label>
    <link:label id="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF_label_en-US" xlink:label="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-downs</link:label>
    <link:label id="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF_documentation_en-US" xlink:label="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory write-downs included in research and development expense on the balance sheet.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_InventoryWriteDowns" xlink:label="loc_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:to="lab_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:type="arc" />
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C_terseLabel_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C_label_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities [Text Block]</link:label>
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C_documentation_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:to="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:to="lab_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:to="lab_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81_label_en-US" xlink:label="lab_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:to="lab_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="arc" />
    <link:label id="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6_terseLabel_en-US" xlink:label="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription Right</link:label>
    <link:label id="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6_label_en-US" xlink:label="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Right [Member]</link:label>
    <link:label id="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6_documentation_en-US" xlink:label="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription Right [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_SubscriptionRightMember" xlink:label="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:to="lab_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="arc" />
    <link:label id="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080_terseLabel_en-US" xlink:label="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable period for warrants (in years)</link:label>
    <link:label id="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080_label_en-US" xlink:label="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights are Exercisable</link:label>
    <link:label id="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080_documentation_en-US" xlink:label="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period from which Warrants or Rights are Exercisable</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable" xlink:label="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:to="lab_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="arc" />
    <link:label id="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1_negatedLabel_en-US" xlink:label="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of warrant liability</link:label>
    <link:label id="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1_label_en-US" xlink:label="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Fair Value Of Warrants</link:label>
    <link:label id="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1_documentation_en-US" xlink:label="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:to="lab_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements, gross</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:type="arc" />
    <link:label id="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A_terseLabel_en-US" xlink:label="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment, gross</link:label>
    <link:label id="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A_label_en-US" xlink:label="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A_documentation_en-US" xlink:label="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross amount of capitalized computer equipment costs as of the balance sheet date.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ComputerEquipment" xlink:label="loc_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:to="lab_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures, gross</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, depletion and amortization, property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and other amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:to="lab_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Consolidated Financial Statements</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:to="lab_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:type="arc" />
    <link:label id="lab_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A_label_en-US" xlink:label="lab_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A_documentation_en-US" xlink:label="lab_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_DocumentAndEntityInformationAbstract" xlink:label="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="lab_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:to="lab_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:to="lab_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:to="lab_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A_label_en-US" xlink:label="lab_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:to="lab_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929_label_en-US" xlink:label="lab_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:to="lab_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258_terseLabel_en-US" xlink:label="lab_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258_label_en-US" xlink:label="lab_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:to="lab_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:to="lab_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:to="lab_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:to="lab_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E_label_en-US" xlink:label="lab_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:to="lab_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:type="arc" />
    <link:label id="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505_terseLabel_en-US" xlink:label="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505_label_en-US" xlink:label="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Policy Text Block]</link:label>
    <link:label id="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505_documentation_en-US" xlink:label="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Policy Text Block]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_RestrictedCashandCashEquivalentsPolicyTextBlock" xlink:label="loc_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:to="lab_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and other amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:type="arc" />
    <link:label id="lab_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2_terseLabel_en-US" xlink:label="lab_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of warrant liability</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:to="lab_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:to="lab_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes (benefit) provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:type="arc" />
    <link:label id="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D_terseLabel_en-US" xlink:label="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D_label_en-US" xlink:label="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Fees Expense</link:label>
    <link:label id="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D_documentation_en-US" xlink:label="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Fees Expense</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_StockIssuanceFeesExpense" xlink:label="loc_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:to="lab_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of employee tax obligations for common stock tendered</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Settled Stock Appreciation Rights</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="arc" />
    <link:label id="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879_terseLabel_en-US" xlink:label="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879_label_en-US" xlink:label="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879_documentation_en-US" xlink:label="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units have been vested but not converted into common stock</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_RestrictedStockUnits" xlink:label="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:to="lab_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5F293A8B81808F3B1BAC6D276CB228BE" xlink:type="arc" />
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506_terseLabel_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506_label_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities [Table Text Block]</link:label>
    <link:label id="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506_documentation_en-US" xlink:label="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:to="lab_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="arc" />
    <link:label id="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6_terseLabel_en-US" xlink:label="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Secured Term Loan</link:label>
    <link:label id="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6_label_en-US" xlink:label="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Secured Term Loan [Member]</link:label>
    <link:label id="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6_documentation_en-US" xlink:label="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Secured Term Loan [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_SeniorSecuredTermLoanMember" xlink:label="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:to="lab_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loan outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:to="lab_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash-short term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:to="lab_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash-long term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:type="arc" />
    <link:label id="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568_verboseLabel_en-US" xlink:label="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Procurement Contract and Research Agreements</link:label>
    <link:label id="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568_label_en-US" xlink:label="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Procurement Contract and Research Agreements [Text Block]</link:label>
    <link:label id="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568_documentation_en-US" xlink:label="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAndResearchAgreementsTextBlock" xlink:label="loc_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:to="lab_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:to="lab_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue-R&amp;D for TPOXX&#174; intravenous formulation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:to="lab_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vacation</link:label>
    <link:label id="lab_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389_label_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:to="lab_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (primarily R&amp;D vendors and CMOs)</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="lab_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:to="lab_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:type="arc" />
    <link:label id="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D_terseLabel_en-US" xlink:label="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D_label_en-US" xlink:label="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Revenue</link:label>
    <link:label id="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D_documentation_en-US" xlink:label="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_ResearchAndDevelopmentRevenue" xlink:label="loc_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:to="lab_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:type="arc" />
    <link:label id="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933_terseLabel_en-US" xlink:label="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent expenses</link:label>
    <link:label id="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933_label_en-US" xlink:label="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Preparation Fees</link:label>
    <link:label id="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933_documentation_en-US" xlink:label="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_PatentPreparationFees" xlink:label="loc_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:to="lab_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:to="lab_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:to="lab_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24_label_en-US" xlink:label="lab_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:to="lab_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:type="arc" />
    <link:label id="lab_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F_negatedTerseLabel_en-US" xlink:label="lab_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss from change in fair value of warrant liability</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:to="lab_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit/(provision) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net and comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:to="lab_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share: basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding: basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:to="lab_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="arc" />
    <link:label id="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF_terseLabel_en-US" xlink:label="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MacAndrews &amp; Forbes</link:label>
    <link:label id="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF_label_en-US" xlink:label="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MacAndrews &amp; Forbes [Member]</link:label>
    <link:label id="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF_documentation_en-US" xlink:label="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MacAndrews &amp; Forbes [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_MacAndrewsForbesMember" xlink:label="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:to="lab_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="lab_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:to="lab_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges (included in selling, general and administrative expenses)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:to="lab_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments, net of sublease income</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:to="lab_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:to="lab_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:to="lab_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="arc" />
    <link:label id="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450_terseLabel_en-US" xlink:label="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Name [Axis]</link:label>
    <link:label id="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450_label_en-US" xlink:label="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Name [Axis]</link:label>
    <link:label id="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450_documentation_en-US" xlink:label="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Name [Axis]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameAxis" xlink:label="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:to="lab_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="arc" />
    <link:label id="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D_terseLabel_en-US" xlink:label="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Name [Domain]</link:label>
    <link:label id="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D_label_en-US" xlink:label="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Name [Domain]</link:label>
    <link:label id="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D_documentation_en-US" xlink:label="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Operating Lease, Name [Axis]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameDomain" xlink:label="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:to="lab_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="arc" />
    <link:label id="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174_terseLabel_en-US" xlink:label="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New HQ Lease</link:label>
    <link:label id="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174_label_en-US" xlink:label="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New HQ Lease [Member]</link:label>
    <link:label id="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174_documentation_en-US" xlink:label="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New HQ Lease [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_NewHQLeaseMember" xlink:label="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:to="lab_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="arc" />
    <link:label id="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8_terseLabel_en-US" xlink:label="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Old HQ Subleas</link:label>
    <link:label id="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8_label_en-US" xlink:label="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Old HQ Sublease [Member]</link:label>
    <link:label id="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8_documentation_en-US" xlink:label="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Old HQ Sublease [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_OldHQSubleaseMember" xlink:label="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:to="lab_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Member of Board of Directors</link:label>
    <link:label id="lab_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E_label_en-US" xlink:label="lab_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:to="lab_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label id="lab_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6_label_en-US" xlink:label="lab_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:to="lab_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable to related party</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of real estate property (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="arc" />
    <link:label id="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF_terseLabel_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly rental payments for initial period</link:label>
    <link:label id="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF_label_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monthly Rental Payments For Initial Period</link:label>
    <link:label id="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF_documentation_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the monthly rental payments due under the sublease entered into for the initial period.</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsForInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:to="lab_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="arc" />
    <link:label id="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933_terseLabel_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly rental payments after initial period</link:label>
    <link:label id="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933_label_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monthly Rental Payments After Initial Period</link:label>
    <link:label id="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933_documentation_en-US" xlink:label="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the monthly rental payments due under the sublease entered into after initial period</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsAfterInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:to="lab_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="arc" />
    <link:label id="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214_terseLabel_en-US" xlink:label="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional facility fee</link:label>
    <link:label id="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214_label_en-US" xlink:label="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Facility Fee</link:label>
    <link:label id="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214_documentation_en-US" xlink:label="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Facility Fee</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_InitialFacilityFee" xlink:label="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:to="lab_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="arc" />
    <link:label id="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D_terseLabel_en-US" xlink:label="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility fee annual increase, percent</link:label>
    <link:label id="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D_label_en-US" xlink:label="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Fee Annual Increase, Percent</link:label>
    <link:label id="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D_documentation_en-US" xlink:label="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Fee Annual Increase</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAnnualIncreasePercent" xlink:label="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:to="lab_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="arc" />
    <link:label id="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF_terseLabel_en-US" xlink:label="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility fee after initial period</link:label>
    <link:label id="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF_label_en-US" xlink:label="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Fee After Initial Period</link:label>
    <link:label id="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF_documentation_en-US" xlink:label="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Fee After Initial Period</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAfterInitialPeriod" xlink:label="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:to="lab_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business exit cost</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:to="lab_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write down of leasehold improvements and furniture</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="arc" />
    <link:label id="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765_terseLabel_en-US" xlink:label="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease termination liability</link:label>
    <link:label id="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765_label_en-US" xlink:label="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Termination Liability</link:label>
    <link:label id="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765_documentation_en-US" xlink:label="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Termination Liability</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_LeaseTerminationLiability" xlink:label="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:to="lab_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="lab_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:to="lab_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:to="lab_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:to="lab_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:to="lab_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:to="lab_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="arc" />
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145_terseLabel_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Capacity by Specific Purpose [Axis]</link:label>
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145_label_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Capacity by Specific Purpose [Axis]</link:label>
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145_documentation_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Capacity by Specific Purpose [Axis]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeAxis" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:to="lab_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="arc" />
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10_terseLabel_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Capacity by Specific Purpose [Domain]</link:label>
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10_label_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Capacity by Specific Purpose [Domain]</link:label>
    <link:label id="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10_documentation_en-US" xlink:label="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Instrument Capacity by Specific Purpose [Axis]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeDomain" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:to="lab_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="arc" />
    <link:label id="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120_terseLabel_en-US" xlink:label="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of Interests</link:label>
    <link:label id="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120_label_en-US" xlink:label="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of Interests [Member]</link:label>
    <link:label id="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120_documentation_en-US" xlink:label="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment of Interests [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_RepaymentofInterestsMember" xlink:label="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:to="lab_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="arc" />
    <link:label id="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2_terseLabel_en-US" xlink:label="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments Related to Litigation</link:label>
    <link:label id="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2_label_en-US" xlink:label="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Litigation [Member]</link:label>
    <link:label id="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2_documentation_en-US" xlink:label="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Related to Litigation [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_PaymentsRelatedtoLitigationMember" xlink:label="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:to="lab_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:to="lab_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:to="lab_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="arc" />
    <link:label id="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1_terseLabel_en-US" xlink:label="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury Rate</link:label>
    <link:label id="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1_label_en-US" xlink:label="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Rate [Member]</link:label>
    <link:label id="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1_documentation_en-US" xlink:label="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US Treasury Rate [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_USTreasuryRateMember" xlink:label="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:to="lab_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:to="lab_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="arc" />
    <link:label id="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF_terseLabel_en-US" xlink:label="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF_label_en-US" xlink:label="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:label id="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF_documentation_en-US" xlink:label="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_LoanAgreementMember" xlink:label="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:to="lab_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="lab_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capacity available for specific purpose other than for trade purchases</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases" xlink:label="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:to="lab_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Margin for term loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:to="lab_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid on term loan</link:label>
    <link:label id="lab_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C_label_en-US" xlink:label="lab_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:to="lab_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense accreted to balance</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="arc" />
    <link:label id="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA_terseLabel_en-US" xlink:label="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional borrowing capacity</link:label>
    <link:label id="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA_label_en-US" xlink:label="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA_documentation_en-US" xlink:label="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:to="lab_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="arc" />
    <link:label id="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C_terseLabel_en-US" xlink:label="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum cash requirement</link:label>
    <link:label id="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C_label_en-US" xlink:label="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Minimum Cash Requirement</link:label>
    <link:label id="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C_documentation_en-US" xlink:label="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Minimum Cash Requirement</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityMinimumCashRequirement" xlink:label="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:to="lab_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="arc" />
    <link:label id="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401_terseLabel_en-US" xlink:label="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential increase in interest rate</link:label>
    <link:label id="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401_label_en-US" xlink:label="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Debt Default, Increase in Interest Rate</link:label>
    <link:label id="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401_documentation_en-US" xlink:label="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Debt Default, Increase in Interest Rate</link:label>
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate" xlink:label="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:to="lab_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and expenses</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:to="lab_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-18</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-18 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:to="lab_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred costs</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:to="lab_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:to="lab_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003_label_en-US" xlink:label="lab_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:to="lab_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7_label_en-US" xlink:label="lab_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:to="lab_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:to="lab_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrant liability at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrant liability at March 31, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per Share Data</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:to="lab_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of accounting change</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Billings in advance of revenue recognition</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:to="lab_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="lab_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="lab_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, short-term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:to="lab_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:to="lab_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash, long-term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7_label_en-US" xlink:label="lab_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:to="lab_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_78F7941205C149E7127D26058843EAE0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_78F7941205C149E7127D26058843EAE0_label_en-US" xlink:label="lab_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:to="lab_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIENCY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:to="lab_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:to="lab_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:to="lab_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:to="lab_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3_label_en-US" xlink:label="lab_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:to="lab_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:to="lab_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficiency</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:to="lab_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock ($.0001 par value, 600,000,000 shares authorized, 79,039,000 issued and outstanding at March 31, 2018, and December 31, 2017, respectively)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:to="lab_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficiency</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:to="lab_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficiency</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>siga-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="siga-20180331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CommitmentsAndContingencies" xlink:href="siga-20180331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:href="siga-20180331.xsd#CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="siga-20180331.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:href="siga-20180331.xsd#ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Debt" xlink:href="siga-20180331.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DebtNarrativeDetails" xlink:href="siga-20180331.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:href="siga-20180331.xsd#DocumentAndEntityInformationDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="siga-20180331.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstruments" xlink:href="siga-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:href="siga-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxes" xlink:href="siga-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/IncomeTaxesDetails" xlink:href="siga-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/Inventory" xlink:href="siga-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryDetails" xlink:href="siga-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/InventoryTables" xlink:href="siga-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareData" xlink:href="siga-20180331.xsd#PerShareData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataDetails" xlink:href="siga-20180331.xsd#PerShareDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PerShareDataTables" xlink:href="siga-20180331.xsd#PerShareDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:href="siga-20180331.xsd#ProcurementContractAndResearchAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:href="siga-20180331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactions" xlink:href="siga-20180331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:href="siga-20180331.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="siga-20180331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0CA89CE66E7A2B2857F62F37607066ED" xlink:to="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_C24E776FE70144932A6B2F376070306C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_AccruedBonusesCurrent_42A35800B74CC186C7774F43A83ED057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_DeferredRevenue_0691CA4B54F8F04267C54F43A841374D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_AE31A10DF1EA932193464F43A841157C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_AccruedVacationCurrent_8265C96D18AABD4E2E1E4F43A841C389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7FF34DD80B43885BCCB74F43A8410232" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1E03FF6741C9F9F8E774F43A83E6B3D" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_37EA7E2684C8DDFCC7014F43A8413165" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_064D79A0FEA6970458272F3760693942" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_064D79A0FEA6970458272F3760693942" xlink:to="loc_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_071C895F6F44E7FE36222F376069E506" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CB6BE8265CA800D3BBDB75DCEC6DD120" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4161C9EE6EFB4AE7A2F975DCEC6DE4A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:to="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E969D11B59491E6637A42605884381BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7B3774AB60814E90247B2605884304BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_EF46A633B91A5D8C1754260588435AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_InventoryNet_4EDC630ED59141EC91F926058843085F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73BA9DDA3C7B2B00AA5226058843F67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_DF99F36A4AC4E42750D026058842AD67" xlink:to="loc_us-gaap_AssetsCurrent_1385D36F469C4FBF37A626058843C54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7F86B4268A2B174BABA726058843DD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_677CAAAD61BC4331B9E426058843E07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_7B3CB8D59E8C40D674FB26058843ACBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_DeferredCosts_7B3CB8D59E8C40D674FB26058843ACBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_E8DCDA6E3B780BDC3BC326058843F925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_Goodwill_3852AF79A9ABE3745595260588438EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_329E31166EA6A9B9CE76260588433410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BC8FE0F8B9C2020D9C42260588422C67" xlink:to="loc_us-gaap_Assets_78F7941205C149E7127D26058843EAE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0ABE6792CE3C80F8DE7626058842EDD9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:to="loc_us-gaap_AccountsPayableCurrent_C068FE283D079CB3A26326058844293A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_A2423AC28181CD093A1B260588448A78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_AB0092D0227C5F70216E260588448583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DB6A635804CB929B4B9D26058843C88A" xlink:to="loc_us-gaap_LiabilitiesCurrent_E0B8BA7CD8B0614B5B26260588449C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_69A860E079C3F82B17BD26058844819A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_OtherLiabilities_9B35DF8569C8B7ABCBFE260588442668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_LongTermDebt_B862D47B007EFDD5D7B226058844118D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_Liabilities_EACF9706EC7EFB5F02B52605884493C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3AB9E2B56AEF1586638C26058844C05B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:to="loc_us-gaap_CommonStockValue_DB6BEA8CFA4E94204748260588443066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23731570991F5B7836D826058844981E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA2520CEA71480C6D49A260588443DEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FA2520CEA71480C6D49A260588443DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_A6248E1CE8DC424603EE260588443EE3" xlink:to="loc_us-gaap_StockholdersEquity_26730CCB7E4CCBAE882926058844460D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D593201D5F379546970026058843EF67" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_72CF11CC1251FF1EF3F9260588448BD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646D6350DDD6C91D2B1475DCEB62E233" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_F82C1AD56E7AA376B9C575DCEB62E3D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1C61BBC024257806F7DD4F2BAD85B7D5" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractTable" xlink:label="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1C61BBC024257806F7DD4F2BAD85B7D5" xlink:to="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAxis" xlink:label="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:to="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractAxis_1200AEBA359128BB34684F2BAD8514D1" xlink:to="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_BardaContractMember" xlink:label="loc_siga_BardaContractMember_78207F9363CE9CD791274F2BAD8A1FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractDomain_7B7B80ED4261FAA1AA2E4F2BAD89835E" xlink:to="loc_siga_BardaContractMember_78207F9363CE9CD791274F2BAD8A1FD8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractLineItems" xlink:label="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractTable_5754C44ECBCC23EDB0C44F2BAD858F09" xlink:to="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_Reducedholdbackamount" xlink:label="loc_siga_Reducedholdbackamount_50D652B100DC9C33F1874F2BAD8A0118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_8A374FA75D93BEA4FB064F2BAD8ADA5F" xlink:to="loc_siga_Reducedholdbackamount_50D652B100DC9C33F1874F2BAD8A0118" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A5383AECB1F585DD2D542710E234686C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:to="loc_us-gaap_NetIncomeLoss_A5383AECB1F585DD2D542710E234686C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6DA33CE0878D50EED4832710E2344E3C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_08CC216A954915E135482710E234CED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_us-gaap_ShareBasedCompensation_76A69E9E02A12622CD872710E234DFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_80E7BCC2025A3FD108DB2710E234669C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_StockIssuanceFeesExpense" xlink:label="loc_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_siga_StockIssuanceFeesExpense_6F9465497E046248C51A2710E234721D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E858A5FCEE6B21C7E0412710E23484BA" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3AF5694D12BDE33329472710E234AA65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_A7B2F2E1C6035A48BE9C2710E234AF4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_10A8B1A405BC944DB4D32710E2346327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_22FBF78482A91A7AFBC42710E234F63B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_F53AE8D9695DDECDEDF72710E234F119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_7998DC74A4250EACD7352710E234FC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DEFFB3DDACA403F3B8882710E23490C1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_C1FBF9522F1D2CA20C6B2710E234445D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6C2B6A4E7E207CBD06FC2710E23426FF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1C965475F25492A315612710E2348328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4012C97FEAE66C0D9CE12710E234A467" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_DED3409BFC220FD3BD432710E2340A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_BA8540AD428095777EDA2710E23434E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03F27DDFFA570DA10C972710E2344F44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_057B0B0E37A67EB2C8802710E234474B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_EA6FF71F81BE33B45CEF2710E23497B8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_05D4939C7ECD1E8A004B27114ABB14D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C583683616BAA6BA06927114BD6CB11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_682A507F82206B770F3E2710E23445AE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96B88C61FEF883B563BF27125C4E4265" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ResearchAndDevelopmentRevenue" xlink:label="loc_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2926A06F756A16E69DB926058837AEB4" xlink:to="loc_siga_ResearchAndDevelopmentRevenue_294CEE86A502F42A75F026058837785D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C48FBF356AC15C3AC87026058837D1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_AAAEE3FABF46F94E9854260588381A00" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_PatentPreparationFees" xlink:label="loc_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="loc_siga_PatentPreparationFees_2EFB1E9377F2027B1381260588381933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="loc_us-gaap_OperatingExpenses_E0F768CDB093E749D80126058838A18C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1EE879EEBCC6D418190A260588373A9B" xlink:to="loc_us-gaap_OperatingIncomeLoss_138B711EE2D7B726B794260588387553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_InterestExpense_5655FB76255FB4F00B5B26058838EB24" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_66356CD3EC088F7557C526058838334F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3F837C060DAC63775871260588380B2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_D1B905773282EAF2F9C02605883819EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_7FE169656E36E601C8A226058838F202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_737F8A47B84402872230260588385C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_NetIncomeLoss_BF0325C6EE14057F51172605883818D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_B4DB0B976060FB96E17F260588380B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_428FB3D400991C44197E2605883701FC" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_45A0D08E4DD189F1680426058838C0DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:href="siga-20180331.xsd#siga_BalanceSheetParentheticalAbstract" xlink:label="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_821872EC71C7B15FAE8075DCEB31DBEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A8EF52179A765BC3BE0575DCEB326A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:to="loc_us-gaap_CommonStockSharesIssued_7C0243BCE3B0F249ADE275DCEB32B5C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_BalanceSheetParentheticalAbstract_10A4F2D756A377ADEF6775DCEB31E896" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_EB48194C6ECB41B51D1475DCEB324546" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9D548AE5D110E42AA17675DCEAAA8D05" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_866497A7273EAC1FA82A75DCEAAABD08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F87BA117A9C2C74CD5442F76DCFC1107" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F87BA117A9C2C74CD5442F76DCFC1107" xlink:to="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_198F94DEB06B60E6EA592F76DCFC1346" xlink:to="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_CB4126C5446851FBE76C2F76DCFC96EA" xlink:to="loc_us-gaap_SecuredDebtMember_1DC342A55BAB0190175C2F76DCFDE602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_DA60A323545E495006B82F76DCFD890C" xlink:to="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_6F41768CB1B29DFD56072F76DCFEC58B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85DC0C5B6F6F6AE480BD2F76DCFDE957" xlink:to="loc_us-gaap_WarrantMember_6F41768CB1B29DFD56072F76DCFEC58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_53332A66F9A3EC4E9C332F76DCFE578F" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_18B685D02050E3646FC62F76DCFE70BB" xlink:to="loc_us-gaap_ScenarioForecastMember_108625D6110D32B6CEF82F76DCFEE8AB" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeAxis" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_DebtInstrumentCapacitybySpecificPurposeDomain" xlink:label="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeAxis_895CB48C2710327AAFDD2F76DCFFA145" xlink:to="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_RepaymentofInterestsMember" xlink:label="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:to="loc_siga_RepaymentofInterestsMember_F85E02171D4FD77967A12F76DD003120" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_PaymentsRelatedtoLitigationMember" xlink:label="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DebtInstrumentCapacitybySpecificPurposeDomain_E679B4602C09F9B8A0E32F76DD006E10" xlink:to="loc_siga_PaymentsRelatedtoLitigationMember_74A9D661B38266BFCB062F76DD01CFC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_5E922FD8F8FB66654BC82F76DD012D1F" xlink:to="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_45A21D7A155AD05A467F2F76DD02BB7F" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_USTreasuryRateMember" xlink:label="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_B400E9C5CC897A5139B22F76DD01AAD4" xlink:to="loc_siga_USTreasuryRateMember_44D4FF8F7670831122882F76DD02CAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_CDAEA1CE7591186F2B752F76DD02101F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LoanAgreementMember" xlink:label="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25083734A572AE1062412F76DD021DDA" xlink:to="loc_siga_LoanAgreementMember_DCB40C237FF4903EAC652F76DD03C3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74F0A3FFD58B9280EBFE2F76DCFCC794" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_F1F1748D781823372CFC2F76DD035565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases" xlink:label="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_4A68EF93199049FB48142F76DD0548EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_97C94DF19AA311ADD3FA2F76DD0334E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_12CFB1D6E974AD6C6BB12F76DD038EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_InterestExpenseDebt_14FE39668DB43A3EEC272F76DD033906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_InterestPaid_3786C5CE23D9847FAAD02F76DD04CD5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_11FC623CC55A408E2E492F76DD04804E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityAdditionalBorrowingCapacity" xlink:label="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityAdditionalBorrowingCapacity_9337B8FB86F5006800B82F76DD0578BA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityMinimumCashRequirement" xlink:label="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityMinimumCashRequirement_71573BCA7377780252822F76DD057A8C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate" xlink:label="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate_450D932813377B0D4ED32F76DD050401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_802E3FEFC6ECABD102532F76DD0574FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_142ADCA79901329AD6C72F76DD05BF23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_58BD71200B6D306E4D1A2F76DD05D679" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_58BD71200B6D306E4D1A2F76DD05D679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3EC867ABA9F18D7397CE2F76DD034C6E" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_06043643E8C969C106F82F76DD051B35" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/DocumentAndEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:href="siga-20180331.xsd#siga_DocumentAndEntityInformationAbstract" xlink:label="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_EntityRegistrantName_A6C4A9E3BE6088CAC5CB75DCEA9C5866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_EntityCentralIndexKey_9AC31FA9AB03A76474BA75DCEA9C83BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_CurrentFiscalYearEndDate_970BBA2AE4659A7397EE75DCEA9C3293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_EntityFilerCategory_ECAB4541685FBA4538C875DCEA9D4A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_TradingSymbol_0EA9D1A3D445A56CEF6A75DCEA9DA929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_DocumentType_583333F59654F5AD30B575DCEA9D4258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_DocumentPeriodEndDate_E547517E3089FCBD530875DCEA9DDDDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_DocumentFiscalYearFocus_C1A8B54C1E57CDD24C5F75DCEA9D54BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_DocumentFiscalPeriodFocus_773DFC27C7E95487C20875DCEA9D25BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_AmendmentFlag_1FD6BB83F577A000DB7875DCEA9D575E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_DocumentAndEntityInformationAbstract_20F02BCE30351AF3D0A075DCEA9C286A" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9ECCB31EB0384A88F69075DCEA9E8018" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9D5DFB8252A4162A241F2F37600C84E5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0B6DEA0DD99B890051D62F37600C98D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FEDF54385CBEDEC476EC2F375FEC8CF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FEDF54385CBEDEC476EC2F375FEC8CF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EEB124F7ABA32C4FBC0B2F375FED5BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FEDF54385CBEDEC476EC2F375FEC8CF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_95E0F21AB8805B7660462F375FED5297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FEDF54385CBEDEC476EC2F375FEC8CF0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4DF3C5C43B218123E9C52F375FEDC81E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3E53AA043A6750C9A7002F76DCE41C5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3E53AA043A6750C9A7002F76DCE41C5E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04146C60827AD72E608C2F76DCE467B4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_718207EEE83D288B7AD02F76DCE59B29" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0906EED5CEF2F3BB58FC2F76DCE5C0D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30FDB5EA70820EA09F9D2F76DCE5FFAD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_SeniorSecuredTermLoanMember" xlink:label="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_439E0B5FEE0EEC480D952F76DCE50F5C" xlink:to="loc_siga_SeniorSecuredTermLoanMember_831E021B0845F80B7F982F76DCE5ECE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A197471304329C9A38162F76DCE66A85" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63DC8848B5C26670790A2F76DCE6BE3D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5C2C646D0805DD17D02D2F76DCE6E18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0C3F6A4EA11CB2FF94752F76DCE6CF52" xlink:to="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_0CF801CAFD6317418BEB2F76DCE6CC6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_82A3AED5EAEAC9FA86D22F76DCE6127B" xlink:to="loc_us-gaap_WarrantMember_0CF801CAFD6317418BEB2F76DCE6CC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1CCDFF2E85C8D70E30122F76DCE4ECC7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_66425583661E463C0BD72F76DCE76BFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_66425583661E463C0BD72F76DCE76BFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1F8AB5264194E7C1B92F2F76DCE76ADE" xlink:to="loc_us-gaap_LongTermDebt_F9D158D553ED02C5C5182F76DCE78886" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35F07300612BD60628752F376006468E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35F07300612BD60628752F376006468E" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_31C9BF47F5F048DE73032F376006283B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_CBD0528BDE6844E10A7275DCEB5A2789" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CBD0528BDE6844E10A7275DCEB5A2789" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_2E5DF1DED9D5444D9F0675DCEB5AA115" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39706269A602E8E9DC4D2F76DD2162D0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2C0D2C7C895920FF5C422F76DD25B262" xlink:to="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_89C38AC7A8EFCCA522612F76DD2542CE" xlink:to="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0F49E623EA83EA404E192F76DD268187" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:to="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_SubscriptionRightMember" xlink:label="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7B19455AB7FC3509C89E2F76DD268146" xlink:to="loc_siga_SubscriptionRightMember_54C03FD7120182E682112F76DD267AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_F20A4A6AF388070E71372F76DD2788D5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4DD42A5685DD94D1B6522F76DD27CEC6" xlink:to="loc_us-gaap_WarrantMember_E0947ACB64FB3925159F2F76DD262D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0BD9845CF04DC34FF8562F76DD22EFC3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7822156124FEF5FE400E2F76DD27FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5C36DB3BB49E58A3BA9C2F76DD288BDE" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable" xlink:label="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable_16679B279FD5164799992F76DD28B080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_D49C1FCD03FA8199CB292F76DD28BF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_E9C8A4369B3D8DA6E77D2F76DD282487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F5F81D4166AB0E6BFF702F76DD2836B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_036EFD7A2B3290B6D0FE2F76DD28277E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_115C63DBE910D715CF0B2F76DD28BD80" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_IncreaseInFairValueOfWarrants" xlink:label="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_01D1DD580B3EB6A0AD2A2F76DD279894" xlink:to="loc_siga_IncreaseInFairValueOfWarrants_B86531FF45A4D1BD377D2F76DD2976C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8192A2EA91A00F249F0D75DCEA600504" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8192A2EA91A00F249F0D75DCEA600504" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ECB0F145894AAE9AD83E75DCEA614155" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9A1AC31CF8416A4C7F061859FCDC2093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F5467EDD70CCDDE3B7141859FCD20D00" xlink:to="loc_us-gaap_NetIncomeLoss_6688325ACB6DAFCF80FD185A686D7507" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_522404F52FC8014F1BAC75DCEB607A43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_522404F52FC8014F1BAC75DCEB607A43" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5CE769655AA489253CCB75DCEB609562" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_276AB0AFBFCE4C20C15C2F76DD398CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A12DA79AA560A4B344632F76DD39EA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="loc_us-gaap_InventoryNet_AD7185E93AAB8419C69C2F76DD3ACCF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="loc_us-gaap_InventoryWriteDown_1C7B4C6924D6232F466D2F76DD3AEEA8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_InventoryWriteDowns" xlink:label="loc_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_10A6F332F078A91B6B722F76DD390680" xlink:to="loc_siga_InventoryWriteDowns_8810468A3CFBD9C767052F76DD3AFCEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_E25FD80EA2A4EDF9CE2F75DCEC57D0C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_E25FD80EA2A4EDF9CE2F75DCEC57D0C7" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9A327740173AE76D81A575DCEC5874D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PerShareData" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7E2B5A6F53556963CD2F75DCEA6BD5E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7E2B5A6F53556963CD2F75DCEA6BD5E6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_BA43EE912455AF06315575DCEA6B3F12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PerShareDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A0AEA10963898910EE19E3A4732D0857" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A0AEA10963898910EE19E3A4732D0857" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E07126F3CA7457E48661E3A4732D40B9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1D56728CDA7C3C6584EAE3A4732DC151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_1FF5BAE540FDCC262E10E3A4732D7125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_C1083B7C8E4A0F66296DE3A4732E8F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_54358D2569AB6A9B6022E3A4732EE7DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_49B77CCB4786D2CB155EE3A4732D5A43" xlink:to="loc_us-gaap_WarrantMember_54358D2569AB6A9B6022E3A4732EE7DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_D7B37080CBC90B15A103E3A4732DFF79" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_DB7CBB604FD057F41500E3A4732EF1D6" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_RestrictedStockUnits" xlink:label="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_CA41E3A487EAECCFAE1BE3A4732E9C56" xlink:to="loc_siga_RestrictedStockUnits_5D37F1AAEF1FE5E61B73E3A7263FF879" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PerShareDataTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2A02BF2E52817B3FB2B375DCEC54861F" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_83E9134CE852D5DEB1BF75DCEC54BABD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_62BC98580CA90541BB0975DCEA48F182" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAndResearchAgreementsTextBlock" xlink:label="loc_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_62BC98580CA90541BB0975DCEA48F182" xlink:to="loc_siga_ProcurementContractAndResearchAgreementsTextBlock_FCC4468520C2F32DBC1475DCEA48D568" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractTable" xlink:label="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_11BCA2D6723ECA64FF67F861D29411A3" xlink:to="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractAxis" xlink:label="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:to="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractDomain" xlink:label="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractAxis_D094D693F745E555C31FF861D2967EC8" xlink:to="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_BardaContractMember" xlink:label="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractDomain_D7B9EB3D4D652C981309F861D2979DC3" xlink:to="loc_siga_BardaContractMember_49C51263766F3D23CC7FF861D298130A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProcurementContractLineItems" xlink:label="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractTable_F2D85604BFC14CBD76ECF861D2954A45" xlink:to="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_NumberOfCoursesToBeDelivered1" xlink:label="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_NumberOfCoursesToBeDelivered1_A1F1A7421FD8FC841D04F861D29AEB98" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractValueOfAward1" xlink:label="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractValueOfAward1_9E12F8192026BA8964C9F861D29B67D3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofManufacturingandDeliveryActivities" xlink:label="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueofManufacturingandDeliveryActivities_26C075C333F4DA59A044F861D29B3021" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract" xlink:label="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract_ED24D34DA7BCE785C78EF861D29BB4B3" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOfDevelopmentAndSupportActivities" xlink:label="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueOfDevelopmentAndSupportActivities_5F12B745804FD7483E2FF861D29CED5E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractNumberofFreeCourses" xlink:label="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractNumberofFreeCourses_7455A8DE2608FBD7A05FF861D29C6C08" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_Reducedholdbackamount" xlink:label="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_Reducedholdbackamount_A2F6FEA4DF194536004EF861D29DE55A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts_E0B3B6D4FBBAD13C3EC1F861D29D296A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromAdvancePaymentsGovernmentContracts" xlink:label="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromAdvancePaymentsGovernmentContracts_AEA3B4DD77D52A013142F861D29DBF15" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MilestonePayment" xlink:label="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_MilestonePayment_5AA6A08E54C89A462372F861D29EBF8A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts" xlink:label="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts_BD5A4D5A3B34693DBF6BF861D29E4830" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered" xlink:label="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered_5B0AE98BAE3EE1CEFF3EF861D29F722A" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueofVariousOptions" xlink:label="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueofVariousOptions_382C40A41E8D652B92BFF861D29F02E2" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry" xlink:label="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry_871131AEFF7C84C694A9F861D29F09BA" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableDevelopmentActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities_5A4A18C299FAE7D0A018F861D2A4E330" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueDetailOfOptionExercisableProductionActivities" xlink:label="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueDetailOfOptionExercisableProductionActivities_C17AB1D1DCD9046D5424F861D2A5021B" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ContractValueOptionFDAApproval" xlink:label="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_siga_ContractValueOptionFDAApproval_8ED6B0FD29F91D0F8A86F861D2A6ED7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_us-gaap_DeferredRevenue_B88CF35E17CCA6071097F861D2A7D268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_ProcurementContractLineItems_B3DE63F128766DD170F2F861D2991783" xlink:to="loc_us-gaap_DeferredCosts_D0836F30BF65C64F7F1DF861D2A75FF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63E23AC625A2C5F7A4CA75DCEC50ABF1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63E23AC625A2C5F7A4CA75DCEC50ABF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6DC379C2812C2612C88E75DCEC5004B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_449D9AC44036EBAD07062F37607CD9E2" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_ComputerEquipment" xlink:label="loc_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_siga_ComputerEquipment_328FCE8FCCB6158D3DEA2F37607CD17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_FEE2A98A04A8707875962F37607C9474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_DCE9D499A4D22836AB912F37607CCED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E604E5830E378A9F80512F37607DAB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_FA88DBA5C05CE2A59D5C2F37607D6430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A4A9527F795D93D3A53D2F37607ABF4F" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_A66B76C46E73A8CC8BB52F37607D3B60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_760F47999707339357B475DCEBD28697" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_760F47999707339357B475DCEBD28697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_12C3222BCD90C0154ED675DCEBD2D9DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5573162C83154539541175DCEB5C46DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5573162C83154539541175DCEB5C46DA" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_CE3B19D32B2AB94AE10375DCEB5D7847" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_BFA4E2CEC4618B4637F8270D856B14A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_BFA4E2CEC4618B4637F8270D856B14A2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_FEF3A0A346B55793CE52270D856EC43E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesMember" xlink:label="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6D2B8FDE663CE93AA6CB270D856E7C2F" xlink:to="loc_us-gaap_OtherLiabilitiesMember_E829B4F4D5F8797CF034270D856E3952" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameAxis" xlink:label="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OperatingLeaseNameDomain" xlink:label="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_OperatingLeaseNameAxis_A6A5A22E1E6C802D5A6D270D856F9450" xlink:to="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_NewHQLeaseMember" xlink:label="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:to="loc_siga_NewHQLeaseMember_0A85D901EA7B6C6C615F270D85705174" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_OldHQSubleaseMember" xlink:label="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_siga_OperatingLeaseNameDomain_9175B1EF6D0134FCB5DE270D856FE39D" xlink:to="loc_siga_OldHQSubleaseMember_0FCCE70D80F85333E541270D857084D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_D4651C77519AA3D5123F270D85700065" xlink:to="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManagementMember" xlink:label="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:to="loc_us-gaap_ManagementMember_F2E95F183D05B6581153270D8570D05E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MacAndrewsForbesMember" xlink:label="loc_siga_MacAndrewsForbesMember_881A1B281AA935AE8164270D85717CFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_817E197A2BAC2449827B270D85706673" xlink:to="loc_siga_MacAndrewsForbesMember_881A1B281AA935AE8164270D85717CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1F685C26D00EAC912F12270D856C59D7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_LegalFees_68B63D1EB35BBAA885D5270D8571CFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_896715CAB3D3FE5CFDA5270D8572C27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_42F2D5559FAAC7834610270D85727B20" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsForInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_MonthlyRentalPaymentsForInitialPeriod_1FB76C6581EA8C295D76270D8572A6EF" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MonthlyRentalPaymentsAfterInitialPeriod" xlink:label="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_MonthlyRentalPaymentsAfterInitialPeriod_E985E1EABC8B96A7132B270D85728933" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_InitialFacilityFee" xlink:label="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_InitialFacilityFee_75CDD37CA424B10E0EC6270D85726214" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAnnualIncreasePercent" xlink:label="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_FacilityFeeAnnualIncreasePercent_69439E3560A9639F7CA8270D85734C9D" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_FacilityFeeAfterInitialPeriod" xlink:label="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_FacilityFeeAfterInitialPeriod_8CC6E03D217CFA25E7DA270D857363AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_BusinessExitCosts1_E891442EADB967C7A45B270D8573D48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_C1F3689641D7BC790D35270D8573A67E" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LeaseTerminationLiability" xlink:label="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7939AFA566E61553C334270D857136E6" xlink:to="loc_siga_LeaseTerminationLiability_E76A0E3D8CC210950EDC270D85739765" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_FE85AA1B6954D0045E0CFDE303571211" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9CA8D1E69BF45C9A1A5CFDE303576D14" xlink:to="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_MacAndrewsForbesMember" xlink:label="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_E17387A5DB5CACF18EC6FDE303576C53" xlink:to="loc_siga_MacAndrewsForbesMember_E1CDDE370FAACF52E4B4FDE30357A2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_55F33665395172C03C54FDE303575A19" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_19014121CF77E9BF329DFDE30358BEF4" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_RestructuringReserve_7EB0341C46066BDE287AFDE303588660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_RestructuringCharges_7CDD172E1E431DE3FBCCFDE3035870A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_PaymentsForRestructuring_14B5D1BA855B312F98D3FDE30358328F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88F3D0238ED5FBEDB45DFDE303585A01" xlink:to="loc_us-gaap_RestructuringReserve_E490DFE12214C1EE88D7FDE303582F7A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_A8DB5581016E9D69EE1D75DCEA41B0CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_A8DB5581016E9D69EE1D75DCEA41B0CD" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6B6C5385A83780C1B4DF75DCEA412670" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_21757F0A51780799550A6D276CA873CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_279FD8DB00F60ABBE99A6D26185E6AE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_21757F0A51780799550A6D276CA873CC" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_279FD8DB00F60ABBE99A6D26185E6AE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8DC09990F7B5E2ED061608B9413ED1F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8DC09990F7B5E2ED061608B9413ED1F2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9D570CF57487B037E74108B9414174F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8DC09990F7B5E2ED061608B9413ED1F2" xlink:to="loc_us-gaap_RestrictedCashCurrent_C2E8AEB738C21B6BBD2808B94148DCD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8DC09990F7B5E2ED061608B9413ED1F2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_28F6114D1D42F7103C6808B94148F7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8DC09990F7B5E2ED061608B9413ED1F2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4D701C342D2436A4428908B94149D8FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B93C61A6453AFA44980A260587C761B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B93C61A6453AFA44980A260587C761B9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5251398B8C8DC41BC209260587C765B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B93C61A6453AFA44980A260587C761B9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_3E4DF91FAD3F044AAAFC260587C70226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B93C61A6453AFA44980A260587C761B9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_C728651B41363A32A63A260587C73E56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B93C61A6453AFA44980A260587C761B9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43CB54155DFAFD4201E9260587C7BF8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8AA1121115F946D23B3F08B941B6FFE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8AA1121115F946D23B3F08B941B6FFE6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6C44A0F30E2016BD339F08BB69EEE1BC" xlink:to="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201618Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_96FF746A10AD9FBFD4DA08BB6D81E6DC" xlink:to="loc_us-gaap_AccountingStandardsUpdate201618Member_D8E2E2637AA63B2102A608BB97B5242B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_58A658235D8AA6BD4B3608B941B73BBF" xlink:to="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_80B9EAA11F963BF2D81908B941B9238E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5790EF627D8B834670F808B941B833C9" xlink:to="loc_us-gaap_SecuredDebtMember_80B9EAA11F963BF2D81908B941B9238E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4DA4BD10C64A9C4BAB1E08B941BAFB9F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:type="arc" />
    <link:loc xlink:href="siga-20180331.xsd#siga_LoanAgreementMember" xlink:label="loc_siga_LoanAgreementMember_C3C25F9101445FFE33EA08B941BA3FF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ACEF904F99FB65CB395A08B941BA9743" xlink:to="loc_siga_LoanAgreementMember_C3C25F9101445FFE33EA08B941BA3FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD345732C1F11F37ADFE08B941BB6717" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D897299EE94697C1ECA08B941BC170B" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_47D971219BF27DC7904308B941BD950E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_CA5E3D02938C1C2E44F808B941BD14E6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_A9D64936B494C5A4541B08B941BDB412" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_33AD0B65ADB48910CC1808B941BE9FE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_223135C0D4C6848C0F4708B941B7513D" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_0F82A122ABFB9BB303D308B941C0FCFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_DeferredRevenue_0F82A122ABFB9BB303D308B941C0FCFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_DeferredCostsCurrentAndNoncurrent_4995AB276172C35CAB6B08B941C0E940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_AccountsReceivableNet_5DDB75D46231E6DD093C08B941C11408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AC98CED7700C410458D108B941C222D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_Revenues_E4A978DCD507D99789A908B941C3F003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_32005B3956F5D97E993E08B941C55E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCash_3DA2892F198DD594C58C08BAC0DB89E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_00154C719AA0D646D9B308B941C5A656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1EA2DA44045F1D1883A108B941BEBFFD" xlink:to="loc_us-gaap_RestrictedCashCurrent_02A247017BDF49E0EE4F08B941C6B7B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0282D91CD27F29388CB6B5761A14D980" xlink:type="locator" />
    <link:loc xlink:href="siga-20180331.xsd#siga_RestrictedCashandCashEquivalentsPolicyTextBlock" xlink:label="loc_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0282D91CD27F29388CB6B5761A14D980" xlink:to="loc_siga_RestrictedCashandCashEquivalentsPolicyTextBlock_557C540249DC6E9DD85EB57634CD0505" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_7B5D8318466FE6E48C5FF861B7EB7871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39B031E108960DF2CCBBF861714767F6" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_DDC760791FD41A9DC260F866D1542212" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802214464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Apr. 25, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SIGA TECHNOLOGIES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001010086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SIGAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,052,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802714016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,934,807<span></span>
</td>
<td class="nump">$ 19,857,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, short-term</a></td>
<td class="nump">10,850,136<span></span>
</td>
<td class="nump">10,701,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,263,680<span></span>
</td>
<td class="nump">1,802,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,983,249<span></span>
</td>
<td class="nump">2,983,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,900,566<span></span>
</td>
<td class="nump">2,019,999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,932,438<span></span>
</td>
<td class="nump">37,364,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">108,850<span></span>
</td>
<td class="nump">138,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, long-term</a></td>
<td class="nump">3,754,940<span></span>
</td>
<td class="nump">6,542,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred costs</a></td>
<td class="nump">94,296,804<span></span>
</td>
<td class="nump">96,592,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset, net</a></td>
<td class="nump">2,441,720<span></span>
</td>
<td class="nump">2,431,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">898,334<span></span>
</td>
<td class="nump">898,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">702,167<span></span>
</td>
<td class="nump">702,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">133,135,253<span></span>
</td>
<td class="nump">144,670,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">432,207<span></span>
</td>
<td class="nump">1,328,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,586,195<span></span>
</td>
<td class="nump">5,481,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">14,769,276<span></span>
</td>
<td class="nump">11,466,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,018,402<span></span>
</td>
<td class="nump">6,810,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">376,030,704<span></span>
</td>
<td class="nump">377,641,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">774,131<span></span>
</td>
<td class="nump">840,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">72,159,240<span></span>
</td>
<td class="nump">71,050,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">467,751,753<span></span>
</td>
<td class="nump">467,808,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficiency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($.0001 par value, 600,000,000 shares authorized, 79,039,000 issued and outstanding at March 31, 2018, and December 31, 2017, respectively)</a></td>
<td class="nump">7,904<span></span>
</td>
<td class="nump">7,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">214,556,941<span></span>
</td>
<td class="nump">214,229,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(549,181,345)<span></span>
</td>
<td class="num">(537,375,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficiency</a></td>
<td class="num">(334,616,500)<span></span>
</td>
<td class="num">(323,138,291)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficiency</a></td>
<td class="nump">$ 133,135,253<span></span>
</td>
<td class="nump">$ 144,670,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806420528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_BalanceSheetParentheticalAbstract', window );"><strong>Balance Sheet Parenthetical [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">79,039,000<span></span>
</td>
<td class="nump">79,039,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">79,039,000<span></span>
</td>
<td class="nump">79,039,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_BalanceSheetParentheticalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Parenthetical [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_BalanceSheetParentheticalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802693328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ResearchAndDevelopmentRevenue', window );">Research and development</a></td>
<td class="nump">$ 1,747,934<span></span>
</td>
<td class="nump">$ 5,201,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,056,546<span></span>
</td>
<td class="nump">2,869,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,007,827<span></span>
</td>
<td class="nump">6,360,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_PatentPreparationFees', window );">Patent expenses</a></td>
<td class="nump">218,472<span></span>
</td>
<td class="nump">240,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,282,845<span></span>
</td>
<td class="nump">9,470,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,534,911)<span></span>
</td>
<td class="num">(4,269,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,748,818)<span></span>
</td>
<td class="num">(3,608,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_IncreaseInFairValueOfWarrants', window );">Loss from change in fair value of warrant liability</a></td>
<td class="num">(3,303,114)<span></span>
</td>
<td class="num">(626,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,235<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(11,584,608)<span></span>
</td>
<td class="num">(8,499,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
<td class="nump">2,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit/(provision) for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,070)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive loss</a></td>
<td class="num">$ (11,582,256)<span></span>
</td>
<td class="num">$ (8,614,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share: basic and diluted</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding: basic and diluted</a></td>
<td class="nump">79,039,000<span></span>
</td>
<td class="nump">78,777,144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_IncreaseInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_IncreaseInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_PatentPreparationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_PatentPreparationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ResearchAndDevelopmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ResearchAndDevelopmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802483824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,582,256)<span></span>
</td>
<td class="num">$ (8,614,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and other amortization</a></td>
<td class="nump">29,790<span></span>
</td>
<td class="nump">36,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_IncreaseInFairValueOfWarrants', window );">Increase in fair value of warrant liability</a></td>
<td class="nump">3,303,114<span></span>
</td>
<td class="nump">626,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">327,360<span></span>
</td>
<td class="nump">87,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes (benefit) provision</a></td>
<td class="num">(9,758)<span></span>
</td>
<td class="nump">21,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_StockIssuanceFeesExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,108,916<span></span>
</td>
<td class="nump">1,108,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">645,730<span></span>
</td>
<td class="num">(1,724,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,090,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred costs</a></td>
<td class="nump">184,864<span></span>
</td>
<td class="num">(6,389,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">119,433<span></span>
</td>
<td class="nump">22,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other current liabilities</a></td>
<td class="num">(2,792,043)<span></span>
</td>
<td class="num">(1,894,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">169,269<span></span>
</td>
<td class="nump">8,719,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(66,122)<span></span>
</td>
<td class="num">(22,165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,561,703)<span></span>
</td>
<td class="num">(932,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations for common stock tendered</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">193,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(193,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(8,561,703)<span></span>
</td>
<td class="num">(1,126,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of period</a></td>
<td class="nump">37,101,586<span></span>
</td>
<td class="nump">56,174,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 28,539,883<span></span>
</td>
<td class="nump">$ 55,048,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_IncreaseInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_IncreaseInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_StockIssuanceFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Fees Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_StockIssuanceFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608065936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Condensed Consolidated Financial Statements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial statements are presented in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for quarterly reports on Form 10-Q and should be read in conjunction with the Company&#8217;s audited financial statements and notes thereto for the year ended December 31, 2017, included in the 2017 Annual Report on Form 10-K. All terms used but not defined elsewhere herein have the meaning ascribed to them in the Company&#8217;s 2017 Annual Report on Form 10-K filed on March 6, 2018. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results of the interim periods presented have been included. The 2017 year-end condensed balance sheet data was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results expected for the full year.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is not entitled to receive additional procurement-related payments under the current BARDA Contract (</font><a style="font-family:inherit;font-size:10pt;" href="#s7E5C538EFD7E1A43B3DD75DCE76FACC5"><font style="font-family:inherit;font-size:10pt;">Note 3</font></a><font style="font-family:inherit;font-size:10pt;color:#222222;">) if and until United States Food &amp; Drug Administration ("FDA") approval of TPOXX&#174; has been achieved, and there is no difference between the approved product and courses of TPOXX&#174; that have been delivered to the U.S. Strategic National Stockpile (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">Strategic Stockpile</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">). Upon meeting the aforementioned requirements, a determination of which is currently expected in the third quarter of 2018, the Company will be entitled to a </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$41 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> hold back payment under the BARDA Contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">In the event that the Company does not receive a substantial portion of the hold back payment, or other substantial cash inflows, by October of 2018, then, based on currently forecasted operating costs, the Company will require additional sources of funding to continue operations and prevent an event of default under the term loan (</font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;color:#222222;">). In this case, the Company would seek to increase cash liquidity by: raising proceeds through a financing, entering into a new contract for TPOXX&#174; or any other product, a sale of assets, or the modification of the existing BARDA Contract; significantly reducing its operating expenses; or modifying the terms of the Term Loan Agreement. There can be no assurance that TPOXX&#174; will receive FDA approval on a timely basis, if at all, or that there will be no difference between the approved product and courses of TPOXX&#174; that have been delivered to the Strategic Stockpile. Furthermore, there can be no assurance that the Company would be able to increase cash liquidity, if needed, through a financing, a new contract for TPOXX&#174; or any other product, a sale of assets, the modification of the existing BARDA Contract, or a significant reduction of its operating expenses or operations, or that the lenders would agree to modify the Term Loan Agreement, if needed. Because of these conditions, substantial doubt exists about the Company's ability to continue as a going concern for one year from the financial statement issuance date.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608842560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 606&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of ASC 606</font><font style="font-family:inherit;font-size:10pt;">. On&#160;January&#160;1, 2018, the Company adopted ASC 606 using the modified retrospective method applied to those contracts that were not completed as of&#160;January&#160;1, 2018. Results for reporting periods beginning after&#160;January&#160;1, 2018&#160;are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cumulative impact of adopting ASC 606 as of January 1, 2018 is: a decrease to deferred revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">; a decrease to deferred costs of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">; an increase to receivables of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and a net increase to opening accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of tax. For the&#160;three months ended March 31, 2018, the impact to revenues as a result of applying ASC 606 was an increase of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Obligations</font><font style="font-family:inherit;font-size:10pt;">.&#160;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in ASC 606.&#160;A contract&#8217;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.&#160;The Company&#8217;s research and development contract for the intravenous (IV) formulation of TPOXX&#174; (see "IV Formulation R&amp;D Contract" in Note 3) has a single performance obligation (research and development); individual services within the contract are not separately identifiable from other promises in the contract and, therefore, are not distinct from each other. The Company&#8217;s BARDA Contract (see Note 3) has three performance obligations: one relates to the manufacture and delivery of product (and performance of services in connection with the manufacture and delivery of product), and the other two performance obligations relate to research and development in connection with TPOXX&#174;. For contracts with multiple performance obligations, the Company allocates the contract&#8217;s transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract modifications may occur during the course of performance of our contracts. Contracts are often modified to account for changes in contract specifications or requirements. In most instances, contract modifications are for services that are not distinct, and, therefore, are accounted for as part of the existing contract.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s performance obligations are satisfied over time as work progresses or at a point in time.&#160;Substantially all of the Company&#8217;s revenue related to research and development performance obligations is recognized over time, because control transfers continuously to our customers.&#160;Typically, revenue is recognized over time using costs incurred to date relative to total estimated costs at completion to measure progress toward satisfying the Company&#8217;s performance obligations. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Contract costs include labor, material, overhead, and third-party services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue connected with courses of TPOXX&#174; delivered to the strategic stockpile and related services, milestones and advance payments (activities in combination that constitute one performance obligation) will be recognized at a point in time. Revenue associated with this performance obligation will be recognized&#160;when BARDA obtains control of the asset, which is upon delivery to and acceptance by the customer and at the point in time when the constraint on the consideration is resolved. The consideration, which is variable consideration, is expected to be constrained until the FDA&#8217;s approval of the final version of TPOXX&#174; (quantification and specification of the Replacement Obligation (as defined herein)) has occurred. It is expected that the possibility of product replacement pursuant to the Replacement Obligation, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&#8217;s regulatory review of the new drug application (NDA) for TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Estimates</font><font style="font-family:inherit;font-size:10pt;">.&#160;Accounting for long-term contracts and grants involves the use of various techniques to estimate total contract revenue and costs.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years.&#160;These assumptions include labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The nature of the work required to be performed on many of the Company&#8217;s performance obligations and the estimation of total revenue and cost at completion is complex, subject to many variables and requires significant judgment. The consideration associated with manufacture and delivery of product as well as research and development services is variable as the consideration is either constrained or the total amount of services to be performed has not been finalized. The Company estimates variable consideration at the most likely amount to which it expects to be entitled. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur and when any uncertainty associated with variable consideration is resolved. The Company&#8217;s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our historical and anticipated performance, external factors, trends and all other information (historical, current and forecasted) that is reasonably available to us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant change in one or more of these estimates could affect the profitability of the Company&#8217;s contracts.&#160;As such, the Company reviews and updates its contract-related estimates regularly. The Company recognizes adjustments in estimated revenues, research and development expenses and cost of sales under the cumulative catch-up method. Under this method, the impact of the adjustment on revenues, research and development expenses and cost of sales recorded to date on a contract is recognized in the period the adjustment is identified.&#160; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Balances</font><font style="font-family:inherit;font-size:10pt;">.&#160;The timing of revenue recognition, billings and cash collections may result in billed accounts receivable, unbilled receivables (contract assets) and customer advances and deposits (contract liabilities) in the Consolidated Balance Sheet. Generally, amounts are billed as work progresses in accordance with agreed-upon contractual terms either at periodic intervals (monthly) or upon achievement of contractual milestones. Under typical payment terms of fixed price arrangements, the customer pays the Company either performance-based payments or progress payments. For the Company&#8217;s cost type arrangements, the customer generally pays the Company for its actual costs incurred. Such payments occur within a short period of time. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining Performance Obligations</font><font style="font-family:inherit;font-size:10pt;">. Remaining performance obligations represents the transaction price for which work has not been performed and excludes unexercised contract options. As of March 31, 2018 the aggregate amount of transaction price allocated to remaining performance obligations for the BARDA Contract and the IV Formulation R&amp;D Contract was </font><font style="font-family:inherit;font-size:10pt;">$20.7 million</font><font style="font-family:inherit;font-size:10pt;">. The Company expects to recognize revenue over the next three to five years as the specific timing for satisfying the performance obligations is subjective and outside the Company&#8217;s control. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When the Company receives consideration, or such consideration is unconditionally due, prior to transferring goods or services to the customer under the terms of a sales contract, the Company records deferred revenue, which represents a contract liability. The Company recognizes deferred revenue as net sales once control of goods and/or services have been transferred to the customer and all revenue recognition criteria have been met and any constraints have been resolved.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has deferred revenue in connection with the manufacture and delivery of TPOXX&#174; under the BARDA contract. Revenue recognition is currently constrained by the possibility of product replacement pursuant to the Replacement Obligation. It is expected that the possibility of required product replacement, and the scale and scope of any such product replacement, will be addressed by August 8, 2018, which is the target final action date of the FDA&#8217;s regulatory review of the new drug application (NDA) for TPOXX&#174;. Upon resolution of this constraint, deferred revenue is expected to be recorded as net sales.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the change in the Company's deferred revenue:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">378,896,803</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumulative effect of accounting change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,780,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Billings in advance of revenue recognition</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169,269</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377,286,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 31, 2018 and December 31, 2017, approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred revenue was classified as accrued expenses and other current liabilities on the condensed consolidated balance sheet.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB&#8217;s Emerging Issues Task Force</font><font style="font-family:inherit;font-size:10pt;">. The new standard required that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities are required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions.  Adoption of this guidance impacts the cash flow disclosure for the three months ended March 31, 2017; cash flows from operating activities, as disclosed herein, is </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> less than the amount disclosed in the 2017 first quarter 10-Q.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the Company&#8217;s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;">, cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;"> for additional information.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,934,807</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,857,833</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,850,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,701,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,754,940</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,542,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,539,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,101,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,103,574</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,701,824</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,805,554</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333,332</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,048,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,174,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 26, 2017, the FASB issued ASU No. 2017-04, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</font><font style="font-family:inherit;font-size:10pt;">. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. The same one-step impairment test will be applied to goodwill at all reporting units, even those with zero or negative carrying amounts. The revised guidance will be applied prospectively, and is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. The Company believes the adoption of ASU No. 2017-04 will not have a significant impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">, which relates to the accounting for leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU No. 2016-02 will have on its consolidated financial statements. The Company expects its real estate leases to be capitalized on its balance sheet.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798978560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Procurement Contract and Research Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractAndResearchAgreementsTextBlock', window );">Procurement Contract and Research Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Procurement Contract and Research Agreements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) pursuant to which SIGA agreed to deliver </font><font style="font-family:inherit;font-size:10pt;">two million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; to the Strategic Stockpile. The contract with BARDA (as amended, modified, or supplemented from time to time, the &#8220;BARDA Contract&#8221;) includes a base contract (&#8220;Base Contract&#8221;) as well as options (described below). The Base Contract contemplates approximately </font><font style="font-family:inherit;font-size:10pt;">$472.3 million</font><font style="font-family:inherit;font-size:10pt;"> of payments, of which </font><font style="font-family:inherit;font-size:10pt;">$409.8 million</font><font style="font-family:inherit;font-size:10pt;"> is consideration for the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; and </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;"> is available for certain development and supportive activities.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Base Contract, BARDA agreed to buy from the Company </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174;. Additionally, the Company agreed to contribute to BARDA </font><font style="font-family:inherit;font-size:10pt;">300,000</font><font style="font-family:inherit;font-size:10pt;"> courses at no additional cost to BARDA. The delivery of </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; to the Strategic Stockpile is a requirement in order for the Company to be eligible to receive a </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;"> hold back payment (see description of hold back payment below).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For courses of TPOXX&#174; that are physically delivered to the Strategic Stockpile, the Company has a product replacement obligation, at no cost to BARDA, in the event that the final version of TPOXX&#174; approved by the FDA is different from any courses of TPOXX&#174; that have been delivered to the Strategic Stockpile or if TPOXX&#174; does not meet any specified label claims, fails release testing or does not meet the </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX&#174; is recalled or deemed to be recalled for any reason (the "Replacement Obligation").</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$368.9 million</font><font style="font-family:inherit;font-size:10pt;"> under the Base Contract related to the manufacture and physical delivery of courses of TPOXX&#174;. Included in this amount are a </font><font style="font-family:inherit;font-size:10pt;">$41.0 million</font><font style="font-family:inherit;font-size:10pt;"> advance payment in 2011 for the completion of certain planning and preparatory activities related to the Base Contract; a </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment in 2012 for the completion of the product labeling strategy for TPOXX&#174;; an </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment in 2013 for the completion of the commercial validation campaign for TPOXX&#174;; a </font><font style="font-family:inherit;font-size:10pt;">$20.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment in 2016 for submission of documentation to BARDA indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study had been submitted to and reviewed by a Data Safety and Monitoring Board (&#8220;DSMB&#8221;) and that such DSMB had recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA; and </font><font style="font-family:inherit;font-size:10pt;">$286.9 million</font><font style="font-family:inherit;font-size:10pt;"> of payments for physical deliveries of TPOXX&#174; to the Strategic Stockpile beginning in 2013. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has cumulatively delivered </font><font style="font-family:inherit;font-size:10pt;">2.0 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; to the Strategic Stockpile. The dosage of courses delivered is </font><font style="font-family:inherit;font-size:10pt;">600</font><font style="font-family:inherit;font-size:10pt;"> mg administered twice per day (</font><font style="font-family:inherit;font-size:10pt;">1,200</font><font style="font-family:inherit;font-size:10pt;"> mg per day). In February 2016, the FDA confirmed (through dose concurrence) its earlier dosage guidance of </font><font style="font-family:inherit;font-size:10pt;">600</font><font style="font-family:inherit;font-size:10pt;"> mg administered twice per day (</font><font style="font-family:inherit;font-size:10pt;">1,200</font><font style="font-family:inherit;font-size:10pt;"> mg per day). Courses delivered to the Strategic Stockpile are currently subject to the Replacement Obligation (as discussed above).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is eligible under the Base Contract to receive a </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;"> hold back payment, which represents an approximate </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> hold back on the </font><font style="font-family:inherit;font-size:10pt;">$409.8 million</font><font style="font-family:inherit;font-size:10pt;"> of total payments related to the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; under the Base Contract. The </font><font style="font-family:inherit;font-size:10pt;">$41 million</font><font style="font-family:inherit;font-size:10pt;"> hold back payment would be triggered by FDA approval of TPOXX&#174;, provided that the Company no longer has the Replacement Obligation to BARDA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the Base Contract, the BARDA Contract also includes remaining options that, if all were exercised by BARDA, would result in aggregate payments to the Company of </font><font style="font-family:inherit;font-size:10pt;">$122.7 million</font><font style="font-family:inherit;font-size:10pt;">, including: a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment to the Company in the event of FDA approval for extension to </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174; (from </font><font style="font-family:inherit;font-size:10pt;">38</font><font style="font-family:inherit;font-size:10pt;">-month expiry as required in the Base Contract); up to </font><font style="font-family:inherit;font-size:10pt;">$58.3 million</font><font style="font-family:inherit;font-size:10pt;"> of funding for development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX&#174;; and/or </font><font style="font-family:inherit;font-size:10pt;">$14.4 million</font><font style="font-family:inherit;font-size:10pt;"> of funding for production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA, in its sole discretion, may choose not to exercise unexercised options. However, BARDA has indicated that it will evaluate, after the FDA&#8217;s review and evaluation of stability data, the Company's request that BARDA exercise the option for the </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment to the Company in the event of FDA approval of </font><font style="font-family:inherit;font-size:10pt;">84</font><font style="font-family:inherit;font-size:10pt;">-month expiry for TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BARDA Contract expires in September 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in Note 2, cash inflows related to delivery of courses are recorded as deferred revenue due to the constraint on the consideration received. As of March 31, 2018, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$375.5 million</font><font style="font-family:inherit;font-size:10pt;"> of deferred revenue in connection with the BARDA contract (of which </font><font style="font-family:inherit;font-size:10pt;">$368.9 million</font><font style="font-family:inherit;font-size:10pt;"> relates to the manufacture and delivery of </font><font style="font-family:inherit;font-size:10pt;">1.7 million</font><font style="font-family:inherit;font-size:10pt;"> courses of TPOXX&#174; and the remainder relates to supportive activities). Deferred revenue under the BARDA Contract is classified as a long-term liability since there can be no assurance that the Replacement Obligation under the BARDA contract will be reasonably satisfied within twelve months. In addition, direct costs incurred by the Company to fulfill the delivery of courses, including the supplementing of courses previously delivered under the BARDA Contract, are being deferred and will be recognized as expenses in the period of the FDA&#8217;s approval of the final version of TPOXX&#174; (quantification and specification of the Replacement Obligation) has occurred. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, deferred direct costs under the BARDA Contract of approximately </font><font style="font-family:inherit;font-size:10pt;">$94.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$96.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, are included in deferred costs on the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Agreements and Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has an R&amp;D program for the intravenous (IV) formulation of TPOXX&#174;. This program is funded by a development contract with BARDA ("IV Formulation R&amp;D Contract"). This contract has a period of performance that terminates on December 30, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contracts and grants include, among other things, options that may or may not be exercised at BARDA&#8217;s discretion. Moreover, contracts and grants contain customary terms and conditions including BARDA&#8217;s right to terminate or restructure a contract or grant for convenience at any time. As such, we may not be able to utilize all available funds.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProcurementContractAndResearchAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProcurementContractAndResearchAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796145088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the deferral of revenue under the BARDA Contract (see </font><a style="font-family:inherit;font-size:10pt;" href="#sC3A91219B5B7B433F4C575DCE76C7E28"><font style="font-family:inherit;font-size:10pt;">Note 2</font></a><font style="font-family:inherit;font-size:10pt;"> for additional information), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs on the condensed consolidated balance sheet. Inventory includes costs related to the manufacture of TPOXX&#174;. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, research and development expenses included net inventory-related losses of approximately</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$536,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">. The</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$536,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">loss for the three months ended</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, related to a</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$686,000</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">inventory write-down, partially offset by credits received from contract manufacturing organizations (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">CMOs</font><font style="font-family:inherit;font-size:10pt;">&#8221;)</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">in connection with the inventory write-down.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796150992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consisted of the following:&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less - accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,376,528</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,346,738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense on property, plant, and equipment was </font><font style="font-family:inherit;font-size:10pt;">$29,790</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$36,175</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796208384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,494</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,538,340</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue-R&amp;D for TPOXX</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#160;intravenous formulation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405,096</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,980</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vacation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (primarily R&amp;D vendors and CMOs) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">977,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,586,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,481,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802775024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Warrant</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, in connection with the entry into the Loan Agreement (see </font><a style="font-family:inherit;font-size:10pt;" href="#sC86DE93E1758717E99EE75DCE80F8DE9"><font style="font-family:inherit;font-size:10pt;">Note 8</font></a><font style="font-family:inherit;font-size:10pt;"> for additional information), the Company issued a warrant (the </font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">Warrant</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) to the Lender to purchase a number of shares of the Company&#8217;s common stock equal to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> divided by the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$2.29</font><font style="font-family:inherit;font-size:10pt;"> per share and (ii) the subscription price paid in connection with the Rights Offering. The Warrant provides for weighted average anti-dilution protection and is exercisable in whole or in part for ten (</font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">) years from the date of issuance. The subscription price paid was </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> in connection with the Rights Offering; accordingly, the exercise price of the Warrant was set at </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reported the change in fair value in the statement of operations. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the issuance date of the Warrant, the fair value of the liability classified Warrant was </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company applied a Monte Carlo Simulation-model to calculate the fair value of the liability classified Warrant using the following assumptions: risk free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.60%</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> dividend yield; an expected life of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years; and a volatility factor of </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">. The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation as of December 31, 2016. These models generated substantially equal fair values for the Warrant. As such, the Company utilized a Black-Scholes model for </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> to determine the fair value of the Warrant.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the Warrant was </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the liability classified Warrant was calculated using the following assumptions: risk free interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.72%</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> dividend yield; an expected life of </font><font style="font-family:inherit;font-size:10pt;">8.42</font><font style="font-family:inherit;font-size:10pt;"> years; and a volatility factor of </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded losses of </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as a result of the change in fair value of the liability classified Warrant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796178624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the &#8220;Loan Agreement&#8221;) with OCM Strategic Credit SIGTEC Holdings, LLC (&#8220;Lender&#8221;), pursuant to which the Company received </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> (less fees and other items) on November 16, 2016 having satisfied certain pre-conditions. Such </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> had been placed in an escrow account on September 30, 2016 (the &#8220;Escrow Funding Date&#8221;). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering (see </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;">) on November 16, 2016. As part of the satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the &#8220;Escrow Release Date&#8221;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Term Loan&#8221;), of which (i) </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> was placed in a reserve account (the &#8220;Reserve Account&#8221;) only to be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> was also placed in the Reserve Account and up to the full amount of such </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> is due and owing and any of such </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> remains in the Reserve Account; and (iii) </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> (net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final payment to satisfy the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus</font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustments as set forth in the Loan Agreement. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the effective interest rate on the Term Loan, which includes interest payments and accretion of unamortized costs and fees, was </font><font style="font-family:inherit;font-size:10pt;">18.96%</font><font style="font-family:inherit;font-size:10pt;">. The Company incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> of interest expense during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> was paid from restricted cash and the remaining </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> accreted to the Term Loan balance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Term Loan shall mature on the earliest to occur of (i) the four-year anniversary of the Escrow Release Date, and (ii) the acceleration of certain obligations pursuant to the Loan Agreement. At maturity, </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> of principal will be repaid, and an additional </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> will be paid (see below). Prior to maturity, there are no scheduled principal payments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the three and one-half year anniversary of the Escrow Release Date, any prepayment of the Term Loan is subject to a make-whole provision in which interest payments related to the prepaid amount are due (subject to a discount of treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Term Loan, the Company has granted the Lender a lien on and security interest in all of the Company&#8217;s right, title and interest in substantially all of the Company&#8217;s tangible and intangible assets, including all intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. These covenants, among other things, require a minimum cash balance throughout the term of the Term Loan and the achievement of regulatory milestones by certain dates, and contain certain limitations on the ability of the Company to incur unreimbursed research and development expenditures over a certain threshold, make capital expenditures over a certain threshold, incur indebtedness, dispose of assets outside of the ordinary course of business and enter into certain merger or consolidation transactions. The aforementioned minimum cash requirement is </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> for 2018 until the earlier of (i) December 31, 2018 or (ii) </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;"> days after FDA approval of TPOXX&#174;; thereafter, the minimum cash requirement will be </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) the material inaccuracy of representations or warranties made thereunder, (iii) non-compliance with covenants thereunder, (iv) non-payment of amounts due under, or the acceleration of, other material indebtedness of the Company and (v) bankruptcy or insolvency events. Upon the occurrence and during the continuance of an event of default under the Loan Agreement, the interest rate may increase by </font><font style="font-family:inherit;font-size:10pt;">2.00%</font><font style="font-family:inherit;font-size:10pt;"> per annum above the rate of interest otherwise in effect, and the Lenders would be entitled to accelerate the maturity of the Company&#8217;s outstanding obligations thereunder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is in compliance with the Loan Agreement covenants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Loan Agreement, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;"> of costs (including interest on amounts held in the escrow account between September 30, 2016 and November 15, 2016). Furthermore, an additional </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> will become payable when principal of the Term Loan is repaid. As part of the Company's entry into the Loan Agreement, the Company issued the Warrant (see Note 7) with a fair market value of </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Warrant, as well as costs related to the Term Loan issuance, were recorded as deductions to the Term Loan balance on the Balance Sheet. These amounts are being amortized using the effective interest method over the life of the related Term Loan. The </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> that will be paid when principal is repaid is being accreted to the Term Loan balance each quarter on a per diem basis. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Term Loan balance is </font><font style="font-family:inherit;font-size:10pt;">$72.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796105888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial INstruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as a liability are recorded at their fair market value as of each reporting period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Quoted prices for identical instruments in active markets.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Instruments where significant value drivers are unobservable to third parties.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of certain common stock warrants on a recurring basis and classify such liability classified warrants in Level 3. As described in </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;">, the fair value of the liability classified warrant was </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the debt was </font><font style="font-family:inherit;font-size:10pt;">$74.9 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and the carrying value of the debt was </font><font style="font-family:inherit;font-size:10pt;">$72.2 million</font><font style="font-family:inherit;font-size:10pt;">. The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement.&#160; The fair value of the loan was measured using level 3 inputs.&#160; The discount rate was determined using market participant assumptions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no transfers between levels of the fair value hierarchy for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">. In addition, there were no Level 1 or Level 2 financial instruments as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements of Level 3 liability classified warrant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,466,162</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,303,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,769,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798912688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Per Share Data<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Per Share Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Per Share Data</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred losses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and as a result, the equity instruments listed below are excluded from the calculation of diluted earnings (loss) per share as the effect of the exercise, conversion or vesting of such instruments would be anti-dilutive. The weighted average number of equity instruments excluded consists of:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,062,467</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709,967</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-Settled Stock Appreciation Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472,001</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,307,464</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Includes </font><font style="font-family:inherit;font-size:8pt;">294,118</font><font style="font-family:inherit;font-size:8pt;"> restricted stock units that have vested but have not converted into common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The appreciation of each stock-settled stock appreciation right was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796187456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796131056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Board of Directors and Outside Counsel</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A member of the Company&#8217;s Board of Directors is a member of the Company&#8217;s outside counsel. During the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred expenses of </font><font style="font-family:inherit;font-size:10pt;">$107,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$78,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to services provided by the outside counsel. On </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> the Company&#8217;s outstanding payables and accrued expenses included a </font><font style="font-family:inherit;font-size:10pt;">$37,000</font><font style="font-family:inherit;font-size:10pt;"> liability to the outside counsel.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Real Estate Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 26, 2017 the Company and MacAndrews &amp; Forbes Incorporated (&#8220;M&amp;F&#8221;) entered into a ten-year Office Lease agreement (the &#8220;New HQ Lease&#8221;), pursuant to which the Company agreed to lease </font><font style="font-family:inherit;font-size:10pt;">3,200</font><font style="font-family:inherit;font-size:10pt;"> square feet at 27 East 62</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">nd</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Street, New York, New York. The Company is utilizing premises leased under the New HQ Lease as its new corporate headquarters. The Company's rental obligations consist of a fixed rent of </font><font style="font-family:inherit;font-size:10pt;">$25,333</font><font style="font-family:inherit;font-size:10pt;"> per month in the first sixty-three months of the term, subject to a rent abatement for the first six months of the term. From the first day of the sixty-fourth month of the term through the expiration or earlier termination of the lease, the Company's rental obligations consist of a fixed rent of </font><font style="font-family:inherit;font-size:10pt;">29,333</font><font style="font-family:inherit;font-size:10pt;"> per month. In addition to the fixed rent, the Company will pay a facility fee in consideration of the landlord making available certain ancillary services, commencing on the first anniversary of entry into the lease. The facility fee will be </font><font style="font-family:inherit;font-size:10pt;">$3,333</font><font style="font-family:inherit;font-size:10pt;"> per month for the second year of the term and increasing by </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> percent each year thereafter, to </font><font style="font-family:inherit;font-size:10pt;">$4,925</font><font style="font-family:inherit;font-size:10pt;"> per month in the final year of the term. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 31, 2017, the Company and M&amp;F entered into a Termination of Sublease Agreement (the &#8220;Old HQ Sublease Termination Agreement&#8221;), pursuant to which the Company and M&amp;F agreed to terminate the sublease dated January 9, 2013 for </font><font style="font-family:inherit;font-size:10pt;">6,676</font><font style="font-family:inherit;font-size:10pt;"> square feet of rental square footage located at 660 Madison Avenue, Suite 1700, New York, New York (such sublease being the &#8220;Old HQ Sublease&#8221; and the location being the &#8220;Old HQ&#8221;). Effectiveness of the Old HQ Sublease Termination Agreement was conditioned upon the commencement of a sublease for the Old HQ between M&amp;F and a new subtenant (the &#8220;Replacement M&amp;F Sublease&#8221;), which occurred on August 2, 2017. The Old HQ Sublease Termination Agreement obligates the Company to pay, on a monthly basis, an amount equal to the discrepancy (the &#8220;Rent Discrepancy&#8221;) between the sum of certain operating expenses and taxes (&#8220;Additional Rent&#8221;) and fixed rent under the overlease between M&amp;F and the landlord at 660 Madison Avenue and the sum of Additional Rent and fixed rent under the Replacement M&amp;F Sublease. Under the Old HQ Sublease Termination Agreement, the Company and M&amp;F release each other from any liability under the Old HQ Sublease. For the time period between August 2, 2017 and August 31, 2020 (the expiration date of the Old HQ Sublease), the Company estimates that it will pay a total of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in Rent Discrepancy under the Old HQ Sublease Termination Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the above-mentioned transactions, the Company has discontinued usage of Old HQ in the third quarter of 2017. As such, during the year ended December 31, 2017 the Company recorded a loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in accordance with Accounting Standards Codification (</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">ASC</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">) 420, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exit or Disposal Obligations</font><font style="font-family:inherit;font-size:10pt;">. This loss primarily represented the discounted value of estimated Rent Discrepancy payments to occur in the future, and included costs related to the termination of the old HQ Sublease. The Company also wrote-off approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of leasehold improvements and furniture and fixtures related to the Old HQ. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity relating to the liability that was recorded as a result of the lease termination:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Termination liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814,622</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges (included in selling, general and administrative expenses) </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,376</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments, net of sublease income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78,153</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the lease termination liability is included in Other liabilities on the Condensed Consolidated Balance sheet with the remainder included in accrued expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802712752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> requires that a valuation allowance be established when it is </font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">more likely than not</font><font style="font-family:inherit;font-size:12pt;">&#8221; </font><font style="font-family:inherit;font-size:10pt;">that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including the company's performance, the market environment in which the company operates, the utilization of past tax credits, length of carryback and carryforward periods, existing contracts, and unsettled circumstances that, if unfavorably resolved, would adversely affect future operations and profit levels in the future years. Based on the available evidence, the Company continues to conclude that its deferred tax assets are not realizable on a more-likely-than-not basis.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 118, which provides guidance on accounting for the tax effects of the 2017 Tax Cuts and Jobs Act ("TCJA"). The purpose of SAB No. 118 was to address any uncertainty or diversity of view in applying&#160;ASC Topic 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;in the reporting period in which the TCJA was enacted. SAB No. 118 addresses situations where the accounting is incomplete for certain income tax effects of the TCJA upon issuance of a company&#8217;s financial statements for the reporting period that includes the enactment date. SAB No. 118 allows for a provisional amount to be recorded if it is a reasonable estimate of the impact of the TCJA. Additionally, SAB No. 118 allows for a measurement period to finalize the impacts of the TCJA, not to extend beyond one year from the date of enactment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company&#8217;s accounting for certain elements of the TCJA was incomplete as of the period ended December 31, 2017, and remains incomplete as of March 31, 2018. However, the Company was able to make reasonable estimates of the effect of the TCJA and, therefore, recorded provisional estimates for these items. The final impact of the TCJA may differ from the provisional amounts that have been recognized, due to, among other things, legislative or administrative actions to clarify the intent of the statutory language as well as any changes in accounting standards for income taxes or related interpretations in response to the TCJA. Additionally, the Company's U.S. tax return for 2017 will be filed during the second or third quarter of 2018 and any changes to the tax positions for temporary differences compared to the estimates used may result in an adjustment of the estimated tax benefit recorded as of December 31, 2017.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded an income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$2,352</font><font style="font-family:inherit;font-size:10pt;"> on a pre-tax loss of </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">. The effective tax rate differs from the statutory rate as no income tax benefit was recorded for current year operating losses due to the Company&#8217;s assessment regarding tax realizability of its deferred tax assets</font><font style="font-family:inherit;font-size:12pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796174688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_RestrictedCashandCashEquivalentsPolicyTextBlock', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB&#8217;s Emerging Issues Task Force</font><font style="font-family:inherit;font-size:10pt;">. The new standard required that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities are required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions.  Adoption of this guidance impacts the cash flow disclosure for the three months ended March 31, 2017; cash flows from operating activities, as disclosed herein, is </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> less than the amount disclosed in the 2017 first quarter 10-Q.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the Company&#8217;s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;">, cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned </font><font style="font-family:inherit;font-size:10pt;">$5 million</font><font style="font-family:inherit;font-size:10pt;"> in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. See </font><a style="font-family:inherit;font-size:10pt;" href="#s5D048EEA20CF789A615B75DCE7B0EADE"><font style="font-family:inherit;font-size:10pt;">Note 7</font></a><font style="font-family:inherit;font-size:10pt;"> for additional information.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_RestrictedCashandCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_RestrictedCashandCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630541824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reconciles cash, cash equivalents and restricted cash per the condensed consolidated statements of cash flows to the condensed consolidated balance sheet for each respective period:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,934,807</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,857,833</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,850,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,701,305</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,754,940</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,542,448</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,539,883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,101,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,103,574</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,701,824</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-short term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,138,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash-long term</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,805,554</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,333,332</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,048,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,174,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798843328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory consisted of the following: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,025,445</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,804</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,983,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796149984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment consisted of the following:&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420,028</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">701,762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,485,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less - accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,376,528</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,346,738</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798823504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities consisted of the following:</font></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bonus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,494</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,538,340</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue-R&amp;D for TPOXX</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#160;intravenous formulation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405,096</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,980</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vacation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361,755</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (primarily R&amp;D vendors and CMOs) </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">977,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,586,195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,481,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630541824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial INstruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the liability-classified warrant measured at fair value using Level 3 inputs:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements of Level 3 liability classified warrant</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,466,162</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,303,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant liability at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,769,276</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799455408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Per Share Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred losses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and as a result, the equity instruments listed below are excluded from the calculation of diluted earnings (loss) per share as the effect of the exercise, conversion or vesting of such instruments would be anti-dilutive. The weighted average number of equity instruments excluded consists of:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Options</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,062,467</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709,967</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-Settled Stock Appreciation Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472,001</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,307,464</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690,950</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796121504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity relating to the liability that was recorded as a result of the lease termination:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Termination liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">814,622</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charges (included in selling, general and administrative expenses) </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,376</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments, net of sublease income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78,153</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">739,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the lease termination liability is included in Other liabilities on the Condensed Consolidated Balance sheet with the remainder included in accrued expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651062336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 13, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractAxis=siga_BardaContractMember', window );">BARDA Contract</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractLineItems', window );"><strong>Procurement Contract [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_Reducedholdbackamount', window );">Reduced holdback amount</a></td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProcurementContractLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Procurement Contract [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProcurementContractLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_Reducedholdbackamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced holdback  be received from BARDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_Reducedholdbackamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProcurementContractAxis=siga_BardaContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProcurementContractAxis=siga_BardaContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808669488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 1,255,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,255,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(549,181,345)<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="num">(537,375,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">10,850,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,701,305<span></span>
</td>
<td class="nump">$ 10,138,890<span></span>
</td>
<td class="nump">$ 10,138,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Difference between Revenue Guidance in Effect before and after Topic 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accrued Liabilities and Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member', window );">Accounting Standards Update 2016-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=SL51747714-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=siga_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=siga_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201618Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649636832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Contract with Customer, Asset and Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2017</a></td>
<td class="nump">$ 378,896,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Cumulative effect of accounting change</a></td>
<td class="num">(1,780,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Billings in advance of revenue recognition</a></td>
<td class="nump">169,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at March 31, 2018</a></td>
<td class="nump">$ 377,286,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=SL51747714-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802816736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents, Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,934,807<span></span>
</td>
<td class="nump">$ 19,857,833<span></span>
</td>
<td class="nump">$ 30,103,574<span></span>
</td>
<td class="nump">$ 28,701,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash-short term</a></td>
<td class="nump">10,850,136<span></span>
</td>
<td class="nump">10,701,305<span></span>
</td>
<td class="nump">10,138,890<span></span>
</td>
<td class="nump">10,138,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash-long term</a></td>
<td class="nump">3,754,940<span></span>
</td>
<td class="nump">6,542,448<span></span>
</td>
<td class="nump">14,805,554<span></span>
</td>
<td class="nump">17,333,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 28,539,883<span></span>
</td>
<td class="nump">$ 37,101,586<span></span>
</td>
<td class="nump">$ 55,048,018<span></span>
</td>
<td class="nump">$ 56,174,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809487360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Procurement Contract and Research Agreements (Details)<br> contract in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 13, 2011 </div>
<div>USD ($) </div>
<div>course </div>
<div>contract</div>
</th>
<th class="th">
<div>May 31, 2011 </div>
<div>course</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>course</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractLineItems', window );"><strong>Procurement Contract [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_NumberOfCoursesToBeDelivered1', window );">Number of courses to be delivered | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_GovernmentContractValueOfAward1', window );">Value of contract</a></td>
<td class="nump">$ 472,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueofManufacturingandDeliveryActivities', window );">Contract Value of Manufacturing and Delivery Activities</a></td>
<td class="nump">$ 409,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract', window );">Number of courses under modified contract | contract</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueOfDevelopmentAndSupportActivities', window );">Contract value of development and support activities</a></td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts', window );">Proceeds from manufacture and physical delivery of courses, government contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProceedsFromAdvancePaymentsGovernmentContracts', window );">Proceeds from advance payments under the BARDA contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueofVariousOptions', window );">Contract value of various options</a></td>
<td class="nump">122,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry', window );">Amount of option to be received from BARDA for approval for extension of 84 moth expiry</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities', window );">Contract Value, Detail Of Option Exercisable, Development Activities</a></td>
<td class="nump">58,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueDetailOfOptionExercisableProductionActivities', window );">Contract Value, Detail Of Option Exercisable, Production Activities</a></td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ContractValueOptionFDAApproval', window );">Contract Value, Option, FDA Approval</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,255,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,296,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,592,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractAxis=siga_BardaContractMember', window );">BARDA Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProcurementContractLineItems', window );"><strong>Procurement Contract [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_GovernmentContractNumberofFreeCourses', window );">Government contract, number of free courses | course</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_Reducedholdbackamount', window );">Reduced holdback amount</a></td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProceedsFromAdvancePaymentsGovernmentContracts', window );">Proceeds from advance payments under the BARDA contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts', window );">Proceeds From Physical Delivery Of Courses, Government Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered', window );">Government contract, total number of courses required to be delivered | course</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of option to be received from BARDA for approval for extension of 84 moth expiry</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_AmountofoptiontobereceivedfromBARDAforapprovalforextensionof84mothexpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueDetailOfOptionExercisableDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueDetailOfOptionExercisableDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueDetailOfOptionExercisableProductionActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueDetailOfOptionExercisableProductionActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueOfDevelopmentAndSupportActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of development and support activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueOfDevelopmentAndSupportActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueOptionFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueOptionFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueofManufacturingandDeliveryActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of manufacturing and delivery activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueofManufacturingandDeliveryActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ContractValueofVariousOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract value of various options exercisable at BARDA's discretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ContractValueofVariousOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government contract, number of courses to be purchased under modified contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_GovernmentContractNumberOfCoursesPurchasedUnderModifiedContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_GovernmentContractNumberofFreeCourses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of courses of tecovirimat to be contributed to the Strategic Stockpile at no cost to the government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_GovernmentContractNumberofFreeCourses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Contract, Total Number of Courses Required to Be Delivered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_GovernmentContractTotalNumberofCoursesRequiredtoBeDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_GovernmentContractValueOfAward1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of base contract award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_GovernmentContractValueOfAward1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from milestone payment, Government contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_NumberOfCoursesToBeDelivered1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_NumberOfCoursesToBeDelivered1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProceedsFromAdvancePaymentsGovernmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from advance payments, government contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProceedsFromAdvancePaymentsGovernmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from manufacture and physical delivery of courses, government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProceedsFromManufactureAndPhysicalDeliveryOfCoursesGovernmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from physical delivery of courses, government contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProceedsFromPhysicalDeliveryOfCoursesGovernmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProcurementContractLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Procurement Contract [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProcurementContractLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_Reducedholdbackamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced holdback  be received from BARDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_Reducedholdbackamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ProcurementContractAxis=siga_BardaContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ProcurementContractAxis=siga_BardaContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797804080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Work in process</a></td>
<td class="nump">$ 2,025,445<span></span>
</td>
<td class="nump">$ 2,025,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">957,804<span></span>
</td>
<td class="nump">957,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,983,249<span></span>
</td>
<td class="nump">$ 2,983,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write down of inventory</a></td>
<td class="nump">536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_InventoryWriteDowns', window );">Inventory write-downs</a></td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_InventoryWriteDowns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory write-downs included in research and development expense on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_InventoryWriteDowns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808834672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements, gross</a></td>
<td class="nump">$ 2,420,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,420,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ComputerEquipment', window );">Computer equipment, gross</a></td>
<td class="nump">701,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures, gross</a></td>
<td class="nump">363,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,588<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">3,485,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,485,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, depletion and amortization, property, plant, and equipment</a></td>
<td class="num">(3,376,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,346,738)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">108,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and other amortization</a></td>
<td class="nump">$ 29,790<span></span>
</td>
<td class="nump">$ 36,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ComputerEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of capitalized computer equipment costs as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ComputerEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797801552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus</a></td>
<td class="nump">$ 454,494<span></span>
</td>
<td class="nump">$ 2,538,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue-R&amp;D for TPOXX&#174; intravenous formulation</a></td>
<td class="nump">1,255,318<span></span>
</td>
<td class="nump">1,255,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">405,096<span></span>
</td>
<td class="nump">381,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Vacation</a></td>
<td class="nump">361,755<span></span>
</td>
<td class="nump">328,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other (primarily R&amp;D vendors and CMOs)</a></td>
<td class="nump">1,109,532<span></span>
</td>
<td class="nump">977,353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,586,195<span></span>
</td>
<td class="nump">$ 5,481,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809327472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants to purchase common stock</a></td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,769,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,466,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_IncreaseInFairValueOfWarrants', window );">Increase in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,303,114)<span></span>
</td>
<td class="num">$ (626,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants to purchase common stock</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable', window );">Exercisable period for warrants (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=siga_SubscriptionRightMember', window );">Subscription Right | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants to purchase common stock</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_IncreaseInFairValueOfWarrants', window );">Increase in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,300,000)<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period from which Warrants or Rights are Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_ClassofWarrantorRightPeriodfromwhichWarrantsorRightsareExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_IncreaseInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_IncreaseInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=siga_SubscriptionRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=siga_SubscriptionRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805816112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 14,769,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,466,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">London Interbank Offered Rate (LIBOR) | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin for term loan</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate (as a percent)</a></td>
<td class="nump">18.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid on term loan</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Interest expense accreted to balance</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate', window );">Potential increase in interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fees and expenses</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="nump">$ 72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | US Treasury Rate | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin for term loan</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Repayment of Interests | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases', window );">Capacity available for specific purpose other than for trade purchases</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Payments Related to Litigation | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases', window );">Capacity available for specific purpose other than for trade purchases</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Forecast | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_LineofCreditFacilityAdditionalBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_LineofCreditFacilityMinimumCashRequirement', window );">Minimum cash requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_LineofCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_LineofCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Debt Default, Increase in Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_LineofCreditFacilityDebtDefaultIncreaseinInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_LineofCreditFacilityMinimumCashRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Minimum Cash Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_LineofCreditFacilityMinimumCashRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for a specific purpose other than for financing goods acquired for inventory or imminent delivery to a customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=siga_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=siga_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=siga_USTreasuryRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=siga_USTreasuryRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_DebtInstrumentCapacitybySpecificPurposeAxis=siga_RepaymentofInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_DebtInstrumentCapacitybySpecificPurposeAxis=siga_RepaymentofInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_DebtInstrumentCapacitybySpecificPurposeAxis=siga_PaymentsRelatedtoLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_DebtInstrumentCapacitybySpecificPurposeAxis=siga_PaymentsRelatedtoLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6798044928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial INstruments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">$ 14,769,276<span></span>
</td>
<td class="nump">$ 11,466,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan outstanding</a></td>
<td class="nump">72,159,240<span></span>
</td>
<td class="nump">$ 71,050,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrant</a></td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=siga_SeniorSecuredTermLoanMember', window );">Senior Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan outstanding</a></td>
<td class="nump">72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Senior Secured Term Loan | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan outstanding</a></td>
<td class="nump">$ 74,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=siga_SeniorSecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=siga_SeniorSecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802584320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial INstruments - Change in Level 3 Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Warrant liability at December 31, 2017</a></td>
<td class="nump">$ 11,466,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Increase in fair value of warrant liability</a></td>
<td class="nump">3,303,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Warrant liability at March 31, 2018</a></td>
<td class="nump">$ 14,769,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809353808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Per Share Data (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_RestrictedStockUnits', window );">Restricted stock units</a></td>
<td class="nump">294,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average</a></td>
<td class="nump">1,062,467<span></span>
</td>
<td class="nump">1,709,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock-Settled Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average</a></td>
<td class="nump">162,393<span></span>
</td>
<td class="nump">360,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average</a></td>
<td class="nump">1,472,001<span></span>
</td>
<td class="nump">1,307,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average</a></td>
<td class="nump">2,690,950<span></span>
</td>
<td class="nump">2,690,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_RestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock Units have been vested but not converted into common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_RestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809807952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 26, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2013 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ManagementMember', window );">Member of Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=siga_MacAndrewsForbesMember', window );">MacAndrews &amp; Forbes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_OperatingLeaseNameAxis=siga_NewHQLeaseMember', window );">New HQ Lease | MacAndrews &amp; Forbes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property (in sq ft) | ft&#178;</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_MonthlyRentalPaymentsForInitialPeriod', window );">Monthly rental payments for initial period</a></td>
<td class="nump">$ 25,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_MonthlyRentalPaymentsAfterInitialPeriod', window );">Monthly rental payments after initial period</a></td>
<td class="nump">29,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_InitialFacilityFee', window );">Additional facility fee</a></td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_FacilityFeeAnnualIncreasePercent', window );">Facility fee annual increase, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_FacilityFeeAfterInitialPeriod', window );">Facility fee after initial period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_OperatingLeaseNameAxis=siga_OldHQSubleaseMember', window );">Old HQ Subleas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Write down of leasehold improvements and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_siga_LeaseTerminationLiability', window );">Lease termination liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_FacilityFeeAfterInitialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility Fee After Initial Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_FacilityFeeAfterInitialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_FacilityFeeAnnualIncreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility Fee Annual Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_FacilityFeeAnnualIncreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_InitialFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_InitialFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_LeaseTerminationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Termination Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_LeaseTerminationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_MonthlyRentalPaymentsAfterInitialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the sublease entered into after initial period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_MonthlyRentalPaymentsAfterInitialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_MonthlyRentalPaymentsForInitialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the sublease entered into for the initial period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_MonthlyRentalPaymentsForInitialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>siga_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=siga_MacAndrewsForbesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=siga_MacAndrewsForbesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_OperatingLeaseNameAxis=siga_NewHQLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_OperatingLeaseNameAxis=siga_NewHQLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_siga_OperatingLeaseNameAxis=siga_OldHQSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">siga_OperatingLeaseNameAxis=siga_OldHQSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797229536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Related Party Activity (Details) - MacAndrews &amp; Forbes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at December 31, 2017</a></td>
<td class="nump">$ 814,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges (included in selling, general and administrative expenses)</a></td>
<td class="nump">3,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments, net of sublease income</a></td>
<td class="num">(78,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at March 31, 2018</a></td>
<td class="nump">$ 739,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=siga_MacAndrewsForbesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=siga_MacAndrewsForbesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802407120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="num">$ (2,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,582,256)<span></span>
</td>
<td class="num">$ (8,614,946)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^HE(4N2<]0&W7ZLC>E.@YT@MYDD/FK4S[U2V0HW>"YB#NPXS*'96@2<*-"J
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M^1S=1#[6W3J2D0V<V9HR&P08:PW:HM74E" UQGFE_0R90$8W.+9?SZY=&;;
M:6LH;8%CU&A$MF$+.M 8PNQ@R[P%#EQ#@0L"2&UPD%OJB0NM"6!G!UHF+G#D
M&HI<$&!JO,O1TVU)4H)Q#AS*KE &+W+P&@I>Y#PU"H)1M'04A"Z 2O-RQI,,
M7N3@-12\R'&JO5,Z%5.4**+4.P,FS!6V,Y4M1Z^AZ$5.5.\-T/*C$'3#@-H9
M\*(,7N3@-12\R('J$=+.P_9-20G**HTS\$49OLCA:RA\D4,UT<M;\ QULC2H
M!(494*&,8.0(IN7G1M"PBN?GFELG,G210]?"3 LR=)%#UU+"(8>IS_GR^$!U
MZT;F+7+>TM>X08Y1!&.MR^EN4<A2Q-R&N5&2F8N<N9;1C9/T4ZHJ(8"FU"E$
M;2J_O?5^[D>NS%W-N6LIXS3'Z:=4""7&6T7GI*C%5#L$S&?&3,OTU9R^EE)N
MTMS^ I<+%4DZ4ZAD5^<<P\'3'V7[LC]TB\>F[YMZ/-AX;IH^IF;5YY3I+I;;
MRTT5G_OATJ?K]GS@<[[IF^-TF)5=3M36_P-02P,$%     @ "X&D3)=0I0SR
M 0  BP4  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E-N.FS 0AE\%
M\0"Q@4 . J0F5=5*K11MU?;:@4E :V-J.V'[]O6!1010FUQ@S_C_Q]\0[+3C
MXE56 ,I[8[21F5\IU>X1DD4%C,@5;Z'1*Q<N&%$Z%%<D6P&DM"9&48AQ@ABI
M&S]/;>XD\I3?%*T;. E/WA@CXL\!*.\R/_#?$R_UM5(F@?*T)5?X#NI'>Q(Z
M0D.5LF;0R)HWGH!+YG\(]L?$Z*W@9PV=',T]T\F9\U<3?"DS'QL@H% H4X'H
MX0Y'H-04TAB_^YK^L*4QCN?OU3_9WG4O9R+AR.FONE15YF]]KX0+N5'UPKO/
MT/<3^U[?_%>X ]5R0Z+W*#B5]ND5-ZDXZZMH%$;>W%@W=NS<2KSM;<N&L#>$
M@R%8_],0]89H8D".S+;ZD2B2IX)WGG!_5DO,-Q'L(_TR"Y.T[\ZNZ6ZESM[S
M>).BNZG32PY.$HXDX:/BN*"(!PG2^P\0X2)$:/W1&&*[[(\6_9'UK\?^W:0)
M)]E:26,E>(4Q#B:=_%?V0+->I%G/:!(\H7&2>+1-@/O?!.@9Y0-3O,@4SYDF
MK1_BV4Z;'8YV<Z0GA ]$R2)1,B>:?%:'Y%FB)X2."(V.A;FFOA%QK1OIG;G2
M)\R>@POG"G11O-+U*GTS#@&%BS+3C9X+=S^X0/&VO_K0</_F?P%02P,$%
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MYG[>43(W_P4NH# ]*,$:I5$N?DDY.&_TS()2M'B93MG%<YSYK[!M )\!_ V
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MGCGIDC( U^<W]B^Q=E_+65BX1_G45:[-Z2TE%=1BD.X1QZ\PUW--R5S\=[B
M].%!B<]1HK1Q)>5@':J9Q4M1XF7:.QWW<;I)]S-L&\!G %\ MS$/FQ)%Y9^%
M$T5F<"1FZGTOPA/O#MSWI@S.V(IXY\5;[[T4NR3-V"40S3''*8:O8Y8(YMF7
M%'PKQ9'_ ^?;\/VFPGV$[]\IO-XF2#<)TDB0_K?$K9B;#TG8JJ<*3!.GR9(2
M!QTG>>5=!O:.QS?Y&SY-^X,P3:<M.:/S+QO[7R,Z\%*2*S]"K?]@BR&A=N'X
MR9_--&:3X;"??Q!;OG'Q!U!+ P04    "  +@:1,46T6N+4!  #2 P  &
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M_C>('H*4W4T8H2Y\L,50T/AXO UG.XW99'CLYQ_$EF]<_@102P,$%     @
M"X&D3($#/FVV 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M;5-A;]L@$/TKB!]0$N*F561;:CI-G;1)4:MMGXE]ME'!YP*.NW]?P*[K=OX"
MW''OW;OC2 <TS[8!<.15J]9FM'&N.S!FBP:TL%?80>MO*C1:.&^:FMG.@"@C
M2"O&-YL]TT*V-$^C[V3R%'NG9 LG0VROM3#_CJ!PR.B6OCL>9=VXX&!YVHD:
MGL#][D[&6VQF*:6&UDILB8$JHW?;PS$)\3'@CX3!+LXD5')&? [&CS*CFR (
M%!0N, B_7> >E I$7L;+Q$GGE &X/+^S?X^U^UK.PL(]JK^R=$U&;RDIH1*]
M<H\X/,!4SS4E4_$_X0+*AP<E/D>!RL:5%+UUJ"<6+T6+UW&7;=R'\6:WGV#K
M #X!^ RXC7G8F"@J_R:<R%.# S%C[SL1GGA[X+XW17#&5L0[+]YZ[R7?\B1E
MET TQ1S'&+Z,F2.89Y]3\+441_X?G*_#=ZL*=Q&^^Z3P>IT@625((D'RB6#_
MI<2UF)LO2=BBIQI,':?)D@+[-D[RPCL/[!V/;_(1/D[[+V%JV5IR1N=?-O:_
M0G3@I6RN_ @U_H/-AH+*A>.-/YMQS$;#83?](#9_X_P-4$L#!!0    (  N!
MI$RPX:GVM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;'U3
M88_4(!#]*X0?<'3IGJZ;MLGM&:.))ILSZF>VG;;DH%2@V_/?.]!NK=K<%V"&
M>6_>#$,V&OOL6@!/7K3J7$Y;[_LC8ZYL00MW9WKH\*8V5@N/IFV8ZRV(*H*T
M8CQ)WC M9$>++/K.MLC,X)7LX&R)&[06]M<)E!ESNJ,WQY-L6A\<K,AZT<!7
M\-_ZLT6++2R5U- Y:3IBH<[IP^YXVH?X&/!=PNA69Q(JN1CS'(Q/54Z3( @4
ME#XP"-RN\ A*!2*4\7/FI$O* %R?;^P?8NU8RT4X>#3JAZQ\F],#)1748E#^
MR8P?8:[GGI*Y^,]P!87A00GF*(UR<27EX+S1,PM*T>)EVF47]W&Z26^P;0"?
M 7P!'"* 38FB\O?"BR*S9B1VZGTOPA/OCAQ[4P9G;$6\0_$.O==BQP\9NP:B
M.>8TQ?!US!+!D'U)P;=2G/A_<+X-3S<5IA&>_J7PW3;!?I-@'PGVKY:X$9,F
M_R1AJYYJL$V<)D=*,W1QDE?>96 ?>'R3/^'3M'\1MI&=(Q?C\65C_VMC/*"4
MY Y'J,4/MA@*:A^.;_%LIS&;#&_Z^0>QY1L7OP%02P,$%     @ "X&D3$1*
M):.U 0  T ,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5/MCM4@
M$'T5P@,LMQ^KZTW;9.\:HXDF-VO4W]QVVI(%I@*]7=]>H-W:N-4_P QSSIP9
MAF)"\V1[ $>>E=2VI+USPY$Q6_>@N+W! ;2_:=$H[KQI.F8' [R)("59>CB\
M88H+3:LB^LZF*G!T4F@X&V)'I;CY=0*)4TD3^N)X%%WO@H-5Q< [^ KNVW V
MWF(K2R,4:"M0$P-M2>^3XRD/\3'@NX#);LXD5')!? K&IZ:DAR ()-0N,'"_
M7>$!I Q$7L;/A9.N*0-P>WYA_Q!K][5<N(4'E#]$X_J2WE'20,M'Z1YQ^@A+
M/;>4+,5_ABM('QZ4^!PU2AM74H_6H5I8O!3%G^==Z+A/\\UMNL#V >D"2%?
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MPK.=QFPRO.GG'\26;US^!5!+ P04    "  +@:1,_E^^E,0!   V!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6QM5-MNG# 0_17+'Q"S7FBC%2!E
M4U6-U$JK5&V>O3!<%%^(;9;T[VL;0LC&+WAF?.:<&=M#/BG];#H BUX%EZ;
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M.;;6!D#<Z@ZO0H</9384M"%N'W#OQNLR&L'VTTM@\W.L_@-02P,$%     @
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M868K92U45/]&570ODDT_R,2V;FXC=5]V1^%N4,N#/N9[_6\-LW]02P,$%
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M%ZFWB=KS?JKU!\G:86"C\:N1_P502P,$%     @ "X&D3!()8Y*$ @  'P@
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M20+Z&TM7@3PW24*M0^S3U87V0!(%KEF-F!/&5N2N]"1ZA4;,XM-)XU33LS/
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MK8A=+@GJV!07%CA#ZATL>P0:4RC6. ,B%S-W8<P'.<UH(B?"U8!"P#5W<NI
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MV1ZDVX;1Q^XC07#Y4K'Z'U!+ P04    "  +@:1,QZ+>#TX"  "Y!P  &0
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M4.Q[0_3?Z(4R#3=.]!I[SJ3]]_9GJ7@]J&@K-7GOVZJQ;3?H7VEN AP(<"0
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M6&<I#=A^-@_6<V-?CCG@<#9NFMNY"O<G!$;VT]. Y_>I_ -02P,$%     @
M"X&D3)=_'B:  @  H @  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
ME5;;CMHP$/V5*!^P\247@B 24%6MU$IHJVZ?#1@2;1*GMB';OZ_MA"R$H65?
ML#TY<V;.X,EDU@KYJG+.M?=6E;6:^[G6S30(U#;G%5-/HN&U>;(7LF+:'.4A
M4(WD;.><JC(@",5!Q8K:SV;.MI;93!QU6=1\+3UUK"HF_RQY*=JYC_VSX;DX
MY-H:@FS6L /_P?7/9BW-*1A8=D7%:U6(VI-\/_<7>+K"L75PB)>"M^IB[UDI
M&R%>[>'K;NXCFQ$O^59;"F:6$U_QLK1,)H_?/:D_Q+2.E_LS^V<GWHC9,,57
MHOQ5['0^]R>^M^-[=BSULVB_\%Y0Y'N]^F_\Q$L#MYF8&%M1*O?K;8]*BZIG
M,:E4[*U;B]JM;<]_=H,=2.] !@<3^U\.M'>@[PZA$]]EYJ1^8IIE,RE:3W;_
M5L/LI<!3:HJYM497._?,J%7&>LK())D%)TO48Y8=AEQ@\( (#/L0@D AEN3&
MG5P'6-TBXA".0$$1U/G3*Q$3F" $"4)'$%X1I*,J=)C(8>H.DX88WXD3@7&B
MVS@I@@EBD"!^7&D"$B1 !GBD-+E1BE%,PGAT+U8 +D%I>H&[2F@")C0!$B(P
M00H2I(^7!".X!] #1>E!5VIC0E,Z*@J HS%"]$[+X#MMB8&4Z!T*L.T6F'R@
M,'!?8?I(8>AM8<+$#!(\K@P I"@)[_4ZAGL5 \U*[UPY#+<ACCY0&K@1<?Q(
M:>+;=T:<HC1"X]+\']@E%5R\URLN#VX$*F\KCK6V;] +ZS!F%\3.A9%]:<>O
MFQ?O--WL_L[DH:B5MQ':3!TW&_9":&[R1$\FP]Q\+@R'DN^UW29F+[N9V1VT
M:/KO@6#X*,G^ E!+ P04    "  +@:1,QMP\5=P"  "Q"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6R55NUNFS 4?17$ Q1_\%DED99DT29M4M6I
MVV\W<1)4P R<I'O[V<:E :Z[[$^PS;GGW'OM$SR[B.:E/7(NO=>RJ-JY?Y2R
MO@^"=GOD)6OO1,TK]68OFI))-6T.05LWG.U,4%D$!*$X*%E>^8N967MH%C-Q
MDD5>\8?&:T]ER9H_2UZ(R]S'_MO"8WXX2KT0+&8U._ ?7#[5#XV:!3W++B]Y
MU>:B\AJ^G_N?\/V&4!U@$#]S?FFOQIXNY5F(%SWYNIO[2&?$"[Z5FH*IQYFO
M>%%H)I7';TOJ]YHZ\'K\QKXQQ:MBGEG+5Z+XE>_D<>ZGOK?C>W8JY*.X?.&V
MH,CW;/7?^)D7"JXS41I;4;3FU]N>6BE*RZ)2*=EK]\PK\[QT;R)LP^  8@-(
M'] UQQE ;0!]#T ?!H0V('P/^#BER 9$MP;$-B#N W!B]J-KENG^FDFVF#7B
MXC7= :J9/J?X/E;[N]6+9CO-.[4!K5H]+T@6SH*S)K*898<A TPTQ*P@3#S$
MK*<8G.(AYC/$DPPQ&PB3]IA U=L73<"BB2$(!P093$!! FH(Z!4!10@F"$&"
M<)(!1:-6K#M,8C!5URZ4H"N=KF-36)(B5S81F$T$9$-&V728Z$J&)DZ9&)2)
M 1D*$R0@07)[VU.0( 4R&)WV33HI-(Z3&%;)0)4,4(E@ HQ@5Z+;*\4.8^-_
MU[JTH,&N$J<0;"8\=1-%\5B(3$XIB2AU[#Z&78<IH)2,E>BD))*YE6![8LB?
MZ5AIZCSJ%H*=AR'K9>/_5@"$79L$6P\#WL-XK!-/"@HSXCJYL$5Q @@1!P5L
M4IS^Q^&''8@!"V(Z_AQEDY.",4+./S4">Y4@0&MDM+4%#;0^DH(]30!/8\?^
M$,>GC]S>7 +;D  VQ.-OO04-SA)4<'!U4=&7V>^L.>15ZST+J>X\YF:R%T)R
MQ8GN5/N.ZO[<3PJ^EWJ8J''372*[B12UO2 '_2U]\1=02P,$%     @ "X&D
M3,/[OWSY 0  #04  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL=51=
MCYLP$/PKB/>>P7Q>1) N5U6MU$K156V?';()Z&Q,;1.N_[ZV(90#]R7V+K,S
MLQO;Q<#%JZP!E/?&:"OW?JU4MT-(5C4P(A]X!ZW^<N&"$:5#<46R$T#.MHA1
MA(,@18PTK5\6-G<49<%[19L6CL*3/6-$_#D Y</>#_U[XJ6YULHD4%ETY K?
M0?WHCD)':&8Y-PQ:V?#6$W#9^T_A[I 9O 7\;&"0B[UG.CEQ_FJ"+^>]'QA#
M0*%2AH'HY0;/0*DATC9^3YS^+&D*E_L[^R?;N^[E1"0\<_JK.:MZ[^>^=X8+
MZ:EZX<-GF/I)?&]J_BO<@&JX<:(U*DZE_?6J7BK.)A9MA9&W<6U:NPX3_[W,
M78"G CP7X+&74<@Z_T@4*0O!!T^,L^^(^8O#'=:SJ4S2CL)^T^:ESM[**,P*
M=#-$$^8P8O "$\X(I-EG">R2..!M>?X?@LCI,;($T3N/N9L@=A+$EB!^YP"O
MFAPQF<6T%I.'<8JQ6R=QZB0;G2A\7.F,F&2A$T59ZE9)G2KI5@4'*Y5TH_(A
MR\,D<NMD3IW,,;5DI9-MII9%CWF<K'30XC@R$%=[$:57\;ZUC\ B.]_U)VR/
M\S_X^%!\(^+:M-([<:4OA3VZ%\X5:#?!@VZXUF_3'%"X*+/-]%Z,-W0,%.^F
MQP?-+V#Y%U!+ P04    "  +@:1,$:F18O8!  #3!   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q]5%MOFS 4_BN(]]7!!I)%!*E)56W2)D6=MCT[
MY'!1;<QL$[I_/U\HH0G:"[:/O\LYQL?9(.2KJ@%T\,99JW9AK76W14@5-7"J
M'D0'K=DIA>14FZ6LD.HDT+,C<8;P:I4B3ILVS#,7.\H\$[UF30M'&:B><RK_
M[H&)81=&X7O@I:EJ;0,HSSI:P0_0/[NC-"LTJ9P;#JUJ1!M(*'?A8[0])!;O
M +\:&-1L'MA*3D*\VL77\RY<V82 0:&M C7#!0[ F!4R:?P9-</)TA+G\W?U
M9U>[J>5$%1P$^]V<=;T+-V%PAI+V3+^(X0N,]21A,!;_#2[ #-QF8CP*P93[
M!D6OM."CBDF%TS<_-JT;![]#UB-MF8!' IX(4?)? AD)Y$J(7?$^,U?J$]4T
MSZ08 NE_5D?MG8BVQ!QF88/N[-R>J5:9Z"4G.,K0Q0J-F+W'X!GFBD!&?;+
M2Q9[?$?''PT.]X@T7G8@BT40QR?S!,EZ62!>%(B=0/SA%&Z2W'O,VF%:A_F$
M28*7;9)%F^3.9D-N7))[ERA*-A@GZ<VA+2 W:11_CM.;E-#L+G"0E6L;%12B
M;[4]]5ETZLQ';._237QO.M8WV%7&M_MW*JNF5<%):'-3W7TJA=!@\EP]F$1K
M\\),"P:EMM.UF4O?9WZA13<^(6AZQ_)_4$L#!!0    (  N!I$S#*CAN[T0
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M ?WY:=-9['!PVO_!Q[3*RF7O1LW9_Y]_^J>=!ZR!]@9^[*!8^TV9-_CNGSJ
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M%\!1Z[3ZFK[X0]0AL$@J'LI\F5;UO_SSQ6AX_A+6MLI@Q&+1Y1I,7VK\"(C
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MO^K,&T=PS5E"UY^)QD#R;8PTZ7:Q+>>M_8*HQ(H+C._@A1"'SQ%B3GXG\W,
M2'(@^M[4@$4+QJ)5PS9  )^E!8H$(LYM*H9+4@B X#-@E G0,@52,K#F);PD
M]^H"L84 BV<-FVBMC:2'.DV_X-R94>\(*KDE@O.G[Z,J :V+)*YRD:9+E VJ
MLKE_0%YEA/$8$2$E/@>L"5&A2!]I1W35D=#J^X*,#M; AR+W"Y&U!MG8T34Z
M.&+Z)=Q1(N;NF--OPF]]7'H9U=E]06_34<$E;$A;R)"]="P]M!0:_LG<)Q9+
M9);/"-5W"-6K>V!"B$Y$*"N$5($7  @(TOB*F"BAKMZH8 "C+5 J1:> )$7;
M;)W"(M%: ;M%*KA%MBD;YVM0I?:R_<\0JP !.HO>-!6N90V8'\NJ>@'013-X
M#;7G'9A&NR\ O9!"!Q'L5T*I9^(3'46BD8I1RGP:1BNB./86>\<9Y:3KU@*9
M!-$*X<)(V(=T"CQGT2L@/DUMQ!H$)4ASF4RE2=RR;.9;WAF0DGG9>&?SK_@;
M66P\ZA.01!#6P%Q8"; 284 $(J,V(0)*26<=2U"S7J.@"PN_4P"]<EK=1Q"P
M GZ=/P1>V:&,'CY/)&9K4D@$$]HJA/B]D&5Z4K'U2%JDK/F4:_@\6@-Y1O64
M@-:2KA)C54+ VN&[ZN[5W77T&520130;@&9BUDJS7]LYZ=5KT"W*->*546WQ
M8_C,J)6@<RW+C4%;>1B=1;=%],<$U", E_4^Z0N<X%>P9?-%4QM"R;>(1(YM
M51K'%,@FVP<0V8 BY9DA*B4CJ0;28RHR.TK8>4H&72)5K=6<P;99;&=@$;='
M;B2:CS/ )"N45EJ?MVP*S"]E+S'*0CD^SF!H'A"-H(VQ1>#R6&T3KYV])+ K
M4KQQ-6%3!=#>"#COMJS(Y:0L%WH-4W>JG])%";A*)\3H(DXZ!&H&A[$@SD_G
M@<.8 PE"#9#U>Q+^A-C">I<M/RX-AFSC6[:&RPILZ&AX=F'%MY=]GY.<$_AX
M=#;4'Q>.TEOE 7E Z-.!^I2<.F37UM]CR!3;_#J>2QP/1AC9$<A!0I<Y^7:&
MJOYA2B2CO0":ELP.+2:(K#O*VO,G?0"H+NOMMM=SAI$P9#Y"Y+A5=E"XDXAV
M]IFSD2*Q29"-K3,V82:.\^&- FY;K]!DCQHVH /\?(^*$FP6G=[9(C7<?"&$
M@?6>C"P[&*G&>V&LQ ED-[@D,Y.E@#2=J)5P619$"T%.*1=T$#!3"NJ56TK/
MGL0>@EC^=[[N!A4?2=)&3BL<NA\JK.-FQJS1)=9A=Z,O.(@)I0(AJ"@;H)EO
M_TQVM[68\=HBTS'(R=&+MW\FPY%YYQ-II:\M)7Z!8&25]H3T3A0;BON\=S?'
M?8L]>4G6BZ_9$LU6<J!,Z$5#L[LQ9*I&>P-?IVR)2MDJ(XF+_5!&*$)LLJ8
M-T:Q%)EN1>*=&=.>)PU"1TPCA2'?UNX19!H:? '#H !BA?(%VQ!J@[KP5H/6
MC :U)X(02:K$UXV<>TP:DAYTY0#&-M$B;9E$#QCWQ)H)!'C;Q[)O[;)LIAD]
MV!=8B<(OIE(+GZ-; :)GVA:;EMM8>T>[XP:;2]N#F\SF4;J=DT,-, &IM9&1
MR-.:Y'AH-;OE95AT^WBTH$V66LAWYC!&2^4U'!*<!U#[*EHVE1$YG-FJ=>3(
M;2W\SI1PA+A<@F!0.'$%U5.A>^2(<DY!>R-0F%%K(<'#F55(K5X#&X1O$!"
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M$P)Y0H:3/2C]])LP_*9(OZ75(N/T!,%G]I0R<84]M,(-Z7K?PV'<(UEPPDZ
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MA9IRQUQSWO&R2AX+$YH(JD8T'@C])+63+F@K:T?,>RJJ%S0N$TQSSK$ +I=
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M$9?>.?5B8]DI_W0Y44R:]*7+V9F.Z]%M;QC>NN!TNS+5X0&!5&N@ZU7 )?S
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MI#K.-JA12V/IVU#6O6+#L^\U\@\#"ZM*\2@[E-.ND=.,L>#J[JFETS;&[N!
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MM)@.6M"#[J:#[NA!R^F@)3WH?CKHGAXD<R#CG)^$L.9K+8!KX7LM &SABRV
M;.&;+0!MX:LM@&WANRT ;N'++8!NX=LM &_AZZU ;^7KK4!O_8>S-CIL\_56
MH+?R]5:@M_+U5J"W\O56H+?R]5:@M_+U5J"W\O56H+?R]3:@M_'U-J"W\?4V
MH+?]P[L2]+*$K[<!O8VOMP&]C:^W ;V-K[<!O8VOMP&]C:^W ;V-K[<'>GN^
MWA[H[?EZ>Z"WY^OM1WK',N_"YC5U^WH7KUUR,OQBS0CNF+ZJ</V,8>K%_2.E
M4[\EN.%Z]2=EF/H3X4[^\WG\!E!+ P04    "  +@:1,,)0TP:\!  ! &@
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MXVCV#5!+ 0(4 Q0    (  N!I$P?(\\#P    !,"   +              "
M 0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  N!I$QF\PM@@@   +$    0
M              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M"X&D3"CJJ,[P    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ "X&D3)E<G",0!@  G"<  !,
M ( !N (  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  +@:1,2.M)
M$F8"   5"   &               @ 'Y"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ "X&D3)R!LN!.!   71,  !@
M ( !E0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  N!
MI$R74*4,\@$  (L%   8              "  1D0  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  +@:1,E[K*\D,#  !<#   &
M        @ %!$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ "X&D3':4Z[G9 P  -A   !@              ( !NA4  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  N!I$SM':;0KP$  -(#   8
M              "  <D9  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  +@:1, \.2G+0!  #2 P  &               @ &N&P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ "X&D3%%M%KBU 0
MT@,  !@              ( !F!T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    (  N!I$P4F1(1M $  - #   8              "  8,?
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  +@:1,S&(B
M8+,!  #2 P  &0              @ %M(0  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    (  N!I$P2DS=%M0$  -(#   9
M  "  5<C  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M"X&D3'8K48ZT 0  T@,  !D              ( !0R4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  +@:1,2$<(9;,!  #2 P  &0
M            @ $N)P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    (  N!I$R! SYMM@$  -(#   9              "  1@I  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ "X&D3+#AJ?:T 0
MT@,  !D              ( !!2L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  +@:1,1$HEH[4!  #0 P  &0              @ 'P
M+   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  N!I$P/
M#LVIM $  -(#   9              "  =PN  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ "X&D3 3J[6>T 0  T@,  !D
M     ( !QS   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  N!I$P=HHS:MP$  -(#   9              "
M 78Z  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "X&D
M3./S2IBQ 0  T@,  !D              ( !9#P  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  +@:1,W$=S(+,!  #2 P  &0
M        @ %,/@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   (  N!I$P.JW,0M0$  -(#   9              "  39   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ "X&D3%M%R$^D 0  F@,
M !D              ( !(D(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  +@:1,&6P1*AT#  ""#   &0              @ ']0P
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  N!I$P_N7\A
M_0$  !<%   9              "  5%'  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ "X&D3&(*B$EJ @  @0<  !D
M ( !A4D  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  +
M@:1,.MCL/I<#  !W$   &0              @ $F3   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  N!I$QGWY=2+0(  $$&   9
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M970S-BYX;6Q02P$"% ,4    "  +@:1,QZ+>#TX"  "Y!P  &0
M    @ %U7@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M  N!I$P%JYH/Z0$  *L$   9              "  ?I@  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ "X&D3)=_'B:  @  H @  !D
M             ( !&F,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  +@:1,QMP\5=P"  "Q"P  &0              @ '190  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  N!I$S#^[]\^0$
M  T%   9              "  >1H  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ "X&D3!&ID6+V 0  TP0  !D              ( !
M%&L  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  +@:1,
MPRHX;N]$  "= @$ %               @ %!;0  >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    "  +@:1,NQO8]$L"  !?"P  #0
M@ %BL@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  N!I$R%HI=Y>@,  )H;
M   /              "  =BT  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  +@:1,Y2$PY+ !   #&@  &@              @ %_N   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  +@:1,,)0TP:\!  ! &@
M$P              @ %GN@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..,P S -<-  !'O      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>67</ContextCount>
  <ElementCount>176</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/DocumentAndEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Condensed Consolidated Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CondensedConsolidatedFinancialStatements</Role>
      <ShortName>Condensed Consolidated Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Procurement Contract and Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/ProcurementContractAndResearchAgreements</Role>
      <ShortName>Procurement Contract and Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Fair Value of Financial INstruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial INstruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Per Share Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PerShareData</Role>
      <ShortName>Per Share Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.siga.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/Inventory</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Fair Value of Financial INstruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial INstruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Per Share Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PerShareDataTables</Role>
      <ShortName>Per Share Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/PerShareData</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.siga.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Condensed Consolidated Financial Statements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/CondensedConsolidatedFinancialStatementsNarrativeDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Contract with Customer, Asset and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesContractWithCustomerAssetAndLiabilityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Contract with Customer, Asset and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents, Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents, Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Procurement Contract and Research Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/ProcurementContractAndResearchAgreementsDetails</Role>
      <ShortName>Procurement Contract and Research Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/ProcurementContractAndResearchAgreements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/InventoryTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Fair Value of Financial INstruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FairValueOfFinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Fair Value of Financial INstruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Fair Value of Financial INstruments - Change in Level 3 Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/FairValueOfFinancialInstrumentsChangeInLevel3LiabilityDetails</Role>
      <ShortName>Fair Value of Financial INstruments - Change in Level 3 Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Per Share Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/PerShareDataDetails</Role>
      <ShortName>Per Share Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/PerShareDataTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Related Party Transactions - Related Party Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/RelatedPartyTransactionsRelatedPartyActivityDetails</Role>
      <ShortName>Related Party Transactions - Related Party Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="siga-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.siga.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.siga.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>siga-20180331.xml</File>
    <File>siga-20180331.xsd</File>
    <File>siga-20180331_cal.xml</File>
    <File>siga-20180331_def.xml</File>
    <File>siga-20180331_lab.xml</File>
    <File>siga-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001010086-18-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001010086-18-000006-xbrl.zip
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M\$@(0:M4G $WNB5K"F7[72 Y!(,V^%O;83@&RFWECX+JP&:4^@)DQY:"4U5
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M<@7UB =!GV])J:LQY@S$I*?040F(AYJ:ZBLB=S(TW>%::()-+$X@708"#49
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MX3@?W9:X!W=Q=H.:X T$FL!UGZ+\=[1.XW@0+[!(\<^ E?,%, #6*=?;4W5
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M&14M4R4'E50T;7>+]D_PKOC+N)$3>I(]FN&%,#&,7[C_]]6XP29M3I0]BMZ
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M*.M\#IR"#U@#^\@34(1%#-&%!XZ1&(DDCO!L5'9TSDI 43U^"U;NK%Y*,IN
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M@[^#D!8GA?E5^)+?^3H/I6BQ:9#$:B@/+)<2<"\080,;WCSS$G3#! ZHNY0
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M##Z/U96--D<"C;'>(R>H"6LC<!A M,61.&.&K$ETL!KMF;2G& ?NZ9@KWSZ
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M12/-4#;*G.W>F)NJSN[OZXJ^9O3+_'N;EPW];'43NG=5>YM_OR_JATT80.A
M1 -/@$,7^Y&+H@E;%/./I19#9#AT]'ZP;ME[,HR97JC*!=0),#K4?3.YQ/X\
M= 'S"O1N"4CE<FW+$9M6V:QB8>S_IA85B).K;%FYD+IT"_-%65T$GPO(BS?@
M"F+W\CY7E^PRLL,^DK=9L7]_TV<@R3&?/-VP?+)-&;D(AMB.HA0E ;$0?9=[
M.,A-'($%2),@EAHR=MBO0(^>K6_U^,&) U>/SEU0/VM!=W.)CCDOV%(J(](_
M=R/)#FDOV%BZ!KQ#E,Y/&ZO?7$5C]CU]5%?F>SH,'N/Z+1T/?ZL.>QK3#]U)
MC*^=N7&UP A:K$6XQM>&&GD%$7P1-\^.S8WRJC%.?ZBKW6'+?GB"!L, Q9!
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MX#V]-6.JX;&19<>IG7AV"(/826,[=@*/X 1[;NA#WB(VZ>>;ZW(C)':$$^A
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M33R.%Q+/#3P8)(X51BF.B4>_&.W0?[AVE<D_?:D^WJ.2F V0)(V_WYOC2U(
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MS'$X/,0)*IXT[^N5/'F7.#1/D2]>T7M7E5^H+-R1_+K]3/^RRR@=*R6QEZ"
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MFB&-_EGUK H+7'-+5(GJ/&ORM^5TI\S[F[]G=7=8UL;W'<_'Q$FP%88IE:,
M>Z-!QW%3 =G08&T9!6&JW!<:;6_ISW-6)G3#[HCZVMU32D?YWWK TZ:8!\7!
M_"PKYP;U>JA<P>!>DR.5]M=,+.+^6I75X_ ^]EHG#9T 6[Y%$/:=(/#"8!HD
M6+$M=,&>O!7#\[7])LVB@W0%REQPX4B!/;X0O QQ8L'X%-.4T@^P%L[JS](S
M$Z/5*5U'M-;@1Z7[99/9)\8"5TJ]8T<1%N6!VA[&&U79Q/E-5>?]YSYGW_/F
MEZ*L:AJZQA0#E;O'3V'' [</O^3M;45_\Y5^I#O*<$-@'%E>$#AV:"<HM=,(
MCROQ(8P2H3.\UX3;\ 1'EU5<=]X,*LGJCD4G1]=$F- FPW5 -CFN.IF0Z;/'
MHZO@Z.OX"O0>@-X%<.+#U1@(.B;Z*QI8F7G5E<F D9)+[(9<I UGQX3K>Y/6
M$<%6R<R+.T%7AE'L[HM^K_<$<(CI<5[F-P4[FB*!?N1[?N+XB6]!'")[-,I6
M%26FV!0M+C->'D">Z-8XN01^&) NG,S.TS:C,)KX7H<HZ'+FZ443.CD22W!?
ML.8$:8C<( Y=U[+#P+:=J:-[V/;'/B>2CHI;D>AG8EUL /+S#]V.-U9L\F-7
MHZ*:2$H0*I+T&6)2)4%;@3J)RY(JF^O0(V4O7DPH5%GAGM[+VY-%NSBU'-O#
M?I) ER8:J0=A,"48(;%$!L%B3S8\3*5@^DN)J[O[.K^EO++M&+-K\F;FHTY)
MF9N#DB)O'1U"$OO3N28%!GA?_B2K2YJJ-Q_R^M-M5N=QUA1;5OY<[ \TF&UB
ME\16' 6^Y5MI'/D)#-+CK);+58JLRY;A>>YN'H<.64##P/TCN&;P^DT3/4"Q
M.*S,+%\\7I)4L;@\(@,4&NBP78%XXI2\PJD1[7F%K!DUTD7S.O1)FS>5F9=1
M3,/^GA=?;NGCT=>\SK[DOQ[NKO/Z_4V'X/VA;5KZOE%43\&X'K*(%28N(3",
M4NB'UE2>@RV2BDB;(0B&%6]$#;(>=J]\#:B.B)5ET%3C\*GC"MI%3#2G)AD0
M@QXRJTWXU#?.">R+ZZD<O3,R:[B]UJ&^IIVL%NT#8EK]8=@E\X&^]6S6E\WS
M=IOLCA>I01L[MFW'F$06MJ#G)L3O+E*+B4TBPG54ET9SAC5X1'@%[AG&?N/1
MB%),:G5PRR>K"],J)J%'1C],C$X P>^?L^M]#G@N^S0BF:]3-R./&GE?AQ3J
M=*@R]HZ*'CW0[0[\D%'CG^NL;+)N2^'QY)<T"3V$8.Q'GDLLR_42"Z<D<2S'
M"Z -(?=F>44[YKK@  UTV, IN N>VCG/UDROTT;T.OJ</G>>[9[7RA/WD4?;
MVWQWV.?O;\X!B!\>_88%@(WGI8[C^YX3>3"PL>6P^^(&+!Z"0E<CF4%@./$8
M0;.AQ?G^>@6N'Y[\NH^@G'=D&VXD/J6\?/N(R:>QIC%SN)(,NS-R:[:UUJ'!
MAGU\>A+3 HRJ9D>/$:#O1;.), H)3/PH3ET/1P@B;PH7/H&NB$1K-&M8EY_T
M: 9)4&MU4JR6BAIF5R4I?87817/0YS1)9*,*7*]#$TTXQIFA*G,GHWZDNLN*
M<I/ P D#Y)'8PPBG,$RP/QG"GM *J\3CEU6S'I2"GO&2)JY;!OA2TJ?7J#*N
M4#T 3B429&]]BB/JP(RR2''!M:7WEXS-T-?YMR:MZNN\^25G<_G4$B;TP8&5
M(FK(LQ,WGC(U9"=<*YDJSS>L(4=4H+MU$_3@! Y#D^5M7D66HDQ,1LZP!7[O
MD7%JKQ)M H?(+4"?W"ERTC3R;0Q_V>\7Q%8'2RO8"J[J0:7OG=$R7GU7E/G;
M-K]K-C"RH MMB-,@2&BVZ-@1&<R&<9+J&*7R&ULTFSM!"'YG&$$'4L]H58!@
MI3&J&6XU+9?PT;KD6'6B2WR$*L[T^K)$-7?X1J.R/ D<C=[6AVW;7<7$3CRN
MO^8?J_V>BNFWK-YMPC!UB&4[84*\-$Y(['J350]94$S0U&P9U[,3>&# !WYG
M",$ 45C-%,GE%;/E>!75,@5*31V7/L?5K)#I87DM.J;)F^>'IFMD247%-D$2
M6XX+L>M;OA^3Q*;C[]%4Z/O6IK]T[E-+)5=>P%XU(]*[GB+B[FAQ1K_=YB!K
M <FW70H,''@%6"]0UZS7J907*JW\:5"GR\N1H 9Q$[A>X>%W@4-M!/F0DAA\
MF]5?\F83T$$F#.P$)JX#J8DTQN.Z0!A8*)#.CG@-&$Z)!AC@A^&VS.XNS>;U
MB[.F,\'/[[G52+*$^)C@5T5\!CP7%)\! :_XB!*X0O$1=F%.?.3XX"Z4SQZZ
M$T]H%O7(Z@:ZL4=@C$+/BQUHIU%(G-&<8X<B!W<JV^+J*^K'D&3-+;@?,'8G
M$++"J.9PO6<G00Y')0B6RDNSRZ<\9AF5O%*FA]0=+_$(U,(%\&>HF9$A93;7
M(47J;CPM<=?#B]*0*W$CBZ0)M&WH8G:G:4B"T92=!F@8<B4EYTDM4D;$!UPC
M'IGAUB_=57##6"O\\XT>>-E<1Z]1<X%G]"#&AWA9.CN_K*04/@P'+'7EE<==
M*!%R["!P:7L[* E\$D+D=;M0,,T?7';BB$PENJ)1PZ.,"9UL%;DJIWQA_")T
MBH7UTUKQ">05&(]NN_1V-UX&9S1,>R.L0]?TNW6VZELK;[SZ-P3,3[=YWKYC
M7!=5V556IDGJ( LYKA][7A Y./%L.[!(Z/D)=AVA0].EC1C6MS%;Z("!$9E4
M-;<\CWP:MPB%8IHFQYX1_3K'SHQ>*1.Z#GU2=Z/2_**IZ\]0F>D3.PYIAN?[
MU%;D(.3C>#088%OHY!<%,Q?2(*D:;!4VY77( )%ZE.@BQ=GG&1)4(T%:UZM'
MHHYP*)(4-]S7/[*K5-X-=PL5Q\K%T(YB-W6)EX9!%.#4<MS1F!-YMH@>29HP
MK$7]'3(GL 3O@93DC4]Y%J!,3'6>L25<=:SI0L@7B9D1&T4FUR$TJDX\O1E2
M!R=<NT.F.RC?L7617[.[O$NOD(\\9+/U*1^'EDT\1,6MMY1&KL<UOZ3R?-/2
M,MVSU,&Z @R8T$A+B;QYB5F*-T%]N2QE MM#%J!.;GN(%(5\6T->]OD%U=7!
MT JVAJAZ4.E[7Y3$=L@<(QAX,4Q2GUC0<5,<>R09;5%EYSJ^3LW"9017:%BI
M2*&4Z!I@3XOL+DF<DO0:(%!.?$?*NE*&197X['!;#V6K5&-1'^;U6(H1+D7^
M-?_V+__:V1E2; N%'HDLF* @]C']/^BEO8W \F# M3-/[LF&%9CB ?_RK_W[
M+B ;X@1QZ*Q1;L3T]906F>W.XOP(R*E1GN1D5(PO/LE\ZN8YJ92F8P42*8^]
MTO%"B"2I^]V__.NGH5!R-)-BG+#'6FGH.8Z3>"X<S80N"?GS4XF'FTY-]SOV
M1@^@1#(J&:)XLE##' DFH(_HD=)(*:)$LD[#A$F.]D6)X\POGSM[-K54X&4%
MDJD$O]+T?HBMU?R2E=F7G+TK@YG43B(OA:%#+"_VO1!"SQG-T!\)U:T(/]RP
M</8H6 U97&7UCGU!BCK?TA=&<*E&G#:^11JCC(G)Z!'*A=9EGG(QLR(C3=LZ
MUF+DX5>:7A\QT7B7?\GV:9XW&S^,?8? )':\.$8HI+F=-SP?XC3U1=2"_ZF&
M9:(# FYRT?5; 5KXU, ,(V(RT).1SI%AI/=/OL]T>W%^UM'?)7!7JF^&6 ]'
MVVUU*-OF0_; JFA/SG I\F:HKT7E[E?J;__-)HS\ 'H8Q0YQTH2=(HI&'#:V
M RRB!/JM&U:,$3#;O]=5HK<5J(?CCN[9P3=B0F* ?3[!N2SQ8L(T<3Z O7IT
M2OQ<\8T1O1*F;D;7S#7#.O3/H'_54B^TH)[6><;.I<_V24-'Y?EX;<_&M5.;
M>)X7L>/\@M!Q?6B-YH+8%MH6)6W$M#I27&RL1?^S!WD'#=P/V-@)#*#Y#W S
M<XNY9D8YI7 ),@45;^"1@0(]*C#"6ECLSI SIVFJ?*Y$NI3=>*I0>GCA.UBY
M*MO;_<-'-C.X/]E6_;8LVH+^I-LSO(%I'/B8#183%&([\DC@CX:1+W+.LA9S
MIN>$>I"@[E!.!S!TB^Y%#Q3TFZE%CA360S3'U/OR' O.(@WT]@#!=#P#A0@&
MC.##A>@5.<!Y<9KEIO _W^8@NV,I#PL4+?WN[LS[O3ODX%!2M>P^-1TS0G^7
MU]UQ2'0(P_H ^^WC?O"3ZJ'0/%R>6R'0VQ K6#/0[%!E[*55C3/HAKY9CTTG
M4>@EU&R,PSCR40 =.QY-AY'#=2F(5H,7BC490ZHYVLC0+1MO##.M)^)T(#7'
M'!F25:..8;+7$'>$^H-"T'E.I5#846B)M08>%9=>#3W*?'$%G\% FFW95J2'
M-,\W@8<)<0*,7-N-H958"9Y"G&_S7;$G^VS3<RN[7<%Z*ENP&E"QE2L!89/A
MBR-0&*9*+":,JC^B8>M9ABD2D'G#5,DINA!E?!K\W,]S<JO R J4505]I>>]
M$-#+D\>CLCQD^[?EMF8QF4KTELV(^Y'K1(GC^1:*?"=*J?5PL.FX6&"KC[(E
MPUJ:G@@HR#J$[-C-NM]P<=^#%) -=68Y='914L54]U0Z0 \.O)WX_' !/@5$
M>5%>Y21ZCE]%J7[-^W/"K8VU%<BX/E\J$^^5I,0_S\%#C/W$<H@- YPBVTL"
M@D:#OH/XY_O5S"PJ[FH3+HI\"JJZ62I5)%UM1D6114DM-\NF#B$7855<S;FG
M//20MC(=5W#DG(BK<L-]TMNA*<J\:9+O18NKIFW@)@DCZ+IV@D@<^0$.D.N-
MLR<.<4.AFCN)QQM6[!$1R"DDL*68! ]SDR!L7IH7XDI,DB>:&!K0P5GXP+9G
M;,R4@2A0MXX"$!4'GA[,ILH%KW2\O;O/BIK%I?<W[ZKRR[OB:[Y#39.WS><J
MSDG1W%=-OGM_L\$P=?PP\EU(@A@'D46<L?K-07X@M/M'GU7#0O/WNFASL*N^
ME6SQHEN/N*WV.U#<W=?5UWQ8HRMWX.904Z$_U(+7<&BDGT^?+L.\X)3LA)&1
MSE"^Z6""'B>KH+[.P0B5?F994>.F<$;K]#?#.B30@%^5Z1=88+3<[5;_G-=W
M19GU-]7VI]H];)+ 1U;B$)K@V="*/"LA>#06!;['/5*6-V%8"OM3$MHC,K ?
MH0F,[!08Y!@;+T.>F)KUO)V FLZU7(@W@='P,OS)C81E>.0; Y_U^MSX5YVF
M%8Q]-3A1:7UU!!/7\4H'JOC;?=70U.MXH8.'J='(]SR$W#"R/0?CN+O0(?8I
M %_H/&$E0X8U6?(6&37N.!/-I6@37>X?8($C+O#[Q6Z'F6-I+GW40>Y*,D8M
MKCQ-$O7QPZM')+]NWY;L<BT6VKH+9C:!FUK(25/BA7%DAU82IXF=!C[!*:8)
M*5=QD<KS#:O/Z<U+W2B-)8>  05'I,UP Y/@=0M2=/(IDVDFQ01)$XE&U.D%
MIF9$2877=6B1D@>5OK=,3'EPG>^*=EQWZ([[A5&81BY)8LNGHI;X"?*BT1!T
M7*&S-R0>;UAW>D3'\C.92Z5D2..3%\-\B:F+(%5&5.0Y(3,BHL#>.C1$Q8%*
MVYNDHB## ;4X=J'M8\]U_="#:4R3)CR:BJAA>0WA-+"TBDA="R5'G8R2&&!-
M44LN<@?42Z1PZXD@AVM4%%$79C5%B@_N^W_S+1UW[5@B-!PY!@EV7!MY7HQB
M"T:T@;W1#DE\2VA:1OSIID=#/: N=1>\U%><*#X!,<N1X#CGA)X+G1KXC(X9
MW9"G;AVBH8#_Z2VZBDQPRP4[XH*-E3YM\S*KBZI+>-AQIC;R_31"3H+=),+T
M^]Y6X@6AT$V5<A:,3Z+T6*1&,9*<<:J'<;I$9TKXF#*C'2^1,:<?2N2M1$/4
M?'BJ(QH8X=:2P<1O97.?;XN;@NI7G^K ,*8Y#K%LR[,2QW?]%/NCO<"*8R$]
MD;:RD*9<@1-HD@,<!2HY9681%N6D1I! ,\ISCI\Y]5'F="4*I.['4Q72Q(RH
M$J55G6^S9DJAK-"W/>)#:!''CGV<I.%H+ F1E P)FC"L02,:.;41I4M,:@PR
M):LS(Z1+#8U>9(9#822I7)>\R#IQ1EN4..&J0WR\N(2S^VQ;M _7#Y]Z3=M^
M.-2L"K++L,+(P[$;8CN EF,'"*6$#.93!%W^RD2=1@V+SY/E4S""!=</8(0+
M!KSBU[YJ97]>N2Y*O)B6_8DX%ZB(O!3W<C62.MN KW92@)\7HHDQBE=07VG$
MK<KPJZD_!@W9=>('4>SZEHVM*(WBD%6$=@"(9?D)Y+^#7:_95<4A\7MP-;>!
MOEAD@'Z3T>CBS.N/2 9:0,-=Q:L-4//W&IOA_,\3I$0=DPA34MQQ!:J/^7#"
M9'7SMCM*LFF;\0ZLT$LL&P:0N"D)@L@/$!RM.9#OB@55&X9#T(2,%9A.V 24
M3H4^CH"R$'-BT>-ETF2N"U5A3R H+,2B7 2099-/X,^[?D[--9"U NG6X46E
M]Q42$.7QX-?AVIVV>E>T].?LO1J,!BZ*B._#V EMWX]3'%O^8!3B%',5"VDR
M95BBIW.HQUNJV@H<,0J(C092.11[63[%A'N>2AD!U\"I@(XORZV<G*MRS"?K
MKS)Q3MWU4;@"D=?H3&7D-1-;#?U;5A?=96O4:E_^D42VG9(P#=/8]WW/C7$X
MFK$)%"KO$GZX85D?\0 &2*J\2YPNOG50HTR)";8024:6/I^2,;/H*<W;.I8[
MY>%7FMX?>;48I@=BU[*2"'L8AU& /.A$L3T:0H@([:B5>/RRBB%5KR5#FKAJ
M&.!+23<N4IGUG!!.[1!D;WWJ(>K C'Y(<<%]&WU5[JJR&\Y>9^4?[V]NV$TR
MS.R[M_'[CT.NXWK(AH2.:3T/$<M#KA^D@VT[C@.A)$2/1<,ZTX,$$THPP.P[
MTP\=4L$[5S4QS:=$RY,L)DY<_%ZHTHN+NQD=T\O].J1-LT^5R;=58([MMT^?
MV?'QA_J!&1OMN,1-:9X6^($5.A#:=CBF:C9&">2>5I-ZNF%A^^T3&$%U?4U@
MGD>.+([I,N,\B6G34XIDYL3DN!*8!C/.F=S,ESAW?'-=+[E[;GI+B9H5S&BI
MX:]TO20JASMU0UY,4((@3@(O@C#T4SL.O-$0M,1FKB0>OW#ADLSLE0QI?/F?
M8;[$!%60J@4.:GIE%DN!O76D:RH.S)[2),&%G(+\FMV- U_;HSH5."YB=RHG
MT/)M%T[F"!$Z9D7:R+)J<@48-,GY+7DB9;3%$(=*"L-+WP)*<Z2'6V\D&%VC
MZLBX,:L]TKSP'5Q>927Z4N?=!NPA52(X=BUL.T&:NI'E) C[H] YV,'\EWO)
M/-SX#%=6@@F3R#G;,D1QC )-<R0Z075*C\P04(HGD9/(#?,E>0:Y(&^<YX\_
M]_7<Z$^%EA4,_I3@5YI>#Y7$[5U1YF_;_*[9. D._0#%*$IA2-A)YC@9K;G8
M%[H.1];&TH- A@QTT)22-@$297(V,_PI#@IYJ%L@89NXX<[7Q-E<8[HFX<5L
MMB;+"O?")7W^^YO'A_7]DGTO[@YW<577U;>B_#)NI=BD,(6!2XV',+0=)[!9
M@=8 P?/X[IXQ8MATDL?Z5'4#MOW!E#<#7,&%2ZU,<ZY?7HIDP2QQX/?)P9]7
M8, *)K#3/JZ%US(%>)Q;TC31'.M003.N/5W@-,>?BEZ.)M'7K-BS<I.TJI]L
M.GO?WN;UY]NLI+_Z7&>[G/Y\>YLU>;-QD1\F:>3 *++<*(W=$+H#3L\-$Z'\
M;GETAI5WVK:9C>B[W9W-N(/S?MC!63$/0$M=Z'[?,B?8+WLOU(7:<!/+J_EZ
M6E>3Y$\MCAZU^+,]N^\?MWCG&/CP:HLO%AZ4&D8PABSS$JPWT"SD/T<T6K(E
MY"86XJPIFD_W=9[MWI>G]9%P0T<4D4M2&"'D0(@(<5(T1DS'34+YF08%HX8#
MS"]9_:48@@:[#V=?99P;X?33*S,'L1"SBNM('4K0PP15"1X555]RFN(\?=SS
M%AI:8!W*JM^MV9D-;;S)Z>"X];@K#3_4=.3P(:^+:K>!=* 00^(G4> BXF,_
MCL=%,2=,8H5Z&VF3AC4PN;G)MVWQ-0?%@!#47?UPUH ,W.?TK\I6L$Q;%]DR
MFK@(SXJ*.&+LR_MZE*"'>4D]/$<=MQHJ<[]&+51W:E8)-7'&?Z%M;R[Y?I^7
M3<ZP;*";)D[D^R&)70<Y28+M8%+<R!*ZQTWF^885;NIM>8_I"NR$+T^1HHU/
MODPS)J95$UG)2-;L33.&KJM]QLB,!*GPMPZ]4?+@V9VTJFR(*LF'K-AMG"#T
ML8<3VR%1Z 8I0L0:3+B8>%A&0K@>O)1VW%,P;/ B.4X4(TM,.+3S)*D8#,=E
MA()9YE ((:+6)0UBT,]H@H3_O&* [JJZ+?ZSJW-Z?Y,6959NV7I,U;3-!D)V
MR8&#L><AUPH3.W&CT61HN4*+'$J&%DXT0+;=UOEP=LUU1C^[Y=PKIH=6/AE9
MC%$Q63F%Q=8*^D%4TQP8BZ!#MZS8S/$T(SY:Z%V'&.EQI3+P^HG4*!=E7CV9
MN$<[^@VUG^V?KR1'CA/$81J'?NI9EA]:5CQN]?*",.;:.6'$L&$Q.T(#UU,!
MQO:U HP%^)Y7M8M3K6DE](1^@?J7!>@7J:Z^8#-(5E[K;0[.PFPQFEZ(-4;9
M7D-!MRG7J@7>5L78]$M1LA(GG#6W'_/_.!1U5XR^": 7.#%&@1,$06C9GAW:
MDW44<@VX==LTO5K;HZ)!J+D%]1&7HAK*$BP9AQ;@5E,(&OEF4,''B_.M&'@6
MX%USS!'F7S[<O$R.2*11I'>E04;5J]?BBQ;6I$,+&U*3_"8[[-NWY9:=<I$7
MY>EZU,;U+!(Y=@AIK MBB[@)&>])\"S7XC_&QXQYPP'G0]72UBAHSE<,^.@7
MCY?)%;500PM(AJ%ER=<4D;HYH $U6T4_-LJC%?7+-XIBK%JV<32'+=5&DH]B
MK](F$M#TM<%*8YM&!U\+<[JYY"_ZNLEKBJ2?5<R[.<6_UE73;&A039PT2;&?
M8!032&/L9"]P4Z&;D>6M&(Y?'1(6NPX,GF@)ES1U?,L.R[ F%GA>6&.X AVH
MI<NRSG S6XFERN<Z%ADT^/&LWDH/,W*EIFF>H[OJ4+(R#!L1FM1'D04=.V(U
M76,9AA>GMB-?6\IOP[#B4" -R,K=N (JN/E*FCE>R3%/FHS@G%2&4E"@1W7)
M0M")&N[*3W$RUZ(VBE[,UG;*LJ*R'_5CSDYW*LHOSV>L+=]R'=]UDA!'?H2A
MY:?3C#6,'>4=_ JF#>O2A$QZ+=,4Y7S*=4&V-0W=CRVPQNW\Y[F<44!#C;(.
M833E',<V2FT<\LKH<#_5AZQN'S[76=ED6S85TI"BV>ZKYE#GG_/O;4SI^6.#
M$R>&$1V<QC:*(Y<=G.<$'L%)[)$@=(/-U[R^KGA55*=ED4Y]"E) 1/N+V#JT
MX!2NF(1JI9M//R_%LYAXGB<8'(&"WQE4T&%=^) G 19G9--$6ZQ#,XUX5IE_
MD\74\M?\&]IN65;+]BK554F_W';K5LW[&M_2%SI_6YY^HBBWQ?T^_\RV>&YL
MVX&.ARWB8C]T0VRE;F"%%!V, P\Z1"0'-8O$<$I*P8,C-O 8/GU70>\ FS=_
M]+'!!RH#S O!$_(,MQV?&*^GV<3DV72+&=%L);)G5'R91ER'KB_D:W6);B*X
MS6/W[X>F[3"D53V#L#OCWL>NBZS4L1+Z<OK_?W57V]LXCJ2_[Z\0<(>[72!S
M$$7JA3A@ ;YI+]C>26.2V<5A/QB*K72,<ULY6^F9W*\_299D=UYD%D7*Z@_3
MD^[I43WU4'I811:+7&),TPH#CZA2"G'0H3"[EIW73O=@F^8BP\IA<NN%Y8'0
M$^[+C0%,J*W2[^8L"83) 15V,R+S4%U'OKT^?N*005U5O:O^]LT#6Q5/)U=C
MTRA-8Q(QY#-)4YY*(EEC2B9(11(DGD8&'&MDC:E>*>Q0&5[48<:=GMXYIPTF
M:W#&G&C7>ZP,2-0H$N>A1.-<*"R^5,!HK9>RVS+;KK+=:O_KTRHK\UJ\4-(U
MM*^/U041CAF+, ^0'["HMDUC'@8D )7"V+'H.CH[A@(]2N\ TZMQ_H028#!F
MAV?-(&QRBH'!UWEV+W0GK19S0\&65>;G(6V6?7H=7#E@#"A^^\_92YT0L^VJ
M^I/=<[[ZM,[NZWVF=;[O;G.,)8U1@"A/@UB*F/H$M[FRI*$/ZT]@SZQ[&:QQ
M>2? FM*=0V]=4=<,;LO3_VHDBE;X!RGCU-0;R>/>:U$VE+\W%!?52 T.SPNE
MS8&8E5I:=>Q]R;3/G7Y;IW5]Y(4]/6W6R^9(P*$?G7C^^KS)ZD:1AXZ1S>93
M<SCV<)\E"Q66?D!Q(I (%"%ITH%!1 %[R#F!X%A/6]3>">RVIZ-W!.X=D'M'
MZ$;+?ZX&24]H9S ^,-%U-#2.>EJ9D#N@QHY':Q[*[-K)-QVU)N#4G6*W-X R
M*B-"<<0))2)D)*QP=' X08%;S=8$,5?5-EJM=#=4KI3;P2A-I-T761PU)=BJ
M?@/'[$=5<*B;HS7<B%?M4T/KREJ5<B]SGI>_Y?GVE_Q;OGW.__*\7M7'EJZW
M!S@\?RAV35[P4,G=7?&T7D9^U*8$&#/I\RAD%9"$(E\(U$TPBJ8*=L1H"D".
MU?WH@W=_<,)KO? Z-^IRG58][AM/FHP\JWWQ&F>\RAO@,:9)AE)/\6<WBC#U
MMS6 %UI.L<'^P-0PZ>#.8YJ8UN77I[NFY]MU5>ZG_HI9I%@@&2$^"5,D49)@
MACI</$TGJ<S51S/WZMQ/II=83S"0>C/'O,80-FU,,GRSJM?M67=0LPL?T7G,
M%1/Z:ZEVUY1I:$.4I@="N\5735,_%X<>(=MR02@-&0_B",6!P*%@/&J3&^$K
M2GR3QBCFUERG!RU ;SG83MP5E9H1_*0L L/SCL +]&,_R\M0X&R-TWDHG45_
M/FB>8HLI:/G&+_DR7W^KMT)_SLM%*"6/0TFB -=U<=*G6+2V$"(^Z))2,PO3
MU*;MO5V/RJSL L@;K,+"'66&Q11'0%=>!>DR-1/?L:)1'F'&XCP$9Z0/'Q0]
MC&%$_[!_F551UDIEN[K'P+ZR?5CPS5>5UJV7ZW+!!$V$DG'L^X*@*@)+9!M[
MB2 (9 Q1&0OFW$M.A\A;'2!!S_./9U1/?R8F$R9&'3BO0^?]\93:%N#'-ZDZ
M.K)_CK$!H;)(]SQ4RZ9#;\[E6^9*7\^:)<C]0A%&XT0*&?JQI-6/E-'V\3BM
MR(*IEN9#'6M3BP.J1[J,Z*J. S*@VG* ,+5X'*P.2@20F[D( 13VF\_=R&_@
M1]UW0OJ<[QZ*W==ZC^'F?K/^<N@KC2O70XYI&*6AI+&B%*O6=A@JI-6=W:[%
M:>3@JLJ.NFYB3T><7M$#-1*,L6R#U&1"HHVDYK1CVPE$[^8\QRZU:)BV\T)E
MB?99J9@MG]Z7.*N,Z>O?OMRMEU7P5%^-L<"2!0D-4D03*<.ZZB:I,T$F?,D3
MJH )&>C1SA6M0]-<:P35+1A+N@+EC""H$O7<B"%N'.G-*0N#PF)$UUP4Q S\
M&ZD8P8&9)K!M\R_UO\_K;]FFWEA;^#X*B8@19<R7$8DDY;B3(A:%H",HHXU-
MJQM-R5/S0W[$.$9,3.@UD1?'S(X2G(;4Y@>E0>H$*O26+&U=&L'S')5JC#N#
MVC6:)S,U:S?6%G[  A)7[P*7*:'*5XJDK:V(Q]R'=I<UL0'YO@S[R'ZG75=>
MNY-XR4]+G-TR'D?F'#\BL ^#7XX9([J?2WLO>+8Y-M=_M^5IH$*9(JDDE2$A
M1-+4C]J6IXPA!&IQ;\NFXU"@AWERD01P[K?&KEX(< EB89' NYS.HPFS)GD#
M2F:;_GEHFW6O"K<O+5#_LO7N[]GF.?];GM7V:O/_6)>/OVZ+^WV^:_;,K[=/
MS\T>>D78>K-NUF?JWU;"7#?3S_;K?==$X*5YUD(IC@*2QHPS' B2<N'S(,5Q
MF"H9<LX63\V)J-LRVY6:FGD1G! A>.V2MB;\(]OMLFWI;3IL7E;?<[ALJOH]
MC*[J]D8Q4'@O,ZR:,CW[L02*>N6/UX"X\DY<\GZK?/).G?(.7GFOW*J7Q%O'
MO,:SJ[YAR\OAN1//!"[&9VC>N.C[,)-9YK(<O)Z39C BKF>P#Z#^)5MO/Q7[
M_?5VN7E>Y:OK;5=YL:"A\M, ,9XD?LCC*/))U.,/*&BW8#ZH'6<1I_?T/M1"
M^:WVNFXW^MOK>6^:*<[!N+N=]BX[Y)-.A4,SX957>^S]L?;Y3U[G=7-(M_7[
MQY@EP</I8.9T]TK]V+.I0UXLS;"N1^ZR>2.1*1:A('6WS@0%6%$1=EA%@E2;
M-ZKMZI)9XSF4\*RQ<VA<SOBW:O >NX3QXU;#LU+#>>4,NB/[8ZN<)0XFR1E@
M(Z*K7ITX?LYWMX_9Z2H;9P0K1:L\)0Q9ZD<8A6&SRL8BCE-8ZS)S*XYC\@J0
MUR#R9%9FL+![!'5Z8?(TK,'"VO[DQ9&YRRW4?TC0@%R.)W4>DF?!C\+VZP:3
M'E%LRUVV;*11/._+XFN^ZS5O$08APC3AB4BD((B+P*=!Y(=)+.(HY E\X7R<
MO4D6P'FV:4J QR][CR173Z"F8Q0F4AVN0[+=(3O)H*>5J4&:!J3*#KWSD"M+
MOA0N7D"+LG7L;"BR<OGXZ]/Q\JN[HBWW[IJ3M-'AS</G7?&E>IOW"ZRJ((^B
ME$F<^H0PQE+1 ?:# %1>>4&8CF.VDYZD^:$I7?'@9<<>0\L&N$6Y=#RH%K1V
M/N-I6:BO3CO0-K[]]/SD';WSRL+KC],<.TZU/M8O1N?EC"1_U&B9SA?3O"(_
MP&0S$1&0F6K*L;$RS?4'EY;%E^WZ__+50L1!$H6($X0CS'# JE\[$%C!3@98
M-NUX.N+KS:;)B"O=R5;?#L<D'[Q=VT-U=P */S)I>P L3#-NN;<^=71M;(]X
M9S0)O.'25-C-!^4'$.L1SD$$>"R'=I8\"!8\)"@,9<I22:JW2O7Y"D\3!MWS
M&6=M@KV;D^6.2^[8N,G/=?G] ;Y"?5] ^3F,(=UO[+;,RF;+Y>:A+RC^7+17
MQ-SO&SP+GW$5Q300"HO$3Q.IXJ@QG9! 24DU9TLKMMS-D3V\.B Y%MQW"+U_
M=A@G7K?7H6W@N[/*^CP^/[LN%0[?4F"/R?T^+_>]$2Z25%4/YU0$?N!+*DC0
M&0E$%,,.WP$?#OG.C$[=L=M;=7<+;"8))$A/EQPR U.@ Y"+"<WW/ Q(BB%A
M\Q /4_"O6T2.X0 F"%V7V\Z63"E-<<0($T21( Y]Z7>VF(Q ]<1F%IRO61_N
M^LT:<"82 :8,HA0NV3(1C*O^<N3+*L<K7LX*B"F/<](18Q_>E9-QC&CGU>_V
M%6"ER':[E_7V2WOJ@D94(L1#2BA247T=.FEMXP1Q!HL^[-AT'I0(<.\2-SFV
M#EM#N;95MN?QO5GVZ77N[8 Q6XV$7J.(.8YCPGCD)X@HZ@<DYAT*GW#0Q4BV
M;3N.#-ZTZM@_%KORI^I)7^UV%P)SKA= 7))N6&BATWNH#SSFU81(7R==#<<\
M%-.9=\".1>-8''5!1]<$1J4D8A'&G"(6RD2@..R%.V0B BZEC#'E?F'%R94=
MVDQJ9E)340A,J#ZXP.-"2C?$TE!Z98/<>6B8'5=TKO<PXT=7G:ZWWZJ'%[N7
M^B(1HJ2(L*]D2!%!2E"4TEX DS"%W7,/>+#CZ*S',O4=YT<*!KX*(Z;F\168
M07]SO[BQ_[IO^>==_I2M5^KWIWR[K^^;O2D?\]UW:QN+&'-&I6185+,^]WW&
MPFZE%*=1#'KY;=AS_$VT$+W\@''?!-)%#;-K,VBTS&F%:;VI>FJ283-VQV\+
MKZ&W >B]6AR=5I,T2!N0*IN4ST/!K'I4N'M!1^S/+!!.0HFC*GZ@=9>:%,>L
MVQ3&(B1R419EMC'8ESG[9)"&]2"TO[&[^G\9)5= H@QV8ZQR-&H7YH);+[I;
M+MIDS4,\#+$/;;$ &= /@(JG?%>^?*Y>D/I:TGH5Y*DN)JECKCA-(E[E$@D+
M.(H)9YS%G4DI8PE;A!AERODB1(?NRGNJ\373<MXAO/*V4]^).<36X$1L@>1Y
M?$1V7'DS]5KCQ]9NR<E-P%$<"\:8C! 7!&/$J>I3>>7'RN9&"<#LU'LDFV+[
MQ<$6"81H.[LCCCAVL3%RA#JOO1&MV\@=C,,\--"%8\#-$&/N=/6QNR#]+OO]
M$/%T)>3K?%^I\HE]55\3R"*%>9SX7 K,!>YS(AJ >M/;L^I8'3N@7IG]?DAE
MAJ,1UQSK*>-EZ(4)8\]L!;)??&GV3BXEAMJL#6BA?>;G(84._"I<O[,P(?Q+
M4:Q^6V\VBRK3"U@:4T895S@F84C#OFI'I< Z>NW'.L^Q.B0P[=*G14^:G/ !
M4YZS1#A1E\[J@'B N9F'-L!A%R/?"=B7?;*^>Z(B.* *(Q1%BD6,<BJ.9W(P
M)LB'A#-F%AR'+H=M#9/E5T/"] 3 /5<P-?A^]^=2L<>[K Q(Q3@6YZ$;(WTH
M;+Y7)ALYBSBIM(J@P \%(E3%*(AEGY$QY<-W<,X^<I*M&_,MF_.40/9JK+)A
MLDESB;V9LYLRVJS,XRN'@GYW&P;HL^YW?))BL.WJMBR6__-8;"I"]O423/ER
M/%D34ER-F@Q3'-.01#3V_=Y\"CU;:\VL\YSATS7CUY^N[Z[5K<=^EM[MW8WX
MZW_=?)+JE]M_^Y<D0/%_>E*EU^):_2S^&Z88]LC7TY2+L Y3G1.(S4+Q =C%
MSNGI,C8@6=9)GX>HV7>K</RR&@OCFT.&O*YW#1.?"$X#R@FGO1*+)&&0O&F$
M&<?)4W=$=G-$:*QN8 ;!>N:2/&,%N_PYXX\9TE,L4UIGIU'&CGRL2N.X@9[2
M^9R]U'7W736.\*,D54&"I1]3P>ON8=T*, DH!AXV-C3B//CJ3Y<\'8"9'<N!
M4J>9H+GG#)BP=62UB"Y\!.=[7H9RNG%$SD-JQCKQP8&;49P )&;WG*_>2MN"
M!23 3 0)2I"0?F4!=0</2<+B!-0XQ=B*XT"G!39TX$ G!G+U,;U/VO#W-)+H
MV7Q28_UX^U5984;WPVHO#ZOSEU_67Q[+_<USN2^KUVN]_;)@W/=I(/T@B$68
MQGZ (M6;#!,,^;9&&7+\>;VY06W:+VB(FH&/R JC\_B.[+A2.'CCQF;D"^7S
MA+-8R(3[$2(\K#[:SA 55$"V'PP>/\E6!&0.LL:;:?YME;+Q>?>EDVU0DJW-
MW3QD98P#9Y-J(!?04L^V(?=I:2EE2>2K.JS&:5*7WW/92Q:BH#4]<RN.I^*^
MX+"]/<"LAM. /#TYF88WF*KTE/77P%RZ-O,-.P,B,Y[1>6B-!3\^J+4<RPRH
M NM$YQ:4XU"F21A1D?"8<<'3/D8*H@B46H,?/DG=E7'  N=*3U^<T@23E0-#
MGRZUK/":B7-E5B:DS4,YS.&_5UQESH-VDE-LO]SENZ\ROR\7/(D"2>(JFXI5
M*F4H8]Z=P2<():"^A: '.]:'3]WY.F]5H9DX2#_A82@\-Z%K'J^\&?37(;FY
M_P;Y_$(QD=+8CY2H+/ P]0,>]N$^%M@PD3_[W$DR>!N9^WF&P"F[57*,<_6+
MI>AZN;DV23/Y]DV0?YR- [W7OZ?JZ]=U<_]@O7Y8W^*SWG[)M\O:(F:<JLI*
MQ%2*PB2*<"(ZB\(/.>RF/W,[KJMKCM .!Z)/P4%O\AO!IIYJ3$4D3$7,.'1T
MQ]>'! WHC U:YZ$[5CQY<[N7+7;T[_;ZL,B010%)%!+UR4L2D,C'JH_VJQ\Q
MK-YFA"'G-3>GV+H"YU7^L*YXWRX_WKRS3JB>,DW$)$R83D']>U?"S,IRM[Y_
M+NMZCOI>Z<_912L#C6J9+; ]#[VRX<B;:] L<0.)HHIM8_;0)ESRB"N6B)01
M14G@DY@DO1D_ O;L!C_>N3(=$'G[&I+WQW_]#]_WD?>4[;QO-;XK+_+]*__P
MC[=_K#ZO*BQX+A^+77WEZI47TRL?T^:_KO?[NN*G*?0Y[EN_O2CTJODK,E_F
M7^_S7??'\957/?LI7]97:F]>_@0/UV##IA^C.1LO>&!6#52#Y<K[^V%TKAO.
MIP_+3CDY$XL9T3</03.'_T[4-8('[9K#U:JY(#+;?,[6J^NMR)[69;8YL;X(
M<(Q1&/N4HC3D<8(CV1NF"5+ $N?Q!IT+W!&C5_=G_6F]]98'F,#"9PODZHG.
MQ*S"9.B$SAJ=5]'9XKOR3B5JXI+.LY0-J)1%ON>A6S8=>EWM:9LK\S1R$40Q
M]H7@L2+5KTPE2=!UCR=5/ CJ=&SP^$F6N?=.$\?S%)HFC%;9<Y8H7CH[!&6%
MVI3.0X3&.' V"P1R8>O@_B(.1(J0$"@(49HBE>+^P@J2<!D9;JF9&9MZGZW)
MVVP*TGBZP?MS[IDVWK0[.9H_K_/X>IMZXYB=AV;9<P=X[A[(DW;0M'S,5\^;
M_.:A:0C[O"R?=^OME^HW^>Y;SE_NJJ?=/(AB7][EOY=\4X=O$8]$B).0)3A.
M?($XD6D<2J$8097J@AJ8N;#O> ^Q@^P5#]YWH+T6M7?_XM6XZ[]0(P?&8"Y&
M1#-(N_!@ *,XZ#AX_[QK@KL:O->@GWKQ'\[O4/SG<+3F(;9./7P=03IG\RC)
MIV_=I^JG/_^A^Y/JE_MLG__Y#_\/4$L#!!0    (  N!I$P]U\=+9D4  "!#
M P 5    <VEG82TR,#$X,#,S,5]P<F4N>&UL[7U9EQLWEN9[_PJ/Y]EE[$N?
MJ>Z#M5IG9*=&DLL]3S@A9F1FC)F,+"ZR5+]^ ))!Y<(ER%@82555V25E @C<
M[WX [@4N+O[7?WZY'__P.9_.BG+RUQ_A7\"//^2347E=3&[_^N-O'WY2'\R;
M-S_^YW_\V__Z'S_]]-_Z_=L?;#E:W.>3^0]FFF?S_/J'/XOYW0^_7^>S/WZX
MF9;W/_Q>3O\H/F<__;2J],/R#^-B\L>_IW]]RF;Y#U]FQ;_/1G?Y??:V'&7S
MY;?OYO.'?__YYS___/,O7SY-QW\II[<_(P#PSYM:.TNDO_U4%?LI_>@GB'["
M\"]?9M<__A EG,R6WZ[QD:KXEQ?E_\3+TE!*^?/RMYNBLV);P=@L_/F_?WG[
M82GG3\5D-L\FH_S'__BW'WY8P3$MQ_G[_.:']/^_O7_SI)%9<9O]953>_YQ^
M^;,:C::+_-I]><@GLWRF)M=7\[M\:A;3:=3$VR+[5(R+>9'/8I^63=]-\YN_
M_I@:B7!  ? *C/]Y=$/SKP]Y:NC^81RQ^;G3SMM\GA7C]F1XUEZ?HGS,/HU;
MU,;3YEH0Q)3W]\4\#>/T55-.YG' QX%?@T(UJK;2P<EU B5]8%:.B^LTU>AL
MG(;0A[L\G\]^FV2+ZR+^]'"'CVZJ*P%\,8E?+;+QAWG\ZQ+#DWJ_IYT>N_YK
M-IW&R?MS7G/@-FVW*]&^??GJQF2S.S\N_VQ(KWI-]B'0U4,^7:ZPJ]%Z_S#-
M[V*%B.[;<M:BE$=^IQW1MP_G=UF:/N_R>3'*:K'RF&9:Z+C-/\T/]>IQF98^
M>>QPW5>GC2ZM[<A(%Q?7D/G7-Y.;<GJ_Y%#UNX-=/**-%KKLLV+Z]VR\R*]N
M-M/6FVC731>UIO*:U;OOJ+G+XI+]9O(V_YR/<65G?*W)BU8:[U[(8^E^8G/=
M"U+/ECRJD38Z?<H Z)CU6YJOJ_S#55OHX)OH6=_G'[,OA]6YI6B[':@)S.X:
MK73G<P2ZG'X]W(MG!=O\>&TDMI=OLROUAOJ.XBUTY%T^_7 7S1Z;S;-#O=A6
MMN4NU-3,GBHM=ZB>?G;7:*,[TVC73)=6=_*]I]DH63_O\UF>34=WZG::U_,K
MCVVGQZ[75?MIS;4C2/1VYE_?16]A:7O^8U$\U+%7#U;LLG/U8:U5O\NNUAQG
M]:JWT-'W^3BYA]$CG'_].,TFL\BUY.H>ZN&A>AUVK::V:U;OL*./?Z[BCS[7
M]T0:--FA0/7(6Z]V"]W\L+B_SZ9?KVX^%+>3XJ88I<$R&I6+Y<;MNW)<U-GU
M/:Z5WKJ=]M;2/VGH?\[&:;J/"\!\6HPBMND7-9G4S=?Z@V&]_OU>S._,8C:/
M)OM4S69YFA6/=>^[^V)O<!SK^C=KM3>QVAVK9QNS]>;'4]HZ283'Y\!R)<<D
MOTUS\]OL4SY^VL]M]<;3Z9-JZ0!:I@-HR):2;&NMY9[^FL_;[>SS!EON;_20
MBO+:35J&>'NSG?3]PSPNW%WT_F7#+??_8SZ=Y>WV_&63;?>YG&?CEOO\HLGV
M^GP",>8ONUF3!0_3Z/%.YLLSC[?Q!^ORJ=TV(TI6W\^_S//)=7Z]C&*I>C N
M1]M$78IYD\T^+65=S'ZZS;*'B!/D/^?C^:SZ29KV^4\ KN-U_N?ZQ^%=]G4Y
MN<>N+3N;C6?JTVQI=%1]&B> _OIC_'ZH42L HX0TCC''%=)(4.X9\I@SP$'\
MH7TJZCA%)I73-=:[9'VY<*6?A/J1'1%1'1O]8XM,)[84#"*.<^8=!Y 0B9%B
MNI(3 V;JR/F856HZ^J&<7N?3O_X(?_PA_N8FCQ]?3;)[0JJ6/)N_F!JRZ>@%
M-Y]67)?X^6%Y /O3Z*X8;\Z-4X19!QHO^T0\RE>-X)^W#N'>!O=62_95CW$/
M'<#>,TZ@D5YZ$?5"/,%*8,<T/FF,MR/K6BFZG"RB3M:ZV"/EUO*!((6I $!S
M8@P4S/!O\EE ^?<SMFMKNFP?UV\CN%O.V+4ZWN>?\\DBW\.69R4#8!(:130E
M7GA $..&KN0A$'-2:QSLX DZEB>?\^FG\A4RI1FF?7%DS>=WT_(FGZ4P[FSL
M\R,FF!T5@W(8*@AL1$_%%0U*3%@E+:2\B16!OZN9IAV >Z;3W[-57'YM&CVK
M$ 1BU$AFH5!*6^*0@ZZ2SF A&]"'?%?T:09L7[19&ICK'C\R, _39W_%P+W'
MQ%H!-,%"4&V,YI6T &'4@$;T^Z!1JP#W/ L=Q:3=,F+N%'>("6*$M=Z8Y*95
M"S=DM &)V-$D>K'O]!I(U!:VPW%]MYT<O&K/%S!BN53 .\4D!X0*Q%=[$$QB
M26K-E*WO;J7>MKC%]:2Y #@T0E+//"&.>X<90I7$C@+V_?C"M75_VCY7$]@[
M'_&U[Z/U.+KW],D6L]&XG"VF>8WQ?E0[P6BFW=(\5 ( B[6VFE-KG&'60@3.
MM_=52XY]\\1I#04"65SGG&/.:Z+2)K"7%2*.J%J(M#5#]+$+TA%?RAZ5T,-\
M<>)UT![GC\W%ND>7.=Z5LV+)P</31IWJ 2CM&)?(.&P$\,(ZSA #5 B"G+6U
M'/2.C/\41U3'''I:,&@CO(N2:&D00,!*0U E$3*LU[WQ/D9[NVI^;O$WP;8W
M-W'9R;7%4ILPS\H'ZZ7TF"FB#'$$<0HLJ&13ME_>=&]'GJK8K?QH!F5?-$FA
MF6FE>AJZJ>8FFTZ_QK5K>6]NG]51IWYPDDD+H::22.@8PUR1M>Q80*TN;?II
MR(#G1D4'&/?%KZ=!P$V8=F1+@6O,.5&: 0&)DP 1KBL\ -&]'O/U-76UQ;AN
ML>YQIS3%Q,[>YZ,\]CQZZK_F\UJ;I3NK!><)4PQC+:&B5AC(Z6:4466:;*P<
M??3W^F:R%J'MBT2;&Z6QIWM(\[A8(,X:AH&S5$("G9'0R\UP$-1?U@%?NQ1I
M &1?E'@WS1^RHMH=K#8'G\"P;Z/Z<.W L5;26H5-G$<U $K1RO+$GO$F!!K@
MT5Z[!&H?W[.X;'5=M0"QH!:S.'E&_\1K'^V^RHO%AC8*9QK@"5[+ZU$#)/N;
M;79<Y=V_(.VK%K@73,?%52BD(2=::<4K2:WE%Q<"UY)CWR*F0_&_?BTGHX,3
M3OU& N/<*!7''-2&8 RU=!LCS@'N+BLTKB5>=89OW\&XIIQ]2XNQ)Q1W62YY
MC4:+:-LY80B(TW2<="M9E-%-PB@':R8WYDH3"/NFP\?LRTKJ1R?F<:JL->?4
M;B,X88U5S&'-!=#68&WPQIB3J$D(TV"-Y=9HU#:\?5'L;V5Y_6<Q'N]A4%4D
M1+,.*<^EDDH[S FEDFYV1IUO<HAQM(7\BJR=$_'K-ZQV*6JM"65K^8"1=!A"
MQIQB2D:(OIT!8DQ@DS (?K&31QM0]NM4'_2F Q>1X00B0 TDTG&(N-T85LHU
M(8(8JAO=TDGGD=CUI?E'*UHTJ3_,R]$?=^4X:F263.OYUQJ'XG6;"-$"P[$;
MEGK,)24ITA!L$/"-SLD'Z5!W&E_1$>IGX%W]\(O=E8+5Z5B$"D",EDAJHN5F
M=!DA>CT\[WZ):E_YN]G5#.F^CS'74<[U#S"?5@@&L#C+(X$MX-)HK!"K#'F"
M)+ZX((PV%+WC_+(1LJ_SHI!"!&%ED( "&@NB5+#::2!"<7%9X13=<*<5:/NB
MS^\II]LJCOE]<7LWGUTMYNF=IO3^U1X&[:L6E 9 (@L0XH9Z#A!D;B,I%?BR
M=H<[(%&+Z)[/'#K*# H.:*$5-U9HP"#1-(Z-2BII9+^[Q)T[9AUPIC&F9TKI
M<=0V\8LZ@4DE&'!I1<9>I#,Y;3>C <HFYLZP%ZQNS.:V@.YU>W!+LK9=.X./
MB@:I,;5>4":-T%QIH_UF(D6,-;%UAKU,=4.=AOCVME"5D]N/^?3^\?M2VY:H
M1\6"%@Q9PN/"RYVWEEJNJXTS J%H$D@QP"/,[GWST[$]@SE3SXX)3AD? 6#.
M1#DT]0!INEELL6EB]!Y_/MFG =/Y_LV1T/9VI^;PM>OC[N\&K+1T43:FG(=4
M,(:%J>0T@.I>8_Q>_S33'M1]4>JDTXL]R"F&B'#0I,-]@@@#V&U6X/C')G/2
MT<>>/>\%=D.IUK#N<Y(J)\MN'[SC]ZQH\D2U4\)X19PD"!!.Q$8BP'K-+M+/
M:5=SY6Z9@AI@VML>\O7U\DPO&[_+BNLW$Y,]%-&">-3[?9O)!RL'A#F&E ,I
MH:>:"\SL1FHI8)-PT8&>F[;.I-91[B\T>9X5D_S:9=-)7']G:C1:W"^63__8
M_*88%?M#D@]5#EXABH!QBD,B@&&62+4!U+HFEV@&Z,5WP*S6,3Z?M724E100
MXQBD;'^.Q'\K)P2JKIV1"%^_7GWG'EL'S&F,Z5!BA!K$!@6.C(?0&(@H]!XZ
MCS>7%XG0MHF5-,"(LC[]_C;P/D\RI4VPU": ZGR9V*ZFM]FD^.<J@^ZFCXEH
MD^MWCT1^%.+UK=<UW,]6V@^,,,LP!=9:9B2T2$.R3)&E&7((U_)4!XC?<;G=
MVOY4\ (9J"Q-KW\HS)F6AFY0Q;;)"<< 8\IZ9N+SXX_S*F\P$]W^1P+_-?$]
MHQLT#&IM "*(<@&8Y]82C[2R(OIPMM:UIN?X[4A:N^6YZ&5BTRTR[BT?(@V)
M(<09;0S"SFH0_[;NL_"@26;[BYU6:NNY;%\#A\WL^HQ17XIMQQO[B@<845=.
M*TPE1$)K3)BH>@N)A9?!EY8T=D#_)P#:IOIM>9\5DR,(L*H0N.9: &<)8M K
M!95";MUC*3!ML@/X"BAPG-(.,. D1$_F@,ZFUUGUZ5_R^T_Y=)?VMQ0-7"#
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M!9C[^)F[6*'XO Q[/7\JDE4([J;']0*=M]4(T:])ITH$I/3_AA H^3J'-^8
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M*\:BU6TL=@8(X2.AN:%5SS$F39*DGGJ7[O70H75\>XM(*2?ET[GN\$2RLT[
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MG%-EW2'JW[)B\K:<S=Y,1N-%G*K>3%PV35$B^Z)3>^M#D-0!CZ#20@"J.6.
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M6.Y2NR^K;#(^PI5LG,5\_8!UE5SF73Y=9H'47[<W<, NZ/"KP2.@B&+*8R$
M!XY#O'X!$'$A[(7=5.C LAB.<LX["-)C4 <-E$-5 [&6($69H-9*8J%FM'(9
MN7'FPJR407"G%I]/5M'K-G;: ^-27-BW-2(8]U<, %IH+15 8Z>9 LHB56$F
MA6R2&&6 H?M].;.GXGM6-OVZ2/R_NODVMDPV'N?7^FL5F;8N>#3=ZK<<N$ (
M4I;293I/O2, 5'9KM&3-A5T$;XL\=3C9F1+.2EKW)9^.BEG^;EJ,\LTO-Z+
M8ZEZJ+U #6968ZV)=%0HK%/Z^14V(IW"?P<N9D<$;1GZD_<BEITKJ^^7J\^O
MWB!) /UY5XSNJLZM?SN+8*Z[O^.0O*66 V2,2QW1]99"1KB,_ZDPT$ T2>KS
M6ES$T^EW'B6\YIL ED@#O;$ >R6@E$:C;Y)ZW*MY>+8-U>;S78L8G^.&U>+^
M896ZMIC]X:=Y_F82AWX^F[_?_M+>L4T$)XU0!#.IL156,<=Y%2$C$&ETHC;
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MNO_YW5U5@G<>*Z P83I.N!(;1RL)(\:X2=*/ =*K8Q:4G8!^3EH=?-EV=Z7
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MI$SH,2BH8\I=6$K--FA4GET+ YE!3#:[2_^D1.*?LW&2>#EG%J,X,Z=?G#M
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M !$              ( !     '-I9V$M,C Q.# S,S$N>&UL4$L! A0#%
M  @ "X&D3,\.K869#0  :(L  !$              ( !KID  '-I9V$M,C Q
M.# S,S$N>'-D4$L! A0#%     @ "X&D3/WE]][2$P  >LL  !4
M     ( !=J<  '-I9V$M,C Q.# S,S%?8V%L+GAM;%!+ 0(4 Q0    (  N!
MI$S0;&$\@28  %7' 0 5              "  7N[  !S:6=A+3(P,3@P,S,Q
M7V1E9BYX;6Q02P$"% ,4    "  +@:1,HLC.ZGET  #FS04 %0
M    @ $OX@  <VEG82TR,#$X,#,S,5]L86(N>&UL4$L! A0#%     @ "X&D
M3#W7QTMF10  ($,# !4              ( !VU8! '-I9V$M,C Q.# S,S%?
=<')E+GAM;%!+!08     !@ & (H!  !TG $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
